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Abstract
Stem cell transplantation (SCT) represents the only curative treatment option for 
leukaemia. The bone marrow or peripheral blood stem cells transferred in the transplant 
procedure restore immune functions, allowing the targeting of infected cells or cells 
expressing tumour antigens. Cytotoxic T lymphocytes (CTL), key mediators of antigen 
specific killing, were investigated in the context of cytomegalovirus (CMV) infection or 
chronic myeloid leukaemia (CML).
CMV infection after SCT in the absence of effective immunological control or 
antiviral therapy is a significant cause of morbidity and mortality. HLA-A*0201 
tetramer reagents were prepared with three candidate peptides and used to test healthy 
donor and SCT patient samples. Only T cells binding to the tetramer made with the 
predominant pp65 epitope (AE42: 495-503) were found for HL A-A*0201 healthy 
individuals and patients after SCT and correlated with the estimation of the responding 
T cell population to this peptide as measured by interferon-yproduction. Parallel 
tetramer and viral load monitoring of patients at risk of CMV infection after SCT 
highlighted an inverse correlation between the state of replication of the virus and the 
number of CMV specific CTL.
Presentation of a CML tumour specific peptide epitope in the context of HLA- 
A*0301 was demonstrated both at the surface of tumour positive cells lines and patient 
cells. HLA/peptide tetramer reagents were prepared with this peptide and used to screen 
CML patient samples. Low frequencies of peptide specific CTL were detected in some 
patients and could be stimulated in vitro.
While donor lymphocytes infusions would improve CTL responses after SCT, 
they also carry the risk of graft versus host disease and may not comprise an effective 
CTL population targeted to the antigen of interest. A better outcome may be obtained 
by infusion of enriched and or expanded specific T cell populations. The enrichment, 
stimulation and expansion of CTL with HLA/peptide tetramer or modified tetramer 
complexes was examined, using the HLA-A*0201/CMV CTL response as a model.
The use of HLA/peptide tetramers to monitor recipients of SCT has implications 
for the improvement of the treatment of CMV after SCT and the definition of targets 
and criteria for effective adoptive transfer. Furthermore, the use of HLA/peptide 
tetramers could be investigated in the assessment of anti-tumour CTL responses, in
1
enhancing existing responses and possibly in inducing primary immune responses to 
viral pathogens and to tumours.
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Chapter I
Chapter I 
Introduction
The immune system
The physical barriers and the cellular and molecular components that collectively 
defend an organism or host against disease constitute the immune system. The different 
components of the immune system have evolved and adapted to face a pathogen rich 
environment.
The immune system can be seen as a layered defence system, with first of all the 
presence of physical barriers such as the skin, mucosa and their protective linings as 
well as the digestive fluids represent the first obstacle to the entry of a pathogen. When 
this first barrier has been overcome, pathogens then face a series of cellular and soluble 
components, which have evolved to recognise characteristics that are common amongst 
pathogens and constitute the inherited arm of the immune response that can function 
without prior exposure of a host to the pathogen. This arm of the immune response is 
also named innate, and constitutes the first active line of defence that a pathogen 
encounters upon entry into the host tissues. The second active layer of defence consists 
of the specific targeting of the pathogen for destruction, as well as the destruction of 
cells that have been infected and harbour this pathogen, in order to avoid both infection 
and spreading. This requires a previous exposure to the pathogen that can thereafter be 
identified and will induce a swifter and stronger response to a repeat infection with the 
same pathogen. This type of response is named adaptive as it has the ability to conserve 
a memory of previous infections and can generate an improved response with time.
The major active components of the adaptive arm of the immune response 
originate from haematopoietic lymphoid progenitor cells in the bone marrow. 
Lymphoid precursors give rise to two progenies that are distinguished firstly by their 
location of maturation and by their specific receptor present at the cell surface. The 
differentiated cells or lymphocytes can be detected in peripheral blood or tissues after 
they have matured in the bone marrow (B lymphocytes) or in the thymus (T 
lymphocytes). B and T lymphocyte cell surface receptors enable the specific recognition
14
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of a portion of the pathogen (or antigen) and are named respectively B cell receptor and 
T cell receptor (TCR). These receptors differ in structure and in expression as the B cell 
receptor is produced both as a transmembrane glycoprotein and as a soluble molecule 
(also named immunoglobulin or antibody) that binds antigen and elicits humoral 
effector functions, while the TCR only exists as a membrane bound molecule that elicits 
cellular effector functions. The functions of B lymphocytes upon pathogen recognition 
are to proliferate and to produce antibody molecules that can bind extracellular 
pathogens and mediate their elimination by phagocytosis or complement mediated lysis. 
By comparison, T lymphocytes recognise pathogen infected cells and will proliferate, 
secrete soluble molecules (or cytokines) that will provide “help” for the activation of B 
cells or can directly mediate killing (cytotoxicity) of the infected cell.
The recognition of pathogens by B or T cells occurs through specific binding of 
the B cell receptor or the TCR respectively. Immunoglobulins and TCRs are highly 
variable molecules, with the specificity concentrated in the region that binds to antigen. 
Both these receptor types are generated by random rearrangement of V, D and J gene 
segments and result in the production of an immunoglobulin molecule for B cells or of 
an ap  or y5 heterodimer for T cells. The majority of T cells present in peripheral blood 
express the a(3 heterodimer. These molecules were shown to bind foreign antigens 
when the latter were presented in peptide form refolded with major histocompatibility 
complex (MHC) proteins present at the cell surface (Zinkemagel and Doherty, 1974). 
There are two major distinct classes of MHC molecules: MHC class I molecules (or 
Human Leucocyte antigen, HLA-A, B and C) that are expressed on almost all nucleated 
cells and MHC class II molecules (or Human Leucocyte antigen, HLA-DR, DP and 
DQ) that are expressed mainly on cells with immunological functions such as dendritic 
cells (DC), B cells and macrophages. However, the expression level of MHC class I and 
MHC class II at the cell surface can vary. Antigens presented in the context of MHC 
class I or MHC class II molecules can be recognised by CD8 or CD4 T cells with 
cytotoxic or helper functions respectively.
To appreciate fully the physiological role of these cells, it is possible to analyse 
what happens when they are absent. Such deficiencies may be genetic, as is the case of 
the bare lymphocyte syndrome when cells lack expression of MHC class I and class II 
and in Omenn syndrome, when a defect in the recombinase genes prevents the 
development of B and T cells. Deficiencies can be induced, as in acquired immuno­
deficiency syndrome (AIDS) and in patients whose immune systems are ablated during 
conditioning for allogeneic stem cell transplants. In this latter case, the recovery of the
15
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immune system occurs after the transfer of donor haematopoietic stem cells and any 
residual mature T cells remaining in the stem cell graft. Reconstitution of the immune 
system is relatively slow in transplanted patients and varies depending on their age and 
the extent of T cell depletion. As a consequence, they may suffer a prolonged period of 
immunodeficiency when they are susceptible to infections and to relapse of the 
underlying malignancy if it has not been entirely ablated by treatment. The aim of this 
thesis is to follow specific immune responses in these patients with the overall goal of 
using specific T cells in adoptive immunotherapy during such prolonged periods of 
immunodeficiency. These studies have been first developed and have been practical in 
the context of MHC class I molecules and are therefore restricted to cytotoxic T cell 
responses. In many cases, these are appropriate cells to be given for adoptive 
immunotherapy since their function is to eliminate virus infected cells or residual 
tumour cells.
Antigen processing and presentation
In order to be recognised by T cells as self or foreign, proteins need to be processed in a 
manageable form at the cellular level so that only a portion of the antigen in the form of 
a peptide can be linked to MHC molecules and bind the TCR. All peptides binding to 
MHC molecules were shown to originate from the cytosolic cell compartment 
(Townsend and Bodmer, 1989). While MHC class II molecules bind peptides 
originating from extracellular pathogens that enter the cell within endosomal or 
lysosomal vesicles (Brodsky and Guagliardi, 1991). The protein fragments binding to 
MHC class I molecules originate in the majority of cases from viruses or intracellular 
bacteria, although peptides may also originate from other sources such as aggregated 
intracellular proteins. In this chapter, emphasis will be put more specifically on MHC 
class I processing and presentation pathway, as it is of relevance to the focus of this 
PhD thesis.
MHC class I structure
MHC class I molecules are heterodimeric molecules composed of a membrane spanning 
a  chain glycoprotein or heavy chain bound non covalently to p2-microglobulin, which 
does not have any transmembrane or intracellular moieties. The a  chain folds into three 
distinct domains: a l ,  a2 and a 3 (see schematic representation Figure 1.2). The a3 
domain and P 2-microglobulin show similarities in amino acid sequence with 
immunoglobulin constant domains and have similar folded structures. The a l  and a2
16
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domains fold together into a single structure consisting of two segmented a  helices 
lying over a sheet of eight antiparallel (3 strands to create a groove. Inside the groove 
formed by the refolded MHC class I molecule, a cluster of tyrosine residues common to 
all MHC class I molecules can form hydrogen bonds to the amino terminus of an 8 to 
10 amino acid long peptide. Typically each MHC class I molecule accommodates a 9 
amino acid long peptide that fits within the binding groove, which forms specific spaces 
or pockets available for the binding of each amino acid, numbered from 1 at the amino 
terminus to 9 at the carboxy terminus. A second cluster of tyrosine residues forms 
hydrogen bonds and ionic interactions with the peptide backbone at the carboxy 
terminus and with the carboxy terminus itself. Therefore the peptide is bound in an 
elongated conformation across the groove with tight binding at either end (or peptide 
anchor sites); with binding of the inner part of the peptide being more lose or flexible to 
accommodate the different peptide lengths (Stem and Wiley, 1994; Bouvier and Wiley, 
1994; Rammensee, 1995). Both binding clusters are invariant between MHC class I 
molecules and are thought to be the main stabilising contacts for MHC/peptide 
interactions. However MHC molecules are highly polymorphic and the main 
differences between MHC variants are found at certain sites within the peptide binding 
groove and result in different amino acid involvement at key peptide interaction sites 
(such as anchor sites) in the different MHC variants (Albert et al, 2002). The anchor 
positions may differ between different MHC molecules, however they are similar for all 
peptides binding to the same MHC molecule. Consequently, different MHC variants 
will bind different peptides. Additionally, the peptide anchor residues that bind the same 
MHC molecule will not necessarily be identical, although they will have similar 
properties (for example, they will all be large hydrophobic residues such as Valine, 
Leucine or Isoleucine).
MHC class I processing and presentation
In the last decade, the detailed mechanisms that lead from pathogen entry into the 
cytosol of the infected cell to the MHC class I presentation of a peptide from that same 
pathogen have been elucidated (Germain, 1994; Lechner and Cresswell, 1996; Pamer 
and Cresswell, 1998). This process is summarised in Figure 1.1. Proteins of pathogen 
origin are marked by ubiquitin and targeted to a cytosolic proteolytic unit named the 
proteasome (Niedermann et aly 1999). The cleaved peptides resulting from proteasome 
processing are then transported from the cytosol to the lumen of the endoplasmic 
reticulum (ER) by the transporter associated with antigen processing complex or TAP.
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Partially folded MHC class I molecules linked to calnexin are present in the ER and are 
chaperoned towards the TAP complex by calreticulin and Erp57 where they bind to 
tapasin (Sadasivan et al, 1996, Li et al, 2000). There, peptides of 8 to 10 amino acids in 
length can bind to MHC class I molecules and form a stable MHC/peptide complex 
providing the affinity of the peptide for the MHC molecule is sufficient. These refolded 
MHC class I/peptide complexes are then transported through the Golgi apparatus and 
onto the cell surface where they are presented and constitute specific ligands for antigen 
restricted T cells.
In order to target pathogens and pathogen infected cells, T cells must 
differentiate between self proteins refolded with an antigenic peptide or refolded with a 
self peptide by screening the surface of cells in the body. The mechanisms that account 
for T cell receptor diversity and that allows T cells to differentiate between self and 
non-self (i.e. pathogen derived) peptides occur in the thymus. These processes are 
known to be composed of three major stages: T cell receptor rearrangement followed by 
positive and negative selection (reviewed in Starr et al> 2003).
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Figure 1.1 MHC class I processing and presentation
The MHC class I processing and presentation pathway is restricted to cytosolic 
proteins that may originate from self or intracellular pathogens. Cytosolic proteins 
bound to ubiquitin are targeted to the proteasome where they are cleaved into 
peptide fragments. These fragments are then chaperoned to the transport associated 
protein (TAP) system composed of TAPI and TAP2 protein sub-units, which 
mediates their transfer to the endoplasmic reticulum (ER). Unfolded MHC class I 
heavy chain proteins are released in the ER after synthesis and are chaperoned by 
calnexin until they refold with (3-2 microglobulin. Once the MHC class I-(3-2 
microglobulin complex is formed, it is released by calnexin and chaperoned towards 
the TAP complex by the calreticulin and erp57 proteins and “docks” near the TAP 
complex via binding to tapasin. There, proteins transported in to the ER from the 
cytosolic compartment can bind to the pre-formed MHC-(3-2 microglobulin complex 
if the peptide is from 8 to 10 amino-acids long and bind the complex with enough 
affinity to form a stable molecule. The refolded MHC class I-(3-2 microglobulin/ 
peptide complex is then exported through the Golgi apparatus to be secreted and 
expressed at the cell surface where it can then be presented to T lymphocytes.
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Professional antigen presentation: dendritic cells
Dendritic cells (DCs) share with their close relatives the macrophages the ability to specifically 
recognise and ingest pathogens. Other extracellular antigens can also be taken up non- 
specifically by macropinocytosis, a process in which large volumes of fluid surrounding the 
cells are engulfed. Unlike macrophages, the primary function of DCs is not to destroy, but to 
process and carry pathogen antigens from the site of infection to peripheral lymphoid organs 
where they can be presented to T lymphocytes (for reviews on dendritic cells, see Banchereau 
et al, 2000; Guermonprez et al, 2002).
DCs are leucocytes that originate from CD34+ haematopoietic progenitor cells in the bone 
marrow. CD34+ cells constitute the precursors of common myeloid and lymphoid progenitors, 
which have been shown to differentiate into DC precursors when they reach the peripheral 
blood circulation. DC precursors further differentiate in several types of immature DCs (which 
have not yet encountered antigen) characterized by their morphology, phenotype and location. 
They constitute the Langerhans, interstitial, monocyte-derived or plasmacytoid type of DCs 
after exposure to GM-CSF and FLT-3 in vivo and locate to peripheral tissues. (Sallusto and 
Lanzavecchia, 1994; Strunk et al, 1997; Bjorck, 2001). Immature DCs are characterized by the 
synthesis of large amounts of MHC class II molecules that remain sequestered in late 
endosomes and lysosomes with internalized antigens, therefore these do not present antigens 
efficiently to T lymphocytes. For efficient antigen presentation to occur, a process of 
maturation is necessary. In vivo, DC maturation is triggered by the cells sensing the presence 
of infectious agents such as microbial products or viral pathogens through specific cell surface 
receptors and by the triggering of tumour necrosis factor (TNF) receptors sensing local 
inflammation. The receptors binding to infectious agents specifically recognize components 
such as for example mannose, liposaccharide (LPS), which are both components of the 
bacterial membrane, and CpG DNA (specific deoxynucleotide motif characteristic of bacterial 
DNA) respectively recognized by the lectin-mannose receptor, the Toll-like receptor 4 (TLR4) 
and TLR9. (Poltorak et al, 1998; Qureshi et al, 1999; Hemmi et al, 2000; Geijtenbeek et al, 
2000). Furthermore, the presence of double stranded RNA characteristic of some viral 
infections triggers the production of TNF-a, an inflammatory cytokine, which also constitutes 
a signal for DC maturation. Likewise in vitro, DCs can be matured by exposure to LPS, 
inflammatory cytokines including TNF-a and IL 4, as well as by CD40 ligation. (Sallusto and 
Lanzavecchia, 1994; Romani et al, 1996; Caux et al, 1994).
While MHC class II molecules accumulate in large numbers in endosomes and lysosomes, this 
is not the case for MHC Class I molecules, which bind cellular peptides in the ER as part of the
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endogenous pathway of antigen presentation. The expression of MHC class I molecules is 
upregulated upon DC maturation, and there is evidence that this may drive the formation of the 
immunoproteasome. DCs are able to present peptide antigen in the context of MHC class II or 
MHC class I for presentation to CD4+ and CD8+ T lymphocytes respectively. To present 
foreign antigens in the context of MHC class I, they specialize in forming MHC class I-peptide 
complexes by the “exogenous” or “cross-presenting” pathway (Albert et al, 1998). This 
property was first described by experiments examining the nature of MHC restriction during T 
lymphocyte priming. Minor histocompatibility antigens were capable of being transferred from 
the cells expressing these antigens to host antigen presenting cells (Bevan, 1976). This type of 
presentation was named “cross-priming” to differentiate it from direct T cell activation by the 
actual cells expressing the minor antigens. Two different routes of cross-presentation have 
been described: the first is termed cytosolic as antigens are thought to be exported from the 
endosomal compartment into the cytosol, from where they follow the endogenous antigen 
processing pathway (TAP dependent, as described previously); the second route involves 
loading of peptide antigens onto MHC class I molecules in the endosomal pathway or directly 
on the cell surface (TAP independent). Cross-priming by DCs is involved in many types of 
immune responses, including these to tumours, viruses, grafted tissues and in some cases 
against self (Albert et al, 1998; den Haan et al, 2000). The cross-presentation of exogenous 
antigens is an important mechanism for CD8+ T lymphocyte priming in infectious diseases as 
this allows the induction of responses to pathogens that do not directly infect antigen 
presenting cells and/or to pathogens that suppress the functions of antigen presenting cells.
While maturing, DCs simultaneously migrate from the peripheral tissue where the antigen was 
encountered into the paracortical region of the nearest draining lymph node where their long 
“dendritic” processes maximize the opportunities for T lymphocyte interaction. Mature DCs 
are then characterized by the redistribution of MHC class II molecules coupled to antigenic 
peptides from the intracellular compartments to the plasma membrane where they accumulate. 
The expression of MHC class I, co-stimulatory CD80 and CD86, as well as adhesion CD48 
and CD58 molecules is also upregulated, which collectively with MHC class I and Class II 
expression confer exceptional capacity for T lymphocyte stimulation. (Inaba et al, 1998; 
Turley et al, 2000; Inaba et al, 2000; Bousso and Robey, 2003). DCs specialize in the 
stimulation of naive T lymphocytes and the development of the adaptive immune response 
(further described in the following paragraphs). However, the outcome of dendritic cell 
stimulation can vary dramatically in its effect depending on the type as well as the quantity and 
quality of the signal the DC receives. Hence mature but quiescent DCs, or resting DCs targeted
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with low doses of soluble antigen were shown to induce peripheral tolerance, in part through 
the induction of peptide-specific regulatory T cells (Dhodaphar et al, 2002; Steinman et al, 
2003). Therefore DCs, while being the trigger of antigen specific T lymphocyte immunity, are 
also key to the maintenance of peripheral tolerance to self. This is particularly important due to 
the fact that some self protein for which tolerance is required may not be included in the 
process of thymic selection (if they are absent from the thymic environment) to remove self- 
reactivity, and that chronic reactivity to most harmless environment proteins must not develop. 
The activation of mature dendritic cells is critical to the induction of primary T lymphocyte 
responses, but cal also trigger memory type responses along with other non-specialised antigen 
presenting cells. The focus of this thesis will be centered more specifically on the generation of 
CD8+ peptide-specific cytotoxic T cell responses. The requirements for T lymphocyte 
recognition and stimulation will be described in further detail in the following paragraphs.
19 iii
Chapter I
T cell development
Common lymphoid progenitors expressing CD34 migrate from the bone marrow to the 
thymus near the cortico-medulary junction (Berenson et al, 1988; Terstappen et al, 
1991). These cells develop and differentiate in the thymic microenvironment through 
cytokine signal and interaction with stromal cells. The relative expression of CD4 and 
CD8 markers is used to refer to the different stages of thymocyte differentiation: the 
first stage produces double negative 1 (DN1) type cells that are also CD44+ and CD25'. 
As these cells migrate towards the subcapsular thymic epithelium, they up-regulate 
CD25 (DN2) then down-regulate CD44 (DN3). At this point, receptor gene 
rearrangements occur and direct thymocytes to the y8 or the a|5 differentiation pathway 
(Mallick et al, 1993; von Boehmer and Fehling, 1997). When productive TCR p 
rearrangement and successful pairing with pre-Ta (composed of an invariant a  chain) 
occur, CD25 is then downregulated (DN4), followed by an extensive proliferation stage 
and with the expression of both CD4 and CD8 (double positive or DP) (Fehling and von 
Boehmer, 1997). The rearrangement of TCR a  follows and multiple successive 
rearrangements can occur until a productive one is obtained. Each developing T cell a  
chain is then tested together with the p chain for recognition of self-MHC: this 
constitutes a positive selection process that will determine their survival. The peptide 
ligands involved in positive selection must have low affinity for the TCR and therefore 
will not be stimulatory for mature T cells (i.e. be antagonist peptides, Hogquist et al, 
1994). Successful positive selection will then determine the down-regulation of either 
CD4 or CD8 and produce thymocytes that will recognise peptides bound to MHC class 
II or MHC class I and go onto become cytokine secreting cells or cytotoxic cells 
respectively (Basson et al, 1998; Singer et al, 1999). The second selection process or 
negative selection involves the clonal deletion of a given T cell if stimulatory ligands 
(foreign, agonist or antigenic peptide) are present in the thymus during development. 
This eliminates self-reactive responses to high affinity ligands (Kishimoto and Sprent, 
1997; Zal et al, 1994). Both processes co-jointly allow only cells with functional TCRs 
that will not be self-reactive in the periphery to pass these checkpoints. As a result, less 
that 5% of thymocytes will successfully pass these two selection processes and migrate 
through the medulla before leaving the thymus.
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T cell receptor composition, specificity and signalling
This paragraph will be focused on the composition, specificity and signalling of a p  T 
cells as they are of main interest in this thesis. By contrast, y8 T cells appear to have 
different antigen recognition properties and functions that will not be detailed here as 
they are outside the scope of the studies described in this thesis.
TCR composition and specificity
The structure of a number of TCR and MHC molecules has been determined by X-ray 
crystallography studies.
The TCR is composed of a glycosylated polymorphic aP heterodimer, which is 
associated with a non-polymorphic membrane bound complex collectively known as 
CD3. Both the a  and p chains of the TCR have an amino terminal region that shows 
homology to an immunoglobulin variable domain and carboxy terminal region that 
shows homology to an immunoglobulin constant domain. Each chain contains a hinge 
region near the cytoplasmic membrane that form a disulphide bond, and ends in 
transmembrane and short cytoplasmic tail fragments (see schematic representation, 
Figure 1.2). Both chains are composed of two domains that resemble the variable and 
constant domains of immunoglobulins and the antigen binding site of the TCR has been 
described to consist of regions analogous to the complementary determining regions (or 
CDR) of immunoglobulins. T cell recognition is focused on peptides bound to class I 
MHC molecules composed of a transmembrane a  chain that folds into three domains: 
a l ,  a2 and a3 (or heavy chain) and is non-covalently linked to P2-microglobulin.
Three CDR regions of the TCR have been shown to contact MHC molecules: 
CDR1, CDR2 and CDR3 (for a review on TCR structure, see Bentley and Mariuzza,
1996). The MHC is highly polymorphic, the majority of the diversity is located within 
the peptide binding groove and will not directly affect recognition by the TCR, which 
binding to MHC is restricted by its CDR1 and CDR2 loops. Most of the contact 
between the TCR and MHC that confers the peptide specificity for both complexes 
resides in the CDR3 domain of the TCR and the peptide binding motifs of the a  1 and a  
2 domains of the MHC heavy chain. The molecular recognition between the TCR and 
MHC/peptide complexes has been further characterised with X-ray crystallography 
studies of bound complexes, which allowed the visualisation of their binding pattern 
(Garcia et al, 1996; Garboczi et al, 1996) as well as their diagonal docking topology 
(Teng et al, 1998; Ding et al, 1998). Furthermore the MHC groove was demonstrated to 
be able to facilitate a degree of peptide binding flexibility to the TCR with 2 amino-
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acids of the typically 9 forming the peptide anchored within the MHC and the others 
exposed for binding the TCR thus enabling relative spatial flexibility (Garcia et al, 
1998). Binding of the TCR to MHC/peptide complexes leads to oligomerisation of TCR 
molecules and triggers activation (Reich et al, 1997), which is characterised by a 
complex cascade of downstream intracellular signalling events.
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Figure 1.2 ap T cell recognition and signalling
The T cell receptor (TCR) is composed of the ap  heterodimer 
associated with four signalling chains: 8, y and e to form the 
TCR/CD3 complex. The TCR/CD3 complex is associated with a £ 
chain homodimer, which possesses immunoreceptor tyrosine-based 
activation motifs or ITAMs. These are similar to the TCR/CD3 
IT AMs. This complex binds specifically the major histocompatibility 
(MHC) class I-P-2 microglobulin/peptide complex in an antigen 
restricted manner. MHC binding induces the clustering of TCRs and 
the activation of receptor associated kinases such as Fyn or Lck. 
Binding of the a  CD8 co-receptor sub-unit to the a  3 domain of MHC 
class I molecules brings Lck in close proximity to the TCR/CD3 
complex and phosphorylates ITAMs, which in turn induce ZAP-70 
phosphorylation and activation. This constitutes the first events 
leading to downstream signalling.
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T cell signalling
The initial stages of T cell activation are summarised in Figure 1.2. T cell activation was 
shown to be dependent on the binding affinity of TCR to the MHC peptide complex and 
on the kinetics of the interaction. This highlighted the facts that low affinity and high 
dissociation rates would not lead to downstream signalling and T cell activation 
although binding could occur (Matsui et al, 1994; Alam et al, 1996; Lyons et al, 1996; 
for a review, see Germain and Stefanova, 1999). Furthermore, interaction of the CD8 
co-receptor with the a3 domain of the MHC class I heavy chains is important to 
triggering T cell activation as it will lead to the co-localisation and phosphorylation of 
Lck followed by that of ZAP-70 and marks early T cell activation events (Figure 1.2). 
These last points serve to demonstrate the facts that TCR-MHC/peptide interaction 
alone may not be sufficient for efficient T cell activation. In fact full T cell activation 
requires a complex system involving multiple molecular recognition complexes and 
spatial segregation at the cell surface is now known to be involved. This was initially 
described and visualised at the cell surface by microscopic studies of what has since 
been named the immunological synapse or IS (Monks et al, 1998; Grakoui et al, 1999; 
Davis et al, 1999; for reviews see Krummel and Davis, 2002; Davis, 2002). The IS 
forms on contact of a T cell with its antigen presenting cell, initially by interactions 
between the lymphocyte function-associated antigen-1 (LFA-1) and the intercellular 
adhesion molecule-1 (ICAM-1) and between CD2 and CD58 respectively. Interestingly, 
these interactions effectively mediate initial binding of the T cell to an antigen 
presenting cell rather than TCR interaction. Once the initial contact has been 
established, TCR-MHC/peptide binding occurs and the CD2/CD58 complex segregate 
together with TCR/MHC and CD8 at the centre of the IS (Gao and Jakobsen, 2000). 
This effectively pushes LFA-l/ICAM-1 outwards as well as other much larger 
molecules such as CD43 and CD45 that can interact and influence T cell recognition 
without disturbing the binding of smaller molecules localised at the centre of the IS 
(Delon et al, 2001). These rearrangements can be visualised at areas of cell contact and 
form what appears like annular molecular clusters driven by changes in the T cell 
cytoskeleton structure (Valitutti et al, 1995; Dustin and Cooper, 2000). Therefore it is 
currently thought that these interactions collectively contribute to T cell recognition and 
signalling.
Additionally, there is recent evidence that co-stimulation can contribute to T cell 
recognition and can influence as well as regulate signalling to enhance or prevent T cell 
activation and proliferation (Wulfing et al, 2002; Egen et al, 2002, Holdorf et al, 2002).
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Although prior evidence of the influence of a number of co-stimulatory molecules on T 
cell activation had been established, there is increasing data demonstrating that their 
contribution to signalling occurs through the IS.
T cell co-stimulation
T cell activation therefore requires the specific recognition of a MHC/peptide complex 
as described above. The co-stimulation of T cell responses involves the simultaneous 
interaction of molecules that are involved in modulating the subsequent response.
As previously mentioned, the direct involvement of CD4 or CD8 in MHC 
recognition and signalling point to them as being the major co-stimulatory molecules. 
However, a number of other molecules that can also influence T cell activation have 
been described more recently and these belong to the same family of molecules, act in a 
similar fashion and may even compete for the same receptor ligands. These molecules 
can be separated into two groups, depending on whether they enhance or suppress T cell 
activation therefore leading to anergy or death. Some of these co-stimulatory molecules 
and their ligands are represented on Figure 1.3.
The main co-stimulatory molecules currently thought to promote T cell 
activation and clonal expansion (positive co-stimulation) include CD28, CD40L, 4-IBB 
and the recently described ICOS (inducible co-stimulator) (Andreasen et al, 2000; 
Liang and Sha, 2002). The opposite effect can also be seen by negative co-stimulation 
with a number of molecules and ligands, which can prevent T cell activation (anergy) or 
can induce programmed cell death. These are thought to be part of the control of the 
immune response as well as a safeguard from excessive or unwanted responses. They 
include CTLA-4, a CD28 analogue that directly competes with the same ligands 
CD80/86 also named B7.1/B7.2, and PD-1 (Wells et al, 2001; Greenwald et al, 2002).
CD28 is a co-stimulatory molecule that is traditionally thought to be enhancing 
significantly T cell activation by lowering the TCR threshold needed to generate a 
response (Bromley et al, 2001). CD28 is expressed on most T lineage cells, plasma cells 
and binds to the structurally related B7.1 (CD80) and B7.2 (CD86) glycoproteins that 
are expressed on peripheral blood monocytes and DCs. CD86 is also expressed at low 
levels on resting B and T cells. Upon T cell activation, the expression of CD80 and 
CD86 are increased rapidly, with CD86 reaching higher levels than CD80 (Linsley and 
Ledbetter, 1993; Linsley et al, 1994; Lenschow et al, 1996). However T cell activation 
also leads to CD28 up-regulation, but ligation leads to transient down-regulation.
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Figure 1.3 Major co-stimulatory and inhibitory signals to ap  T 
lymphocytes
Representation of the molecular complexes currently thought to be the 
major co-stimulatory or inhibitory mediators of a p  T lymphocyte 
activation. Panel A summarises positive co-stimulatory signals 
mediated by binding to CD28 (thought to constitute a major 
co-stimulatory signal necessary for naive T cell priming), CD 154 (also 
known as CD40L, an accessory co-stimulatory signal) and CD 137 
(also referred to as 4-1BB, thought to be important for T cell survival 
and proliferation). Panel B summarises negative signals mediated by 
CD 152 (also known as CTLA-4, in direct competition with CD28) 
and CD95 (which induces the apoptotic pathway). Both these signals 
are involved in direct inhibition of the response and are part of the 
negative feedback mechanism resulting from T cell activation.
The common names for these molecules are highlighted in bold and 
will be used in this thesis.
Binding of CD80 or CD86 to CD28 is considered to be the main co-stimulatory 
signal necessary to induce the activation of naive T cells (or signal 2) co-jointly with 
MHC/peptide interaction (or signal 1). Once a naive T cell becomes activated, it 
expresses a number of proteins that contribute to the co-stimulatory signal and help 
drive proliferation (clonal expansion) and differentiation.
The CTLA-4 (CD 152) sequence closely resembles that of CD28, consequently, 
the CTLA-4 molecule directly competes for binding to the same ligands (CD80 and 
CD86) as CD28. It is expressed on activated, but not on resting T lymphocytes.
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However, CTLA-4 binds these ligands 20 times more avidly and delivers a negative co­
signal to T cells. This signal renders naive T cells less sensitive to stimulation and limits 
the proliferation of activated T cells. This was demonstrated using a blocking CD 152 
antibody, which was able to induce an enhancement of T cell responses in vitro and in 
vivo (Kearney et al, 1995; Leach et al, 1996). Furthermore, CD152 deficient mice were 
shown to develop a fatal lymphoproliferative disorder, confirming the importance of the 
T cell inhibitory feedback by CTLA-4 (Tivol et al, 1995; Waterhouse et al, 1996).
CD40L (CD 154) is also absent from the surface of resting lymphocytes, but is 
rapidly expressed upon activation, mostly on CD4+ T cells but also on a small number 
of CD8+ T cells and binds CD40. When expressed on CD4+ T cells, it binds to CD40 on 
B cells and is required for secondary immune responses and germinal centre formation. 
When expressed on CD8+ T cells, it induces antigen presenting cells to up-regulate 
CD80 and CD86, therefore stimulating further activation and/or proliferation (van 
Kooten and Banchereau, 1996; Grass and Dower, 1995; Foy et al, 1996). Confirming 
the points described previously, the study of CD40L deficient mice revealed an 
increased susceptibility to parasite infections, therefore pointing to deficiencies in both 
cell mediated and humoral immunity (Noelle et al, 1996).
Similarly to CTLA-4 and CD40L, 4-IBB (CD 137) is also absent from the 
surface of resting T cells, but is induced upon activation in T cells, B cells and 
monocytes (Schwarz et al, 1995; Pollok et al, 1994). Its ligand, 4-1BBL, is expressed 
on activated B and T lymphocytes and co-stimulates T cell growth; reciprocally, 4-IBB 
binding 4-1BBL co-stimulates B cells (Hurtado et al, 1995; DeBenedette et al, 1995).
Although the pathway that leads to programmed cell death by cross-linking 
CD95 (Fas) is not usually thought of as being part of a negative co-stimulatory system, 
it can be considered as such in this context, similarly to the range of molecules 
described previously, as it also plays a role in the feed-back mechanism induced after T 
cell activation. CD95 is expressed by activated lymphocytes, monocytes, neutrophils 
and fibroblasts, while its ligand (CD95L or FasL) is mainly restricted to T lymphocytes 
and is induced rapidly upon activation (Nagata and Golstein, 1995; Takahashi et al,
1994). Programmed cell death of activated lymphocytes occurs mainly through CD95 
and is thought to be crucial to the maintenance of peripheral tolerance (Lynch et al, 
1995; Takayama et al, 1995). Fas mediated killing also represents part of the T cell 
effector functions and will be described in further detail below.
Therefore it is becoming clear that signalling through the TCR may depend on 
the summation of all these potential co-stimulatory effects along with the affinity and
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kinetics of the TCR-MHC/peptide interaction. These may collectively contribute to the 
rise, inhibition or elimination of T cell immune responses.
T cell activation
CD 69 is not expressed on resting peripheral blood lymphocytes but appears within 2 hr 
of TCR triggering, and therefore is one of the first molecules that becomes up-regulated 
at the cell surface. Consequently, detection of up-regulated CD69 expression constitutes 
an early marker of T cell activation (Hamann et al, 1993).
T cell effector function
Upon activation and differentiation into effector cells, the T cell subsets, CD4+ or CD8+, 
differ in their effector functions. The main aim of CD8+ T cells is to induce cytotoxicity 
and eliminate pathogen infected cells. Processes involved in CD8+ T cell effector 
function and cytotoxicity are detailed in the following paragraph.
Cytokine secretion
The activation of CD8+ T cells or cytotoxic T lymphocytes (CTLs) induces the 
synthesis of soluble secretory molecules named cytokines. The two main effector 
cytokines that have roles in T cell clonal expansion and effector function are 
interleukin-2 (IL2) and interferon-y (IFN-y) respectively.
Upon T cell activation, IL2 synthesis is induced along with the a  chain of the 
IL2 receptor (CD25). The IL2 receptor has different binding affinities to its ligand 
depending on the formation of a low affinity receptor composed only of the P and y 
chains or of the high affinity receptor composed of a , p and y chains. This system 
allows resting T cells to respond to high concentrations of IL2 whereas activated T cells 
can respond to low concentrations of IL2. IL2 binding triggers T cell progression 
through the cell cycle and can induce exponential divisions leading to clonal expansion 
and differentiation (Minami et al, 1993). As T cell activation induces both IL2 and IL2 
receptor, it is therefore possible for a T cell to stimulate its own proliferation and 
differentiation as well as that of other activated T cells. Additionally, co-stimulation 
through CD28 is needed for the long-term induction of the IL2 receptor (Cerdan et al,
1995).
The release of IFN-y by T cells upon T cell activation is one of the first effector 
functions that will have an effect on pathogen destruction. The main function of IFN-y 
resides in macrophage and NK cell activation (Munoz-Femandez et al, 1992; Stout and
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Bottomly, 1989). It is also implicated in the induction of MHC class I and MHC class II 
molecules expression as well as the enhancement the antigen presenting functions 
mainly of professional antigen presenting cells such as DCs and macrophages as well as 
other somatic cells (Steimle et al, 1994). It achieves this by acting on proteasomes, 
which are IFN-y inducible and the LMP components are altered to provide faster and 
more efficient processing of antigens. For both MHC class I and MHC class II the 
increased export to the cell surface means that more peptides will be presented. Both 
these effects will therefore contribute to and improve immune reactivity towards the 
pathogen infected cell.
Cell mediated cytotoxicity
Fas (CD95) mediated killing is the first mechanism of T cell mediated cytotoxicity and 
is also referred to as programmed cell death. The binding of tumour necrosis factor 
(TNF) family receptor CD95L to CD95 induces the trimerisation of the latter and 
regroups the cytoplasmic tails of CD95 that include motifs known as death domains 
(Nagata et al, 1996). These will bind to the death domain protein with the cystein 
protease caspase, which in turn activates a cascade of caspase enzymes and leads to the 
cleavage of the cytoplasmic inactive caspase-activable DNase (CAD). CAD then 
translocates to the nucleus where it cleaves DNA and leads to cell death (Henkart, 1994; 
Squier and Cohen, 1994; Medana et al, 2000).
The second and main mechanism by which cytotoxic T cells mediate killing is 
through the calcium dependent release of lytic granules upon recognition of an 
MHC/peptide antigenic target (for a review, see Trapani et al, 1999). These granules 
comprise two types of molecules with different effects, but that act synergistically to 
achieve effective cell killing. The first of these enzymes is a pore forming protein 
named perforin that inserts into the target cell where it breaks the integrity of the 
cytoplasmic membrane by forming pores (Griffiths and Argon, 1995). This allows for 
the cellular uptake of a second family of enzymes contained in the granules named 
granzymes. The principal component consists of the serine protease granzyme B (GrB), 
which acts by activating a caspase enzyme that leads to DNA degradation and apoptosis 
as described above.
Phagocytes then target cells undergoing apoptosis and ingest them, therefore 
eliminating both pathogen and infected cell.
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ap T cell differentiation and cytokine requirements
As described earlier, naive CD8+ T lymphocytes leave the thymus for the peripheral 
blood circulation. Their differentiation pathway can be separated into different stages 
that are characterised by the expression of cell surface marker and include: 1) naive, 
before the T cell has encountered its specific MHC/peptide ligand; 2) memory/effector, 
after encountering specific antigen and migrating into the lymph nodes therefore 
acquiring a more rapid response potential to secondary exposure, clonal proliferative 
potential as well as effector functions; 3) effector/memory when the cell acquires 
cytotoxic properties while retaining a proliferative potential; 4) effector when the cell is 
mainly destined for cytotoxic function and has limited or no replicative potential. Each 
of these differentiation stages, or compartments, are represented on Figure 1.4, together 
with the cell surface molecule expression, or markers, and secretory molecules 
characteristic of each stage. These markers include the common leucocyte antigen 
CD45, the co-stimulatory molecules CD27 and CD28 as well as the lymph node homing 
factor CCR7. The relative levels of effector and cytotoxic molecules released by these 
cells are also specific to the T cell differentiation stage (for a review, see van Baarle et 
al, 2002).
Naive or unprimed T cells express CD45RA, the co-stimulatory molecules 
CD28 and CD27, as well as CCR7, but have no effector function. Upon TCR activation, 
CD45RA expression is lost and CD45RO expression becomes up regulated. The 
CD45RO+ CD27+ CD28+ memory T cells have very high proliferative potential, but 
only become cytotoxic after re-stimulation (Hamann et al, 1997). After successful 
homing to the lymph nodes, CCR7 become down-regulated and further stimulation will 
then induce CD28 down-regulation (Azuma et al, 1993). Additionally, after prolonged 
stimulation, CD27 co-stimulation will induce further T cell proliferation, induce 
cytotoxic functions, enhance cytokine production, which will result in the irreversible 
down regulation of the receptor from the cell surface (Gruss and Dower, 1995; Kobata 
et al, 1995). The effector and cytotoxic pathways are now fully up regulated and 
effector T cell will re-express CD45RA. Although these cells were thought to be 
terminal effectors that would be irreversibly committed to this compartment and die 
after encountering antigen, there has been in vitro evidence that they may revert to less 
differentiated CD45RO+ cells.
30
Chapter I
A Memory/effector effector
effectornaive memory
O ©QO © o
B
CD45 RA+ CD45 RO+ CD45 RA+
 ►  ►  ►
CD28+ CD28-
 ►  ►
CD27+ CD27-
CCR7+ ^ ____________________ CCR7
c iFN r IFNy^
GrB- . GrB+ GrB++
w
Perforin' Perforin+/'
w
Perforin++
w
w w w
Figure 1.4 aP T lymphocyte differentiation: cell surface expression 
and effector function
Activation of CD8+ ap T lymphocytes results in differentiation of the 
cell characteristics and changes in the expression of cell surface 
molecules and the secretion of effector molecules. The general stages 
of CD8+ T cell differentiation pathway is summarised in Panel A.
Panel B summarises the expression pattern of markers of activation 
such as CD45, CD28 and CD27. CCR7 is a lymph node homing 
receptor that is expressed on cells that localise to lymph node (termed 
“central memory” in the case of memory cells). Panel C summarises 
the effector and cytotoxic properties of these cells. Collectively, the 
expression of these marker expression patterns and effector functions 
are characteristic of the level of differentiation of CD8+ a  p T 
lymphocytes and referred to as their phenotype.
The survival, proliferation and differentiation of CTLs are also dependent on the 
specific cytokine signals that these cells receive. As T cells can remain in peripheral 
blood for prolonged periods of time without specific antigen stimulation, the effect of 
cytokines explains their capacity to survive.
The four main cytokines involved in T cell survival and/or proliferation are IL7, 
IL12, IL2 and IL15 (reviewed in Marrack et al, 2000). IL7 is mainly implicated in T 
cell survival and in the cycling of resting T cells. Together with IL12, which is thought 
to provide a third activatory signal to naive T cells, it contributes to the priming and
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long-term maintenance of antigen specific T cells (Curtsinger et al, 1999; Schmidt and 
Mescher, 2002; Montagna et al, 2001). Although IL2, as described previously, induces 
very potent clonal expansion of activated T cells, it is also involved in the feedback 
mechanism controlling the immune response and is therefore capable of activating the 
programmed cell death pathway. Similarly, IL15, which can bind to the same p and y 
receptor chains as IL2 but has its own specific IL15 receptor a  chain, is also capable of 
inducing clonal expansion but cannot induce the programmed cell death pathway 
(Waldmann et al, 2001). There is also recent evidence that the presence of IL15 in the 
generation of primary and memory antigen specific T cells can increase the overall 
magnitude of the response (Schluns et al, 2002).
Haematopoietic stem cell transplantation
Haematopoietic stem cell transplantation (SCT) constitutes the standard and only 
curative treatment option for many haematological malignancies. These are clonal 
diseases thought to derive from a single cell in the marrow or peripheral lymphoid 
tissue that has undergone one or several genetic alterations that leads to malignant 
transformation.
The general principal of SCT consists of the destruction of cancer cells by a 
combination of radiation therapy and chemotherapy (or conditioning regimen), followed 
by bone marrow rescue and reconstitution of the immune system achieved by the 
infusion of haematopoietic stem cells from a healthy donor (Figure 1.5). Historically, 
the first trials involving SCT in human patients were based on experimental work in 
murine and canine models and were attempted in the 1950’s by Thomas et al. The 
results from mouse experimental models were the first to report the graft versus tumour 
(or graft versus leukaemia, GvL) effect when leukaemic cells were eradicated mice that 
received allogeneic (not genetically identical), but not syngeneic (genetically identical) 
bone marrow transplantation (Barnes et al, 1956). This suggested that a reaction 
originating from the donor haematopoietic stem cells could kill leukaemic cells in the 
host. However, the first experimental human SCTs were mostly unsuccessful and 
resulted in graft rejection in many cases of allogeneic transplants, but not in the case of 
a SCT transplant from a twin donor (Thomas et al, 1957; Thomas et al, 1959). In the 
latter case, haematological recovery was achieved, but the disease relapsed after a few 
months. The first case of a patient surviving after an allogeneic bone marrow 
transplantation was described in a leukaemia patient in whom chimerism, tolerance and 
anti-leukaemic effect were induced. Although the transplant was successful, the patient
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later succumbed to the complications of graft versus host disease (GvHD). SCT settings 
have much improved since these early trials and involve several aspects of treatment 
and preventive strategies to better the patient’s outcome by ameliorating the treatment 
while controlling the potential side effects and complications.
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Figure 1.5 Haematopoietic stem cell transplantation (HSCT)
HSCT is the only curative treatment option for haematological 
malignancies. This involves eliminating an individual’s 
haematopoietic stem cells and all the cells that derive from them, 
including the hemopoietic, lymphoid, histiocytic and myeloid 
lineages. This is achieved by a process referred to as conditioning, 
which usually comprises both radiation and chemo therapies. The 
depleted stem cells are replaced by stem cells from another individual 
(or allo-SCT) which are infused in the patients’ blood and will 
relocate to the bone marrow to reconstitute the haematopoietic system. 
A proportion of these cells will be CD4+ or CD8+ T lymphocytes 
directly present in the graft or reconstituted when haematopoiesis is 
re-established after transplant. These cell subsets mediate cellular 
adaptive immune responses. After HSCT, some of these responses can 
be beneficial and sought after in conducting the transplant procedure 
such as the response to pathogen infected cells and the graft versus 
leukaemia (GvL or anti-tumour effect); however, some are deleterious 
and can be life threatening such as graft versus host disease (GvHD, 
an immune response mediated by the grafted cells and directed 
towards host tissues).
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Conditioning regimen
The conditioning regimens aim at ablating the patient’s bone marrow and malignant 
cells, as well as at suppressing the host immune response so that the graft is not 
rejected. Total body irradiation (TBI) is often used because it has good 
immunosuppressive properties and acts against a wide variety of malignancies by 
causing damage to dividing cells and result in tumour cytoreduction. Irradiation 
treatment is usually applied in combination with chemotherapy with alkylating agents 
such as cyclophophamide, busulphan or melphalan and/or with antimetabolite agents 
such as methotrexate and mycophenolate mofetil, this mainly covers the agents used for 
the treatment of patients included in this PhD thesis. The common feature of the 
alkylating agents is that, upon cell entry, their alkyl groups bind to electrophilic sites in 
DNA and other biologically active molecules. As a result, the dominant bifunctional 
alkylation of DNA effect results in cross-links between DNA strands, which prevents 
subsequent DNA replication. By contrast, antimetabolite agents are analogues of 
biochemical substrates that lead to cell death (methotrexate) or are involved in the 
negative feedback of T cell activation (mycophenolate mofetil). Therefore both 
alkylating agents and antimetabolites can be combined to contribute to tumour 
cytoreduction and induce graft tolerance.
However, the most efficient way to obtain graft tolerance is to match the 
histocompatibility antigens of the patients with these of a stem cell donor.
Histocompatibility matching
In the absence of immunosuppressive drugs, the transplantation of haematopoietic stem 
cells from a healthy donor to a patient will result in an immune reaction that will lead to 
graft rejection. This reactivity results from differences in cell surface determinants such 
as MHC molecules or histocompatibility antigens (HLA for human cells). Non self 
MHC molecules are recognised by 1 to 10% of T cells. They are involved in the 
rejection of organs and tissues where very large numbers of T cells are specifically 
reactive to non self or alloreactive. This can occur through cross-reactivity of the TCR, 
which normally recognises foreign peptides displayed by self MHC molecules as 
described earlier. Two distinct mechanisms can be involved in such cross-reactive 
recognition: 1) peptide binding to non-self MHC may strongly interact with the TCR, 
which represents peptide dominant binding (Speir et al> 1998); 2) binding may occur 
directly between the TCR and distinctive features of a non self MHC molecule, which 
represents MHC dominant binding (Smith et al, 1997).
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As only 35% of the patients who need SCT have HLA matched siblings, bone 
marrow donor registries have been set up, such as the Anthony Nolan Trust, and have 
compiled a resource of HLA typed volunteer donors willing to donate a fraction of their 
bone marrow or peripheral blood stem cells to patients who require stem cell 
transplants. Matching of patients and donors to achieve as complete as possible 
compatibility is achieved by matching the HLA types of the individuals concerned. The 
typing for major HLA molecules is usually performed at the molecular level, which 
includes typing for HLA class I genes: HLA-A, HLA-B and HLA-C; as well as for 
HLA class II genes: HLA-DR, HLA-DQ and HLA-DP prior to donor selection. 
However, even in allogeneic transplants where major HLA molecules have been fully 
matched, the donor infused lymphocytes can become sensitised to cell surface antigens 
that are expressed on patients’ cells but are not a part of the MHC system. These are 
referred to as minor histocompatibility antigens and can mediate a graft versus host 
effect, one of the main complications after SCT.
Immune reconstitution
As described previously, the conditioning inherent to the SCT procedures leads to a 
stage of temporary but profound immunodeficiency. In particular, the early stage after 
SCT is characterised by a period of severe neutropenia when over 90% of the infections 
occurring in this phase are due to bacteria, to the reactivation of latent herpesviruses or 
to Candida spp invasion. At later stages after SCT, sibling and unrelated allotransplant 
recipients differ in their susceptibility to viral and fungal infections, as the intensity of 
the treatment they receive differs to prevent graft rejection and graft versus host disease 
(GvHD) as detailed below. At these stages, the pathogens that cause the most mortality 
are cytomegalovirus (CMV) and Aspergillus fumigatus, as both these are pathogens 
which are normally controlled by the host cellular immune response, this might suggest 
a deficiency in T cell reconstitution as well as neutropenia. The impaired T cell 
reconstitution after SCT is likely due in part to the limitations in the numbers of 
progenitor cell clones that were infused and survived and engrafted, as well as to 
alterations in the host microenvironment that disrupts normal T cell development. The 
factors that are known to contribute to alterations of the thymic environment as well as 
that of other lymphoid tissues include the age of the recipient, the toxicity of the 
conditioning regimen as well as the occurrence of GvHD (Mackall et al, 1997; 
Weinberg et al, 2001).
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Complications after SCT
Treatment induced toxicity, a prolonged period of immunodeficiency and an extended 
recovery progress are at the origin of most post SCT complications. The major 
complications that are encountered include graft failure, GvHD, host defence defects 
and disease relapse. Graft failure resulting from the rejection of donor haematopoietic 
cells by host T cells that have survived the conditioning regimen can be prevented by in 
vivo T cell depletion of the host (Bunjes et al, 1987; Keman et al, 1987) This process 
will be described in further detail below.
Graft versus host disease
The term GvHD describes the direction of the immunological damage caused by the 
introduction of immunologically competent cells in a immunoincompetent host. This 
phenomenon was recognised in SCT patients and also in immunodeficient children who 
were transplanted with allogeneic bone marrow (Lum et al, 1985). Its incidence and 
degree of severity correlates with the degree of HLA diversity between patient and 
donor (Lum et al, 1986), additionally, severe extended GvHD is associated with poor 
survival. It can be divided into two related syndromes, acute GvHD, which usually 
occurs within 30 days after SCT, and chronic GvHD, which occurs later than 100 days 
after SCT.
Acute GvHD is triggered by rapid and massive cytokine production or “cytokine 
storm” generated through T cell activation induced by genetic disparity between patient 
and donor, and as a direct consequence of the conditioning regimen toxicity (Ferrara et 
al, 1995). This perturbation of the cytokine network is considered to lead to a final 
common pathway involving macrophages and NK cells activated by T cell derived 
cytokines and resulting in organ damage involving the skin, liver and gastro-intestinal 
tract (reviewed in Antin and Ferrara, 1992 and Klingebiel and Schlegel, 1998). This 
response was characterised by the presence of CD4+ T cells capable of producing IL2 
and IFN-y (or T helper 1), generally accompanied by a modest CD8+ T lymphocyte 
infiltrate (Rus et al, 1995; Fowler et al, 1994; Szebeni et al, 1994). By contrast, chronic 
GvHD can either be interpreted as a late phase of acute GvHD or as a distinct disease 
with autoimmune features such as thymic atrophy, loss of thymal epithelial secretory 
function and lymphocyte depletion. Although multiple organs and organ systems may 
also be impaired, the skin and mucous membrane are the main targets of chronic GvHD. 
Furthermore, GvHD (both acute and chronic) is known to have deleterious effects on 
immune functions and cause profound lymphoid hypoplasia, B cell defects and damage
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to the thymic stroma, which will result in impaired T cell development (Baker et al, 
1997; Weinberg et al, 2001).
Prevention and treatment of GvHD
In early SCT studies, GvHD occurred in over half of the patients, even if they were 
HLA matched (Storb et al, 1977). The concept of GvHD prophylaxis resides in the fact 
that pharmacological immunosuppression induced at the time of SCT and for up to 
several months thereafter can prevent or blunt the initiation of T cell recognition and the 
proliferative response that is characteristic of GvHD. Significant improvements were 
made with the use of T cell depletion or inhibition of T cell activation for GvHD 
prophylaxis and treatment. This approach has successfully reduced the frequency and 
severity of GvHD. The agents that are used in the clinic to this effect include 
pharmacological drugs and immunological drugs (reviewed in Ho and Soiffer, 2001). 
The drugs used for GvHD prophylaxis are usually first administered at or near the time 
of transplant and include methotrexate, cyclosporin A and corticosteroids (Nash et al, 
1992; Ramsay et al, 1982; Shorb et al, 1989; Chao et al, 1993).
Methotrexate is an analogue of aminopterin (folic acid antagonist) that acts by 
binding to dihydrofolate reductase (DHFR), subsequently preventing its ability to 
reduce oxidised folates to tetrahydrofolate, blocking further purine or thymidylate 
synthesis and therefore leading to cell death. Cyclosporin A represents a more targeted 
immunosuppressive function as it inhibits the production of IL2 without inducing cell 
death. It acts by binding to cyclophilin to form a complex that will inhibit the 
serine/threonine phosphatase activity of the calcium-activated calcineurin, which 
transmits signal from the TCR to the nucleus. Significant improvements in GvHD 
prevention have been made by combining methotrexate therapy with Cyclosporin A 
therapy (Storb et al, 1986; Ratanatharathom et al, 1998). Similarly to methotrexate, 
corticosteroids have a wide activity range; they are a family of drugs that are related to 
steroids, which are naturally produced in the adrenal cortex, such as cortisone. They are 
powerful anti-inflammatory drugs that alter the transcription of many genes. The most 
widely used corticosteroid drugs prednisone and prednisolone are synthetic analogues 
of cortisol and can kill lymphocytes and especially developing thymocytes by inducing 
apoptotic cell death. They also affect cytokine production and cell trafficking. 
Cyclosporin A and corticosteroids are the main drugs that are used for the treatment of 
GvHD as well as prophylaxis, with the possibility of escalating the dose of steroids used 
to combat the symptoms.
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The immunological drugs that are used for GvHD prophylaxis are usually 
administered prior to or at the time of transplant and include anti thymocyte globulin 
(ATG, also named anti lymphocyte or anti leucocyte globulin) and the more recently 
available Campath-IH. Although they are normally used to prevent GvHD by depleting 
alloreactive donor T cells, Campath-IH can also be used in vivo to prevent graft 
rejection by depleting patient T cells (Hale et al, 2000; Kottaridis et al, 2000). Both 
ATG and Campath-IH are immunoglobulins and act in a similar fashion by binding to 
their target on the cell surface and inducing their killing by phagocytosis or antibody 
dependent cytotoxicity. ATG is normally prepared by immunising horses with human 
lymphocytes, whereas Campath-IH is a recombinant humanised monoclonal antibody 
to CD52. CD52, a very short glycoprotein bearing a GPI anchor, is expressed at high 
levels (5x10s molecules per cell) on lymphocytes and monocytes, but not on plasma 
cells, platelets or erythrocytes. It is a very good target for complement mediated lysis 
and antibody mediated cellular cytotoxicity and CD52 monoclonal antibodies have 
proven to be very effective in vivo for lymphocyte depletion (Xia et al, 1993). Campath- 
IH monoclonal antibodies have been engineered with a human immunoglobulin 
framework and constant regions, but with the complementary determining regions of a 
rat monoclonal antibody to CD52 to reduce their immunogenicity (Jones et al, 1986; 
Riechmann et al, 1988).
The use of these drugs, and of these included in the conditioning regimen, which 
induce the suppression of the immune response allows the emergence of opportunistic 
pathogens to become manifest in these patients. As a result, the second most common 
complication after SCT is due to the (3 herpesvirus cytomegalovirus (CMV or human 
herpes virus 5, HHV-5).
Cytomegalovirus infection
In healthy individuals, CMV seroprevalence is widespread with up to 80% of 
individuals in the developed world having detectable levels of antibody to CMV by 
early adulthood (Nelson et al, 1997). Approximately 10% of primary infections in 
immunocompetent individuals are associated with a mononucleosis like syndrome, 
while the vast majority of primary infections remain clinically silent and mainly located 
to the salivary glands. At the end of the primary infection, CMV will have established 
lifelong latency mainly in peripheral blood mononuclear cells (monocytes) but can also 
infect and become latent in haematopoietic progenitor cells (Hahn et al, 1998; 
Mendelson et al, 1996; Sindre et al, 1996; Taylor-Wiedeman et al, 1994). Thus CMV is
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able to reactivate when immune control fails and may affect haematopoietic 
reconstitution after SCT.
By contrast to the situation in healthy individuals, CMV infection is the major 
cause of interstitial pneumonitis in immunocompromised individuals such as patients 
after SCT or organ transplant, but also in individuals suffering from congenital 
immunodeficiencies or acquired immunodeficiency syndrome (AIDS) (Weiner et al, 
1986; Ho, 1994; Yow and Demmler, 1992; Spector et al, 1996). CMV interstitial 
pneumonitis after SCT is related to CMV infection in 50% of incidences while the other 
cases include bacterial involvement or conditioning cytotoxicity (Inoue et al, 1990). 
CMV infection can also affect numerous other organs.
The most important risk factor predisposing to CMV infection is the 
seropositivity of the SCT recipient prior to transplant (Meyers et al, 1986; Miller et al, 
1986), indicating that the majority of CMV infections after SCT are due to the 
reactivation of latent virus. Additionally, CMV related disease in SCT recipients is 
controlled primarily by a CD8+ T cell response, however sustained viral control is also 
dependent on the presence of CD4+ T cells (Li et al, 1994; Walter et al, 1995; Podlech 
et al, 1998). Indeed, the infection risk increases in recipients of unrelated donor 
allografts, as well as in recipients suffering from acute or chronic GvHD (Ochs et al, 
1995; Hoyle and Goldman, 1994).
The understanding and assessment of the immune response to CMV and the 
application of adequate CMV prevention and treatment are therefore crucial to the 
improvement of patient care after SCT. All components of the virion can potentially be 
involved in immune targeting and are described below.
CMV structure and replication cycle
CMV viruses are species specific, and all the different human CMV strains are 95% 
homologous. The CMV virion has a complex structure composed of a large DNA core 
packed into an icosahedral capsid (Figure 1.6, panel A). CMV has the largest genome of 
all herpesviruses that can be arranged into 4 different isomers of Long (L) and short (S) 
genomic strands that are separated by repeat sequences (Mocarski, 1996). The capsid is 
surrounded by an amorphous layer of tegument, which includes at least 20 different 
proteins. The most abundant proteins are pp65 (UL83) or lower matrix protein 
representing 95% of the tegument and ppl50 (UL32) which is also the largest (Landini 
et al, 1987). The protein pp28 is also a tegument phosphoprotein involved in virus 
maturation but is not as abundant as pp65 or ppl50. The tegument is enclosed in a cell
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derived lipid membrane envelope containing virus encoded glycoproteins important for 
the attachment of the virus particle to the host cell. Once CMV has entered a cell by 
fusion of its outer membrane with the cellular membrane, the capsid then translocates to 
the nucleus where CMV DNA replicates. CMV DNA replicates in nuclear domains 
named viral replication centres where the first genes are transcribed; they are referred to 
as immediate early (IE, Figure 1.6, panel B). The first translated CMV protein is IE-1 
(UL123); it accumulates in the nucleus of infected cells where it can regulate viral gene 
expression, and constitutes an autoregulatory transactivator in primary or latent infected 
cells. This is followed by the transcription of early (E), then of late (L) genes. The 
newly replicated DNA is then inserted in preformed capsids in the nucleus. The 
particles then acquire some of their tegument proteins and primary envelope by budding 
from the nuclear membrane. The nucleocapsids are directed to the Golgi complex in the 
cytoplasm where they acquire additional tegument proteins and their mature envelope. 
The first stage of virion release is thought to occur through budding into Golgi derived 
vesicles that travel to the plasma membrane, where the virions are released by 
exocytosis (reviewed in Sanchez and Spector, 2002; Mettenleiter, 2002). The entire 
replication cycle of CMV is complete within 48 hr of infection in healthy individuals.
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Figure 1.6 Cytomegalovirus (CMV) virion structure and 
replication
Panel A: Schematic representation of CMV virion structure. The most abundant 
CMV components form part of the tegument component separating the phospholipid 
envelope (membrane) from the nucleocapsid enclosing the CMV genome. The 
tegument phosphoprotein 65 (pp65) is the most abundant CMV component 
accounting for 95% of tegument proteins. Panel B: CMV replication cycle. After 
attachment to the cell surface, and penetration of the virus in the target cell, full 
replication usually occurs within 48 hr from infection. The viral capsid and genome 
locate to the cell nucleus where viral genes are transcribed. They are referred to as 
upper long (UL) or upper short (US) genes depending on their situation on either 
side of a separating DNA repeat sequence in the CMV genome. Viral gene 
expression can be divided into 3 consecutive stages: 1) immediate early (IE) stage, 
which includes the expression of transcriptional transactivators that initiate and 
stimulates CMV replication such as IE-1 (also named phosphoprotein 72 or pp72); 
2) early (E) stage, which includes the expression of proteins involved in DNA 
replication and metabolism; 3) late stage (L), which includes the expression of 
structural and packaging proteins.
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Immune response to CMV
The adaptive immune response to productive CMV infection was shown to include both 
T and B cell responses. Additionally, the reconstitution of CMV specific immune 
responses in the context of SCT has been shown to be protective against CMV disease 
(Reusser et al, 1991; Li et al, 1994; Ljungman et al, 1993; Krause et al, 1997). 
Antibodies to the surface glycoprotein B (gB) can be detected in the blood of all CMV 
seropositive individuals, and this can be exploited to test if individuals have previously 
contracted CMV infection. The main targets for CTL reactivity were shown to be 
diverse depending on individuals and are mainly directed against pp65, IE-1 and gB, 
and their relative prevalence was assessed and established the immunodominance of 
pp65 (Wills et al, 1996; Boppana and Britt, 1996; Borysiewicz et al, 1988; Alp et al, 
1991; Utz et al, 1992; Guylai et al, 2000). Further details about the CTL immune 
response to CMV will be discussed in Chapter III.
Diagnosis of CMV infection
The diagnosis of CMV infection is based on the detection of virus or viral particles in 
peripheral blood or biological samples. This used to be tested using viral culture 
techniques, which were very lengthy and somewhat unreliable. Diagnostic tools have 
now progressed significantly and involve the quantitative detection of CMV proteins 
such as pp65 by quantitative immunoassay (antigenemia) or the detection of CMV 
DNA by quantitative polymerase chain reaction (reviewed in Boeckh and Boivin, 
1998).
CMV prevention and treatment
As described previously, the most powerful risk factor for the development of CMV 
infection after SCT is the seropositivity (CMV+) of the recipient. Therefore the first 
means of CMV prevention after SCT to reduce the chances of CMV infection are to 
select a CMV seronegative (CMV) donor whenever possible and to use CMV' blood 
products in early post transplant care. This guarantees that CMV infections in CMV' 
recipients are extremely rare and if they did occur would result from a primary 
infection. CMV infection or reactivation has extremely serious consequences after SCT 
and can lead to interstitial pneumonitis, which once established is often non responsive 
to treatment and may result in fatal disease.
Efficient control of CMV replication can be achieved by prophylactic and 
treatment strategies with antiviral drugs such as Aciclovir, Valaciclovir, Ganciclovir
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and Foscamet. However, despite their good efficiency, none of these drugs are virus 
specific and are mainly virustatic so do not eliminate the virus entirely. Consequently, 
CMV infection will inevitably re-occur until adequate immune protection is recovered 
after SCT.
Aciclovir and Valaciclovir are mainly used for CMV prophylaxis after SCT and 
have moderate effect on CMV replication, but are most effective against herpes simplex 
virus (HSV) and varicella Zoster virus (VZV). They are acyclic analogues of 
deoxyguanosine; upon entry in the cell, they are phosphorylated to the monophosphate 
form by the CMV encoded UL97 protein kinase, then cellular kinases will 
phosphorylate these compounds to the di- then triphosphate forms (Matthews and 
Boehme, 1988; Littler et al, 1992; Sullivan et al, 1992). Active triphosphate drugs then 
act as a competitive inhibitor for the viral DNA polymerase. In the case of normal DNA 
elongation, the nucleoside hydroxyl group allows the binding for the next incoming 
nucleoside in the elongating DNA chain by the formation of a second phosphate ester 
bond. Aciclovir or Valaciclovir triphosphate lack the 3’ hydroxyl group necessary to 
form this 3’-5’ phosphodiester bond, their incorporation in DNA leads to termination 
(Perry et al, 1996; Smiley and Murray, 1996). Both these drugs have low levels of 
toxicity and in particular are not toxic to haematopoietic stem cells and do not show any 
immunosuppressive effect (Steele et al, 1980; McGuffin et al, 1980).
Ganciclovir (Gan) is also a deoxyguanosine analogue that contains a 
hydroxylmethyl group, which causes its improved antiviral activity compared to 
Aciclovir or Valaciclovir, but this also increases its cellular toxicity substantially. 
However Gan is very effective against a broad range of herpesviruses, and its 
mechanism of action is similar to that described previously. As with Aciclovir or 
Valaciclovir it is a competitive inhibitor of viral DNA polymerase, but the main 
difference resides in the fact that it is not an obligatory DNA chain terminator due to the 
presence of a 3’hydroxyl group. This fact is also the principal explanation for the high 
level of toxicity of Gan towards uninfected cells. Gan treatment needs to be monitored 
closely as Gan was shown to be mutagenic, carcinogenic, but particularly was also 
shown to inhibit the growth of haematopoietic stem cells as well as causing severe 
neutropenia. The latter two side effects of Gan treatment have very serious 
consequences in the SCT setting, and granulocyte colony stimulating factor (G-CSF) is 
used in combination with Gan therapy to increase the number of neutrophils (Salzberger 
et al, 1997; Randolph-Habecker et al, 2002). Additionally, Gan was shown to limit 
CMV specific immune reconstitution after SCT (Li et al, 1994).
4 4
Chapter I
By contrast with the drugs described previously, Foscamet (Fos) or trisodium 
phosphonoformate is a non nucleoside molecule with a pyrophosphate group. It acts as 
a non competitive inhibitor of the viral polymerase without the requirement for cellular 
activation by cellular enzymes, by blocking pyrophosphate exchange from dinucleotide 
triphosphates (dNTPs) rather that incorporating in DNA. It is very efficient at 
suppressing CMV replication, but its major side effect is nephrotoxicity. Fos can be 
used as a second line therapy for patients who develop dose limiting neutropenia on 
Gan treatment, and is also often used in combination with Gan to prevent both viral 
replication and the emergence of resistant viral strains as both drugs have different 
antiviral activities. Dual resistance to both Gan and Fos occurs rarely.
These drugs can be used in different strategies after SCT: 1) prophylaxis, which 
involves treating CMV+ patients from the time of SCT and continuously for the next 
100 days either with low toxicity drugs or with Gan (Meyers et al, 1988; Prentice et al, 
1997; Goodrich et al, 1991; Winston et al, 1993); 2) pre-emptive therapy administered 
at the time of detected antigenemia or viraemia with Gan or a combination of Gan with 
Fos (Boeckh et al, 1996; Hebart et al, 1996; Einsele et al, 1995). Both strategies have 
been shown to reduce the occurrence of CMV infection after SCT and to improve 
patient survival. However, the major toxicities associated with the use of these drugs 
gives rise to major concern that warrants the research for new drugs with lower toxicity 
and/or a different mode of action, and for non pharmacological treatment alternatives 
such as immunotherapy.
Association of CMV with GvHD
The association of CMV with GvHD has been well documented in patients after SCT 
(Miller et al, 1986; Einsele et al, 1988). This remains the case despite the continuous 
improvement in prophylaxis and treatment of both conditions. No causative effect has 
yet been demonstrated for the effect that both CMV infection and GvHD have on each 
other, and this will be the subject of further discussion in Chapter IV.
Cytomegalovirus immune evasion
CMV has devised multilevel strategies to influence its cellular host in order to avoid 
recognition. The first level of strategies used by CMV involve blocking the MHC 
class I processing and presentation pathway so that no viral peptides can be presented to 
T cells at the cell surface. Four separate CMV genes are responsible for this effect: 
1) US3 is expressed at the beginning of CMV infection and impairs the transport of
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MHC Class I molecules, inducing their accumulation in the ER (Ahn et al, 1996; Jones 
et al, 1996); 2) US2 and US 11 are glycoproteins highly expressed at around 24 hours 
after infection, which misdirect MHC class I molecules by rapid translocation from the 
ER into the cytosol where they are degraded by proteasomes (Wiertz et al, 1996); 3) 
US6 is expressed at its highest levels from 48 to 96 hours after infection when the other 
genes interfering with the MHC Class I pathway are almost silent. It prevents peptide 
loading of MHC class I molecules by inhibiting TAP mediated peptide translocation 
into the ER (Lehner et al, 1997; Ahn et al, 1997; Hengel et al, 1997). As a consequence 
of the activity of these CMV genes, more than 90% of MHC class I molecules are 
absent from the cell surface of in vitro cultured fibroblasts at 24 to 48 Hr after infection. 
This constitutes the main known mechanisms for CTL evasion. However, this dramatic 
down-regulation of MHC class I by CMV would trigger recognition by natural killer 
(NK) cells, which react to the lack of self MHC molecules. Consequently, the second 
group of CMV immune evasion strategies is aimed at avoiding NK cell recognition and 
killing. This involves the production of MHC class I homologue molecules such as UL 
18 and UL16, which provide a decoy function at the cell surface and engage killer 
inhibitory receptors (KIRs) on the surface of NK cells (Cosman et al, 2001). A second 
process also involves the up-regulation of the cell surface expression of the non- 
classical HLA-E molecule, which interacts with the NKG2-A receptor on the NK cell 
surface. The surface expression of HLA-E depends on the binding from conserved 
peptides derived from classical MHC class I molecules. However the same peptide is 
present in the leader sequence of the CMV glycoprotein UL40, thus inducing HLA-E 
expression and avoiding NK recognition. Finally, the last known strategy used by CMV 
to escape immune recognition involves the synthesis of an IL10 analogue, which 
inhibits macrophage activation, antigen presentation and CD4+ T helper 1 polarisation 
(Rennick et al, 1997; Kotenko et al, 2000). The combined effect of these escape 
mechanisms makes CMV a successful pathogen and may in part contribute to the 
establishment of viral latency.
Disease relapse
In some instances when the conditioning regimen has not been sufficiently intense to 
eradicate the leukaemic clone, malignant proliferation reoccurs. There are then only two 
treatment options available to combat the returning malignancy, which are to perform a 
second SCT, or alternatively to attempt to rescue the patient by enhancing donor
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derived immune responses against the leukaemia or graft versus leukaemia effect 
(GvL).
Graft versus leukaemia
The GvL effect was first described in a murine model of bone marrow transplantation, 
when mice that received an allogeneic bone marrow transplant showed eradication of 
the leukaemic cells, while these that received a syngeneic transplant did not (Barnes et 
al, 1956). Further evidence that alloreactive immune responses were mediated by T 
cells and were responsible for an anti-tumour effect came from their links with firstly 
the effects of GvHD, which was associated with a lesser risk of disease relapse, and 
secondly with T cell depletion, which was associated with a higher risk of relapse 
(Weiden et al, 1981; Goldman et al, 1988). Therefore donor lymphocyte infusions (DLI) 
were introduced in an effort to enhance the anti-tumour effect and to restore disease 
remission. DLI was shown to be most effective in chronic myeloid leukaemia (CML) 
patients with impressive results of up to 75% of patients experiencing disease 
remission, but also caused significant GvHD associated with the procedure (Kolb et al, 
1995; MacKinnon et al, 1995). The infused donor lymphocytes are thought to bind to 
surface antigens expressed on leukaemic cells in the context of MHC molecules and be 
specific for polymorphic minor histocompatibility antigens (or polymorphic self 
antigens presented to T cells), leukaemia associated antigens (or over-expressed 
leukaemia restricted self antigens presented to T cells) and leukaemia specific antigens. 
As CML is a well described disease resulting from a chromosomal translocation, it is 
constitute a good model disease for the study of the GvL effect.
Chronic myeloid leukaemia
The critical transformation events in CML affect immature CD34+ progenitor cells and 
lead to uncontrolled proliferation. CML is characterised by the presence of a small 
abnormal chromosome named Philadelphia chromosome that results from the 
translocation between chromosome 9 and chromosome 22 (or t 9;22 (q34,qll)); 
(Nowell and Hungerford, 1960), see Figure 1.7.
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Figure 1.7 Molecular etiology of Chronic Myeloid Leukaemia 
(CML): Philadelphia chromosome
Schematic representation of the Philadelphia chromosome resulting 
from the reciprocal translocation of the BCR gene situated on the long 
arm of chromosome 22 and displacing it to chromosome 9 (t 9;22), 
thus inserting within the ABL gene encoding for a tyrosine kinase.
The majority of breakpoints in BCR and ABL are conserved and 
occur either after exon 2 or exon 3 of the BCR gene to join onto exon 
2 of the ABL gene, creating the translocation types referred to as b2a2 
and b3a2 respectively. The resulting chromosome 22 can be detected 
by karyotype analysis as one of the chromosome arms is shorter than 
the other. The BCR/ABL fusion gene is transcribed and translated as a 
functional protein characterised by the insertion of a new lysine (K) 
amino-acid at the intersection between the BCR and ABL gene 
segments.
Over 95% of the patients with CML have the Philadelphia chromosome and the 
leukaemic cells express a BCR/ABL chimeric protein (de Klein et al, 1982; Bartram et 
al, 1983). The translocation between chromosomes 9 and 22 juxtaposes variable 
sequences from the BCR gene (or breakpoint cluster region) on chromosome 22 to the 
majority of the c-ABL gene on chromosome 9. The breakpoints in the BCR gene occur 
either between BCR exons 2 (b2) and 3 (b3) or alternatively between exons 3 and 4. 
Therefore in the mature BCR/ABL mRNA, either b2 or b3 is spliced to exon 2 from c- 
ABL (a2), which results in two alternative chimeric p210 BCR/ABL proteins 
comprising either the b2a2 or the b3a2 junction with tyrosine kinase activity (see Figure 
1.7). The b3a2 resulting protein is further characterised by the insertion of a lysine 
residue (K) at the junction segment. This would therefore make it a good candidate for the 
investigation
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leukaemic specific T cell responses. Comparisons between the p210 BCR/ABL protein 
and its normal homologue the p i45 c-ABL kinase have indicated that this translocation 
modifies the intracellular location of the kinase from the nucleus to the cytoplasmic 
fraction (Oda et al, 1995; Yaish et al, 1988). Additionally, the fact that the BCR/ABL 
gene is under the control of the BCR gene promoter induces an up to 40 times over­
expression of the protein in leukaemic cells compared to the expression level of c-ABL 
in normal cells. In experimental settings, the over-expression of c-ABL results in cell 
cycle arrest and induction of apoptosis whereas the expression of BCR/ABL promotes 
continuous cell cycle progression and diminution of sensitivity to apoptosis inducing 
agents (Melo, 1996; Wen et al, 1996). The expression of BCR/ABL is central to 
malignant transformation in CML, but the expression of p210 BCR/ABL appears to 
have a relatively subtle effect on the growth of haematopoietic progenitor cells and does 
not block their ability to differentiate (Fialkow et al, 1977). Consequently, CML 
manifests itself by an initial chronic phase of 2 to 5 years leading to a “blast crisis” 
phase, which resembles an acute leukaemia and is generally fatal.
Approximately 40% of CML patients express the b3a2 BCR/ABL protein, while 
another 40% express the b2a2 protein and the remaining 20% can express both 
transcripts. Both these transcripts are unique to BCR/ABL positive cells and therefore 
may constitute good candidates for the investigation of tumour specific T cell responses 
and the possible use of tumour specific immunotherapy for CML and/or relapse after 
SCT for CML.
Treatment o f CML
The classical treatment for CML consists of conventional chemotherapy (described 
previously in the context of SCT conditioning regimen) to eradicate the malignant clone 
and induce cytogenetic remission, followed either by SCT or, for those patients who are 
not candidates for SCT, by long term treatment with IFN-a or Imatinib Mesylate 
(STI571, Gleevec or Glivec). Both these drugs can also be used to attempt to induce 
remission of disease relapse after SCT. IFN-a was until recently the standard treatment 
for newly diagnosed patients or for patients who were not candidates for SCT; it can 
induce remission in 70 to 80% of cases. The mechanism of action of IFN-a in CML 
remains unclear, but there is in vitro evidence of anti proliferative effects, of 
normalisation of adhesion and of improved cellular interaction of BCR/ABL positive 
cells. Additionally, there is some evidence for the promotion of NK and T cell cytotoxic 
activity by IFN-a, which is thought to contribute to the GvL effect. Imatinib Mesylate
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was introduced recently as a selective inhibitor of the BCR/ABL tyrosine kinase. This 
synthetic molecule is an ATP mimetic that prevents the phosphorylation of the 
BCR/ABL substrate and can induce long term cytogenetic remission very efficiently 
with no major side effects (this is currently estimated at over two years after the 
induction of treatment, as this drug was only widely available for use in recent years), in 
contrast with IFN-a, which is not well tolerated (Druker et aL 1996). However, 
Imatinib Mesylate as a single agent does not appear to constitute a cure for CML, 
individuals do relapse and it is possible that overall it may eventually cease to be 
effective and disease will return, bringing the next treatment options of SCT and/or 
alternative immunotherapy.
Adoptive immunotherapy
Since the initial description of adoptive immunotherapy to describe haematopoietic SCT 
(Mathe et al, 1965), the term has evolved to include all immunological cells or 
molecules that can be used to that effect. Most of these strategies will require the prior 
definition of the antigen specific target (Boon et al, 1997). Many strategies are currently 
being tested and are aimed at enhancing anti-tumour or anti-viral immune responses. 
They include: 1) passive immunotherapy with monoclonal antibodies such as anti­
idiotype monoclonal antibody for the treatment of B cell lymphoma (Miller et al, 1982) 
or cytokines such as IFN-y, IFN-a and IL2 (described in further detail previously); 2) 
active immunotherapy with the enhancement of cellular cytotoxic responses, which can 
be achieved at different levels. The first possibility is to adoptively transfer antigen 
presenting cells (DCs) previously exposed to the antigen, or to transfer in vitro 
expanded antigen specific T lymphocytes (Szmania et al, 2000; Peggs et al, 2001). The 
second possibility consists in enhancing (or suppressing) the response of DCs or T cells 
to antigens. The strategies that have been used to this effect involve the optimisation of 
the interaction between the antigenic peptide, the antigen presenting cell and the T cell. 
For example, this could include the alteration of an antigenic peptide to increase its 
affinity to MHC molecules therefore enhancing T cell activation (Parkhurst et al, 1996). 
It could also involve the use or enhancement of co-stimulation, which was described 
previously and will be examined in Chapter V.
In the case of possible active immunotherapy approaches for CML, leukaemia 
reactive T cells can be selected and transferred into patients in order to induce 
cytogenetic remission (Falkenburg et al> 1999). As described previously, the targets for 
such responses in CML can be of different origin. Firstly, GvL can be induced by the
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presence of minor histocompatibility antigen specific T cells (Horowitz et al, 1990). In 
some cases, antigens such as HA-1 and HA-2 show restricted expression to 
haematopoietic tissues and donors can show restricted cytotoxicity to cells expressing 
these minor antigens; however they are also linked to GvHD (Mutis et al, 1999). 
Therefore minor histocompatibility antigens may not constitute ideal targets for 
adoptive T cell immunotherapy. Other potential targets, which may have a reduced 
likelihood of inducing GvHD together with a GvL effect, include tumour associated 
antigens. These targets are proteins that are over-expressed in CML such as: 1) 
proteinase 3, a primary granule exclusively expressed in myeloid cells (Smit et al,
1997); 2) Wilm’s tumour antigen, a zinc finger polypeptide that plays a key role in the 
pathogenesis of Wilm’s tumour and is over-expressed in CML; 3) in contrast, 
telomerase, an enzyme which expression correlates with telomere lengthening is 
downregulated in accelerated phase CML, which is thought to contribute to genetic 
instability (Brammendorf et al, 2000; Engelhardt et al, 2000). Peptides derived from all 
these cited tumour associated proteins have been shown to be presented in the context 
of HLA molecules and to elicit antigen specific cytotoxic responses in vitro or to be 
associated with good prognosis (Molldrem et al, 1997; Molldrem et al, 2000; Minev et 
al, 2000;). Although these tumour reactive cells are associated with GvL activity, they 
are not solely restricted to the targeting of the tumour and may contribute to the GvHD 
effect. The only type of antigen that would generate a GvL response only would be 
restricted to a tumour specific antigen. In the case of CML, the b3a2 and the b2a2 
proteins are good candidates for inducing anti-CML T cell responses and will be 
discussed in more detail in Chapter HI.
The study of the physiological role of antigens specific immune responses in the 
context of immunodeficiency induced by the stem cell transplantation procedure has 
become possible with the labelling of antigen specific T cells.
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Labelling antigen specific T cells
Direct labelling of antigen specific T cells has only become a possibility in recent years. 
This was due to the facts that unlike immunoglobulins, TCRs only exists as membrane 
bound molecules and have a very low affinity for their ligand (Braden et al, 1998; 
Garcia et al, 1996). Additionally, the labelling of antigen specific T cells relies on the 
prior knowledge of their MHC/peptide ligand combination, and in particular of the 
antigen specific peptide sequence. Without that knowledge or the possibility to use 
soluble MHC/peptide complexes to label antigen specific T cells because of the too low 
affinity for the TCR, the only methods available for the detection and quantification of 
antigen specific T cell responses relied on the use of transgenic T cells in mouse models 
of primary infection and on monitoring of the responses by detecting MHC/peptide 
restricted a  or (3 chains at the T cell surface or by limiting dilution assay (MacDonald 
et al, 1993; Walker et al, 1995; Selin et al, 1996). The only barrier to labelling antigen 
specific T cells with soluble MHC molecules resided in their low affinity for the TCR. 
However the binding efficiency of a TCR to its ligand was shown to depend on both 
binding affinity, but also on binding avidity of the complexes, which included the 
relative density of the TCR at the cell surface (Schodin et al, 1996; Sykulev et al,
1998). The possibility of increasing MHC density to enhance the binding to TCRs and 
to extend the binding time was exploited by Altman et al, who resorted to multimerise 
MHC/peptide complexes by linking them to tetravalent streptavidin (Altman et al,
1996). This tetravalent complex or tetramer has enough avidity to form a stable bound 
with TCR molecules on the T cell surface, and labelled T cell can then be visualised by 
flow cytometry. The synthesis of such complexes will be described in further detail in 
Chapter II. This technique, in contrast with these described previously, allows the direct 
ex vivo visualisation and analysis of antigen specific T cells on a single cell basis. 
Alternative techniques to label antigen specific T cells have been developed since the 
discovery of MHC/peptide tetramers and include: 1) dimer MHCiimmunoglobulin 
fusion proteins where the MHC molecule is fused to the variable region of the antibody 
heavy chain and the peptide of choice can be loaded onto the complexes prior to 
labelling. Similarly to MHC/peptide tetramer reagents, they possess increased avidity 
for the TCR, which allows their stable interaction (Fisher et al, 2002); 2) a cytokine 
capture method, which relies on prior labelling of the T cells with a cytokine capture 
antibody, IFN-y for example, and stimulation with the specific antigen followed by 
secondary labelling of the antigen captured at the cell surface for fluorescent detection
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or purification (Brosterhus et al, 1999). Although this technique allows the visualisation 
or purification of effector T cells only, it presents the advantage of being available to 
assess CD8 or CD4 restricted T cell responses.
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Aims of this thesis
Haematological malignancies and their only available treatment SCT are at the origin of 
profound modifications of the immune system and its protective capabilities. Therefore 
an adequate recovery of immune functions is crucial to optimising patient survival after 
therapeutic intervention. Some of the most important factors implicated in decreased 
survival after SCT are due to disease relapse, viral infection or GvHD. As described in 
the previous chapter, it was shown that cytotoxic T lymphocytes play an important role 
in the elimination of virus infected cells, or cells expressing modified self-proteins (in 
some cases tumour cells).
Consequently, the aim of this PhD thesis was to develop an accurate method for 
the detection and quantification of the relevant antigen specific T cell responses to key 
components of the anti-tumour and anti-viral responses following SCT. The binding 
specificity of the T cell receptor for its HLA/peptide combination can be exploited to 
this end and required testing in order to confirm their potential usefulness for the 
immune response being studied.
This would allow one to use this information and these reagents in the 
investigation of a patient’s progress throughout the course of their SCT, monitoring 
both their antigen specific immune reconstitution, and to correlate this information with 
the presence or absence of stimuli such as viral infections, as well as with the effects of 
various treatment procedures inherent in the SCT settings. This might be beneficial to 
the improvement of treatment protocols currently in place for elimination of tumour 
cells or virus-infected cells in this setting.
The accurate detection and monitoring of antigen specific T cell responses 
would in turn provide both targets and means of achieving efficient T cell adoptive 
transfer, by specific selection and/or activation of antigen specific T cells that might 
mediate the increase of antigen specific immune responses. This might provide new 
options for the treatment of tumours and/or infections in combination with previously 
established treatment strategies or on a sole basis in the context of haematological 
malignancies.
The findings from this PhD thesis and the techniques applied might be used in 
much wider areas where the detection, monitoring, and/or modulation of antigen 
specific immune responses would be useful. The materials and methods implicated in 
this project will be described in the following chapter.
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Chapter II 
Materials and Methods
Introduction
The materials and methods described in this chapter have been used to perform the 
work mentioned throughout all chapters.
Buffers and Solutions
All buffers and solutions mentioned in the following paragraphs have been prepared 
with chemicals purchased from BDH or Sigma. They were all filtered and autoclaved or 
filtered sterilised through 0.2 pm hydrophilic polypropylene filters (Gelman 
Laboratory) placed over re-usable bottle top filter units (Nalgene™).
Patient groups: recruitment and protocols
Recruitment and ethical approval
The patients recruited to participate in these projects were selected for the two distinct 
studies that were approved by local ethical approval authorities at the Royal Free 
Hospital (RFH), London and at the Liverpool Royal Infirmary where the studies were 
performed. All patients were undergoing treatment for haematological malignancies and 
had been typed for all major classical HLA antigens (HLA-A, HLA-B, HLA-C, HLA- 
DR, HLA-DQ and HLA-DP) at the allelic level and performed by molecular techniques 
if they were candidates for stem cell transplantation. HLA typing was performed at the 
serological level if the patients were on Imatinib Mesylate (STI571 or Gleevec) therapy 
for chronic myeloid leukaemia (CML). The majority of all typing assays for both 
patient cohorts were performed at the Histocompatibility Laboratories at the Anthony 
Nolan Trust (ANT).
The patients testing positive for any of the HLA antigens relevant to our studies, 
HLA-A*0201 and HLA-A*0301 were selected as potential candidates. Additionally, in 
a second stage of the CML study, a few patients of unknown HLA type were also 
selected. This was done prospectively as the study was extended to cover other HLA
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types of interest which were being studied by a fellow student, Sylvie Rusakiewicz, and 
also to collect samples that could act as irrelevant HLA type controls for our 
experiments. On receipt of the first blood sample, these patients were typed 
serologically for their HLA phenotype so that they could be categorised to the test or 
control groups.
A member of the medical team from the treating hospital approached each 
patient and informed him/her of the objective of the study they could enter. Each patient 
was given an information sheet summarising the objectives (see Appendix) and the 
protocol of the study that they could choose to enter into. Subsequently, the patients 
who decided to enter the study were asked to sign a consent form (see Appendix).
Blood collection protocols
In parallel with blood being taken for other routine tests required to assess patient 
progress at clinic visits, an additional peripheral sample of 20 ml was drawn; therefore 
participating in these studies did not require any additional venupuncture for the 
volunteers. The blood samples obtained from Crowley Ward at the RFH were drawn 
into tubes containing 20 \±\ of Heparin (Monoparin (1000 U/ml), CP Pharmaceuticals) 
to prevent coagulation and were collected on the same day so that they could be 
processed as promptly as possible.
The blood samples obtained from the Liverpool Royal Infirmary were drawn 
into tubes containing 20 ml of transport medium to which an equal volume of blood 
was added. Briefly, sterile Falcon tubes (50 ml, BD) were filled with 20 ml of transport 
medium composed of sterile filtered RPMI 1640 cell culture medium supplemented 
with tri-sodium citrate (at a final concentration of 3.3% (w/v)) and P-mercaptoethanol 
(at a final concentration of 5 |iM). They were sent to Dr Richard Clark, our collaborator 
at the Liverpool Royal Infirmary, and were used to collect and dispatch peripheral 
blood samples that were sent by overnight mail delivery service so that they could be 
processed on the following day at the Anthony Nolan Research Institute (ANRI).
Control blood samples
Blood samples from healthy laboratory personnel from the ANRI and the RFH 
department of haematology were obtained. All samples were typed for the major HLA 
antigens at the allelic level by molecular techniques at the ANRI. Fourteen individuals 
were selected to provide control samples for the CMV study and had the following 
characteristics: 8 were HLA-A*0201 positive and CMV seropositive; 5 were HLA-
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A*0201 positive and CMV seronegative; and one was HLA-A*0201 negative (HLA- 
A*30/HLA-A*31) and CMV seropositive.
Patients’ characteristics 
CMV study
CMV serostatus
Previous human Cytomegalovirus (CMV) infection is characterised by the presence of 
specific immunoglobulins (Ig) in the serum. A recent infection can be confirmed by the 
detection of both IgM and IgG subtypes; an older infection is characterised by the 
presence of the IgG subtype only.
All patients recruited into the CMV study and their respective donors were 
assessed for a previous CMV infection (Table II. 1). Also, all of our healthy volunteers 
recruited in the laboratory were also tested for their CMV serostatus.
This was performed in the Histocompatibility Laboratories at the ANT, using 
the Bioelisa CMV IgG kit (Biokit) to test heat inactivated serum (this is necessary to 
avoid false positive results). Briefly, the test consisted of adding diluted sera specimen 
to inactivated CMV antigen coated on a 96-well plate (U 96 Maxisorb immunoplate, 
Nunc). If there were antibodies present in the sample tested, they bound to the antigen 
coated wells and, after washing, remained in the well while the rest of the sample was 
discarded. An enzyme labelled antibody to human IgG (rabbit anti-human IgG coupled 
to peroxidase) was then added. This bound to any CMV antigen/CMV IgG complex 
formed in the previous step. After another washing step to eliminate any excess or 
unbound material, the enzyme substrate solution (citrate-acetate buffer containing 
hydrogen peroxide) containing a chromogen (3,3’-5,5’-Tetramethylbenzidine dissolved 
in dimethylsulphoxide) was added. A blue colour developed if the sample tested 
contains CMV IgG (0.25-2.5 IU/ml). The blue colour was converted to yellow upon 
addition of sulphuric acid, which stopped the reaction and the optical density of the 
sample was measured at 450 nm. The intensity of the colour was proportional to the 
amount of CMV IgG in the tested samples and gives a qualitative result, as compared 
with negative, low positive and highly positive controls.
Sample collection and consultation of clinical data
PBMC samples were obtained from Crowley Ward at the RFH, and routine 
haematology clinical data was consulted with the help of research nurse Sarah Grace.
57
Chapter II
This included general patient information, cell counts determined at the same time as 
the samples that were analysed for our studies so that the absolute number of HLA- 
peptide tetramer cells could be calculated after staining. The qualitative 
cytomegalovirus polymerase chain reaction results from the RFH Department of 
Virology were also obtained.
Patients’ characteristics
Twenty-five HLA-A*0201 positive patients treated for haematological malignancies by 
bone marrow or peripheral blood SCT in 1999 and 2001 at the RFH were enrolled in 
the study after they gave informed consent. Patient details as well as the patient and 
donor CMV serology are summarised in Table II. 1. Conditioning prior to transplant for 
those 25 patients consisted of total body irradiation (n=18), cyclophosphamide (n=21), 
melphalan (n=4), busulphan (n=l) with additional fludarabine (n=15) and in vivo 
Campath-IH (10 or 20 mg for 5 days, n=14). Twelve patients received a T cell depleted 
graft (10 or 20 mg of Campath-IH with the graft also referred to as “in the bag”) and no 
or low post-transplant immunosuppression. Patient 8 received a graft prepared by CD34 
selection (an indirect form of T cell depletion). Thirteen patients received a non-T cell 
depleted graft and post-transplant immunosuppression with Cyclosporin A and a short 
course of Methotrexate. The patients were monitored weekly from engraftment if they 
had sufficient cell counts until discharged from hospital and at each visit to the clinic 
thereafter. From the start of conditioning until engraftment, patients received high dose 
intravenous Aciclovir (800 mg, 4 times a day), to suppress CMV (as well as Varicella 
Zoster and Herpes Simplex viruses). Aciclovir or Valcyclovir were also used 
preventively between courses of intravenous Ganciclovir (5 mg/kg of body weight 
twice a day) ± Foscamet (90 mg/kg of body weight) antiviral therapy and continued 
until at least five months post-transplant. CMV DNAemia was assessed by routine 
qualitative PCR performed at the RFH Department of Virology (Royal Free Hospital). 
Treatment with Ganciclovir ± Foscamet was initiated after two consecutive positive 
tests for ten days or until the CMV PCR amplification became negative. Simultaneously 
to Ganciclovir, patients were given GCSF to counteract the myelo-suppressive effect of 
Ganciclovir. Patients were followed closely for acute or chronic graft versus host 
disease (GvHD) and treated accordingly with Methylprednisolone (the dose and length 
of treatment varied depending on the severity of the symptoms and the response to 
treatment) and or horse anti-leucocyte globulin (ALG).
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Age, Patient/Donor
Sex years CMV serology Stem cell source
Conditioning
regimend
1
2
3
4
5
6
7
8
9
10 
11 
12
13
14
15
16
17
18
19
20 
21 
22
23
24
25
AML
ALL
AML
AML
AA
NHL
BJM
AML
ALL
AA
AML
NHL
CML
CML
WAS
ALL
CML
MDS
AML
AML
CML
AML
CLL
AML
AML
M
F
M
M
M
M
F
M
F
M
F
F
M
F
M
M
M
M
M
F
F
M
M
M
M
39
40
32 
54
30
48
49 
35 
18 
21 
15 
54
33 
25 
18 
11  
25 
23
40
31
41 
12 
51 
18 
37
+ / -
+/+
+7+
+/+
+/+
H+
t/+
m
+ / -
SIB PB (F)
SIB PB
MM UD BM (F) 
SIB PB 
SIB PB 
SIB PB 
SIB PB (MM) 
SIB PB 
UD BM 
SIB PB
SIB BM (MM) 
SIB PB 
SIB PB 
UD BM (MM) 
UD PB 
SIB PB 
UD BM 
SIB BM (F)
UD BM (MM,F) 
UD PB (M)
SIB PB 
UD BM 
UD PB (F)
UD PB (MM) 
SIB PB
Cyclo and TBI 
Melph and TBI 
Flu, Cyclo and TBI 
Cyclo and TBI 
Flu and Cyclo 
Cyclo and TBI 
Cyclo and TBI 
Cyclo and TBI 
Flu, Cyclo and TBI 
Flu and Cyclo 
Flu, Cyclo and TBI 
Melph and Flu 
Cyclo and TBI 
Flu, Cyclo and TBI 
Melph and Flu 
Cyclo and TBI 
Flu and Cyclo 
Flu, Bus and Cyclo 
Flu, Cyclo and TBI 
Flu, Cyclo and TBI 
Flu, Cyclo and TBI 
Flu, Cyclo and TBI 
Flu and Melph 
Flu, Cyclo and TBI 
Flu, Cyclo and TBI
Campath-IH 
in v/vo/in graft
~ No7HT
None
GvHD
prophylaxis6
Follow-up,
days
None
^^No
None
No/ H
None
f f
H N o
^^No
None
BS
None
■  ''No
None
MTX and CsA 
CsA
MTX and CsA 
MTX and CsA 
MTX and CsA 
None 
None 
None
Myco and MTX 
MTX and CsA 
MTX
MTX and CsA 
CsA
MTX and CsA 
MTX and CsA 
None
MTX and CsA
CsA
CsA
None
CsA
MTX
CsA
None
495
188-603
102-419
447
531
553
221
793
682
506
376
111
66
125
149
131
244
97
227
242
39
180
119
134
93
Table II.1 CMV study: Patient’s characteristics
This table summarises the characteristics o f  all 25 H LA-A*02 positive patients recruited to the cytomegalovirus study.
‘  ALL, acute lymphoblastic leukaemia; AM L, acute m yeloid leukaemia; BJM, Bence Jones M yeloma; NHL, non-Hodgkin’s lymphoma; A A , aplastic anaemia; CML, chronic m yeloid leukaemia; 
W AS, Wiskott-Aldrich syndrome; M DS, m yelodysplastic syndrome; CLL, chronic lymphocytic leukaemia.
b + , cytom egalovirus serology positive; -, cytom egalovirus serology negative. c SIB, sibling; UD, unrelated donor; PB, peripheral blood; BM , bone marrow; M M, HLA mismatched; (F), sex  
mismatched transplant o f  a male patient with a fem ale d o n o r .d C yclo, cyclophospham ide; Flu, fludarabine; M elph, Melphalan; Bus, busulphan; TBI, total body irradiation. * C sA , cyclosporin A; 
GvH D, graft-versus-host disease; M TX, methotrexate; M yco, mycophenalate. Patients could be segregated into different groups depending on their CM V serostatus: seronegative patient and donor; 
seropositive patient and donor, blue; seropositive patient and seronegative donor, yellow ; seronegative patient and seropositive donor, pink. They could a lso be separated into different levels o f  
Campath-IH T cell depletion (TCD): no TCD; in vivo TCD: red; TCD graft: green. The highest level o f  T cell depletion being highlighted with both red and green.
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CML study 
CML transcript type
Transcript specific polymerase chain reaction (PCR) was performed after extraction of 
mRNA from PBMC samples at the treating hospital and was verified prior to sample 
collection. The majority of the patients in this study were chosen for their possession of 
the BCR/ABL b3a2 transcript, which was the fusion protein transcript targeted in our 
study.
Patients’ characteristics
The clinical details of the patients and controls included in the CML tetramer study are 
summarised in Table H.2, together with HLA assignments and BCR/ABL transcript 
type. The first four patients entered in the tetramer staining study (patients 26 to 29) 
expressed the b3a2 transcript. The controls were one BCR/ABL negative AML patient 
(patient 30) and a patient with severe aplastic anaemia (Patient 5, as a control for 
tetramer staining, see also Table II. 1), three patients were positive for HLA-A*0301 
and two patients were negative for HLA-A*0301. The remaining patients, patients 31 to 
37 were also tested by tetramer staining, whereas patients 38 to 45 (as well as control 
patient 6, see Table II. 1), were enrolled in the second phase of the study, where PBMC 
samples were collected and cryopreserved and the HLA type was only determined 
retrospectively. They were used in specific stimulation experiments described in 
Chapter V.
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Patient HLA type Disease1* Transcript type Treatment
26 A2/A3 CML b3a2 SCT1
27 A3/A29 CML b3a2 SCT
28 A2/A3 CML b3a2 SCT
29 A1/A31 CML b3a2 SCT
30 A2/A2 AML NAC SCT
5 A2/A30 AA NA SCT
31 A1/A3 CML b2a2 SCT
32 A1/A3 CML b3a2 autograft + IFNoce
33 A3/A3 CML b3a2 SCT + DLf
34 A2/A68 CML b3a2 SCT
35 A3/A11 CML b3a2 SCT
36 A3/A29 CML b3a2 SCT + IFNa
37 A1/A2 CML not available SCT + DLI
38 A2/A3 CML b3a2 IMg
39 A3/A3 CML b3a2 SCT
40 A3/Un CML b3a2 SCT
41 A2/A3 CML b3a2 IM
42 A2/A3 CML b3a2 IM
43 A3/Un CML b3a2 SCT
44 A3/A11 CML b3a2 IM
45 A1/A3 CML b3a2 IM
6 A2/A3 NHL NA SCT
Table 11.2 CML patient characteristics
This table summarises the characteristics of all patients entered in 
the tetramer CML study. Serological HLA types are reported, as 
well as the type of disease the patients were treated for and the 
BCR/ABL transcript type of their tumour.
a Cytomegalovirus; bCML: chronic myeloid leukaemia, AML: acute 
myeloid leukaemia, AA, aplastic anaemia, NHL, non-Hodgkin 
lymphoma; c NA, not applicable; d stem cell transplantation; e 
interferon-a;f donor leucocyte infusion; 8 Imatinib Mesylate 
(Gleevec or STI 571). A line separates the group of patients studied 
in Chapter III from the group of patients studied in Chapter V.
Cell separation and cell culture
Peripheral Blood Mononuclear Cell (PBMC) separation
PBMCs were isolated from whole blood by density gradient centrifugation. This 
consisted of layering a volume (typically 10 ml) of blood over an equal volume of 
Lymphoprep™ (Axis-Shield) reagent in a sterile Universal tube (Bibby Sterilin), 
followed by centrifugation at 1,000 g for 25 min at room temperature (RT). The 
centrifugation was terminated without braking so as not to disturb the interface cellular 
layer. PBMCs were then recovered from the interface layer and transferred to a fresh 50 
ml Falcon tube (Becton Dickinson) containing a small volume of RPMI 1640 (with L- 
Glutamine, Bio Whittaker) cell culture medium. The tubes were then filled with RPMI
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1640 medium to wash the cells free from remaining cell separation reagent, the tubes 
were then centrifuged at 680 g at RT for 10 min. This last step was repeated, and the 
cell pellets were resuspended in 1 ml of RPMI 1640, counted, and split into two 
fractions: one of approximately 2xl06 cells to be stained directly with HLA tetramers 
and the rest to be cryopreserved for later analysis.
Cell enumeration and viability
Cells were mixed to obtain a homogenous suspension before a 10 pi aliquot was taken. 
This was mixed with an identical volume of 0.4% sterile filtered Trypan Blue dye 
solution (Trypan Blue powder, BDH) in Phosphate Buffer Saline (PBS, 1.7 pM 
KH2P04, 50 mM Na2HP04, 150 mM NaCl, pH7.4) to stain for dead cells. The cell 
suspension was then placed in a counting chamber (Neubaur Chamber, Weber). The 
number of live (translucent) and the number of dead cells (staining blue) were counted 
using a phase contrast microscope (DMLB, Leica) to estimate the concentration and the 
viability of the cells in culture.
Cell Cryopreservation
Cells to be cryopreserved were transferred to a 50 ml Falcon tube (BD), this was then 
filled with RPMI 1640 (with L-Glutamine, Bio Whittaker) warmed at 37°C before 
centrifugation at 680 g for 10 min at RT. The supernatant was discarded and the cells 
were immediately re-suspended in RPMI supplemented with 10% heat inactivated (1 hr 
at 55°C) sterile filtered Foetal Calf Serum (FCS, Serum Supreme from Bio-Whittaker) 
and 15% Dimethylsulphoxide (DMSO). Aliquots of 1 ml at a maximum concentration 
of lOxlO6 cells per ml were then transferred to 1.5 ml cryovials (Cryotube Vials, Nunc) 
and immediately placed in a polystyrene box at -80°C for 24 hrs. The next day, vials 
were placed in a liquid nitrogen tank for long term storage.
All primary human leucocyte samples that were cryopreserved were put back in 
culture for at least 12 hr prior to setting up any assays or stainings to allow for recovery 
of cell surface molecules and cellular function.
Cell culture
Cells were cultured at 37°C in a humidified incubator (IG 150, Jouan) with 5% C 02. If 
the cells were used following a period of cryopreservation, they were first transferred to 
a 50 ml Falcon (BD) tube, and were washed in 50 ml warmed (37°C) RPMI 1640 (with 
L-Glutamine, Bio Whittaker) and centrifuged at 680 g for 10 min at RT. This step was
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repeated to ensure removal of DMSO, then the cells were re-suspended in warm (37°C) 
RPMI 1640 medium supplemented with 10% FCS or human AB serum and placed in 
either sterile tissue culture dish or flask).
Primary Leucocyte culture
Freshly isolated human primary PBMCs were cultured in RPMI 1640 (with 
L-Glutamine, Bio Whittaker) supplemented with 1% (v/v) Penicillin/Streptomycin 
(respectively 10,000 units/ml and 10,000 pg/ml, Bio-Whittaker) to prevent bacterial 
contamination. The medium was also enriched with 10% heat inactivated sterile filtered 
(1 hr at 55°C) human AB serum (Bio-Whittaker). Cells in suspension were dispensed at 
0.5 or 2xl06 cells per ml of supplemented medium in 24 well plates (Falcon, BD). 
Interleukin (IL) 7 and/or IL 15 were also added typically every 3 to 4 days or when 
culture conditions dictated to ensure the survival and growth of lymphocytes. As soon 
as the cultures showed signs of medium exhaustion as shown by a change of pH and 
indicated by a change in the cell culture medium colour, half of the medium was 
renewed.
CMV specific T cell line culture
Following CMV tetramer staining and single cell sorting, Mirjam Heemskerk, a 
collaborator at the Leiden University Medical Center, raised a CMV tetramer specific 
CD8 T cell line. This line was stimulated with antigen specific peptide and was grown 
in Dulbecco’s Modified Eagles Medium DMEM) supplemented with 
penicillin/streptomycin and 10% human AB serum (both from Bio-Whittaker) before 
use in assays.
Immortal cell culture: T2
Unlike primary cells, the T2 cell line results from a fusion between an EBV 
transformed B cell line and a T lymphoma cell line. It is an immortalised cell line 
selected for a lack of HLA class I expression. T2 cells only require a basic cell culture 
medium to proliferate in vitro. For our experiments, they were grown in RPMI 1640 
(with L-Glutamine, Bio Whittaker) supplemented with Penicillin and Streptomycin to 
prevent bacterial infections and with 10% heat inactivated FCS. Typically, they were 
cultured in flasks (15 ml, BD) and grown at a concentration of 0.3 to 0.7xl06 cells/ml of 
medium; medium was renewed when it showed signs of exhaustion. On the day 
preceding an experiment, T2 cells were counted and cultured at 0.5 to 0.6x106 cells/ml 
of fresh medium to ensure maximum cell viability.
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Some cells (2xl06) were cryopreserved to replace cell stocks and as a backup 
vial that could be accessed if there were any results that needed confirmation.
Peptide pulsing of T2 cells
The T2 cell line is HLA-A*0201 positive but TAP (Transporter associated with Antigen 
Processing) deficient; the endogenous HLA-A*0201 molecules can be stabilised by 
using the leader peptide from HLA-A2 and consequently will present folded HLA- 
A*0201 molecules at the T2 cell surface. However these tend to be somewhat unstable 
and only small amounts of refolded HLA/peptide complexes can be detected at the cell 
surface. It is possible to compete out any remaining leader peptide and to stabilise 
empty molecules at the cell surface by pulsing the cells with a higher affinity peptide of 
choice.
Typically for peptide pulsing, T2 cells were cultured at lxlO6 cells/ml of 
medium and were incubated with 10 mg/ml of CMV specific peptide for 3 to 4 hours. 
The peptide excess was then washed off: the cells were transferred to a Falcon tube 
(BD) that was then filled with RPMI 1640 (with L-Glutamine, Bio-Whittaker) warmed 
at 37°C, and the tube was centrifuged at 680 g for 10 min at RT. The supernatant 
containing the excess peptide was discarded and the cells were resuspended in fresh 
supplemented culture medium, ready for use in assays.
Cell labelling
PKH-67 and PKH-26 membrane dyes
The long aliphatic tailed PKH-67 (MINI-67 kit, Sigma) and PKH-26 (MINI-26 kit, 
Sigma) dyes are composed of respectively a green and a red fluorescent molecule that 
can incorporate into the cell membrane lipid layer by selective partitioning.
An aliquot of 2xl07 T2 cells was taken and the cells were washed once with 
RPMI 1640 (with L-Glutamine, Bio-Whittaker) without serum. The cells were 
centrifuged at 680 g for 5 min into a loose pellet. The supernatant was carefully 
aspirated, leaving no more than 25 |il at the bottom of the tube and the pellet was 
resuspended by gentle tapping. First, the cells were resuspended and dyed according to 
the manufacturer’s instructions. The labelling reaction was then stopped by adding an 
equal volume of sterile filtered heat inactivated FCS (Serum Supreme, Bio-Whittaker), 
followed by the addition of an equal volume of medium. The cells were centrifuged at 
680 g for 10 min at RT to remove the excess staining solution, then washed with 
supplemented medium before repeating the centrifugation cycle. The labelled cells were
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then resuspended at lx l06/ml of medium and their fluorescence checked using a 
fluorescence microscope (DMLB, Leica) before use in assays (PKH 67 labelling, 
Figure II. 1). This was used to label the T2 cell population so that it could be 
distinguished from PBMCs by flow cytometry or fluorescence microscopy in killing 
assays using the T2 cells as targets.
■S>„
Figure IL1 PKH 67 labelling of T2 cells
Cell membrane labelling of T2 cells with the green fluorescent 
compound PKH 67 was checked by fluorescence microscopy with a 
DMLB Leica microscope at a forty times magnification. The 
photograph was taken using the WILD MPS 52 Photoautomat 
(Leica).
C y t o k in e s  a n d  p o ly c lo n a l  s t im u la t io n
The following cytokines and stimulator were periodically added to primary leucocyte 
cell cultures:
Interleukin 2
Recombinant human IL 2 (R&D Systems) was used to promote CD8 T cell 
proliferation after antigen specific stimulation. It was used three days after antigenic 
stimulation at a concentration varying between 10 and 50 U/ml depending on the 
experimental setting.
Interleukin 7
Recombinant human IL 7 (R&D Systems) was used to promote lymphocyte survival 
and proliferation and was added at the beginning of the culture, three days after 
antigenic stimulation and at each medium change thereafter at a concentration of 10 
ng/ml of culture medium.
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Interleukin 12
Recombinant human IL 12 (R&D Systems) was used to promote naive T cell priming 
and proliferation. It was added simultaneously to the antigenic stimulation on the first 
day of culture. It was used at a concentration of 50 U/ml of culture medium.
Interleukin 15
Recombinant human IL 15 (First Link Ltd) was used as a potent lymphoid cell growth 
factor. It binds to the IL15 receptor (composed of identical (3 and y  chain sub-units as 
the IL2 receptor, but with a distinct a  chain sub-unit) on the T cell surface and induces 
proliferation. It was used three days after antigenic stimulation and at each medium 
change thereafter at a concentration of 10 ng per ml of culture medium.
Polyclonal stimulation
Purified Phytohemagglutinin (PHA, Abbot Murex) is a non-specific mitogenic stimulus 
that can induce polyclonal T cell mitosis, in a similar way to poly-antigenic stimulation. 
It was used in tissue culture experiments and ELIspot (Enzyme Linked Immuno-spot) 
assays to act as strong promoter of T cell proliferation and activation and to act as a 
positive control. It was used at a concentration of 1 jig/ml of culture medium in parallel 
to antigen stimulation tests and negative controls (no stimulation).
Staining Solution
Freshly isolated PBMCs and cultured cells were tested for T cell receptor specificity by 
staining for with HLA-peptide tetramers and/or for cell surface marker expression by 
staining with fluorescently labelled antibodies. These staining reactions were performed 
in sterile filtered RPMI 1640 medium (with L-Glutamine, Bio-Whittaker) containing 
10% of heat inactivated FCS (Serum Supreme, Bio-Whittaker) and 5 mM Sodium 
Azide (NaN3, BDH) to prevent internalisation of the receptor/antibody complexes.
Fixative solution
Stained cells were resuspended in a small volume (200 fil) of fixative solution 
composed of RPMI 1640 (with L-Glutamine, Bio-Whittaker) and 1% of 
paraformaldehyde (BDH). Although this killed the cells, it ensured that the bound 
antibody and tetrameric molecules would not dissociate from their ligand molecule on 
the cell surface. Samples were analysed by flow cytometry within 24 hours.
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Molecular biology and bacterial cloning 
Purification of Ribonucleic acid (RNA) from cells
Cryopreserved PBMCs from a selected HLA-A*0201 healthy individual and a selected 
HLA-A*0301 healthy individual were cultured briefly overnight before they were used 
for RNA extraction. This was done using the RNeasy mini Kit (Qiagen), using Rnase 
free materials on a cleaned and RNase free bench (RNase Away, Molecular Bio 
Products). The cells (5xl06) were first pelleted and resuspended in RNA Stabilisation 
Reagent, then they were lysed, homogenised, and ethanol was added to provide optimal 
binding conditions. The lysate was then loaded onto the RNeasy silica gel membrane 
contained in the mini column. The RNA bound to the membrane and the contaminants 
passed through the mini column following centrifugation and were washed away with 
buffer. The mini column was then transferred to a new microcentrifuge tube and the 
RNA (~ 2 jig) was eluted in 30 pi of water and recovered after centrifugation.
After extraction, the mRNA concentration was measured by UV 
spectrophotometry (Jenway 6405 UV/visible spectrophotometer) at 260 nm (one optical 
density unit is equivalent to a concentration of 40 mg/ml of single stranded RNA) and 
was used immediately as a template for complementary deoxyribunucleic acid (cDNA) 
synthesis.
Primers design and sequences
Primers were designed to amplify the extracellular portion of the HLA-A*0201 
molecule (bases 73 to 910). The trans-membrane region as well as the intracellular 
portion of the molecule were excluded because they tend to be hydrophobic and would 
have made the solubilisation and refolding of the molecule difficult; moreover, they are 
not needed for the molecule to bind the T cell receptor. Identical primers were used to 
amplify the extracellular portion of the HLA-A*0301 molecule, as there was only one 
base mismatch between the HLA-A*0201 and HLA-A*0301 sequences for each primer 
annealing site (Figure II.2).
The primers were designed to be complementary to bases of the HLA-A*0201 
sequence to amplify in the Polymerase chain Reaction (PCR) and were modified to 
contain specific endonuclease enzyme cleavage sites (highlighted in Table II.3 and 
Figure II.2). The restriction sites were chosen to allow cloning in a protein expression
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vector and encode for the start codon and that were necessary to define the DNA 
reading frame.
PRIMER SEQUENCES: HLA-A*0201 Polymerase Chain Reaction
Forward oligo primer (5’-3’): 23 mers
g c a ^ ^ ^ H g c t c t c a c t c c a t g
■ I  restriction site
Reverse oligo primer (5’-3’): 27 mers 
CTGGGAAGACGGATCCCATCTCAGGGT 
Bam HI restriction site
Table II.3 Primer sequences: HLA-A*0201 Polymerase Chain 
Reaction (PCR)
Summary of oligo-primers length and sequence used to amplify the 
HLA-A*0201 and HLA-A*0301 molecules by PCR. Enzyme 
restriction sites were included in the primer sequence to allow 
cloning in a protein expression vector: Nco I (turquoise) and BamHI 
(yellow). The underlined codon encoded for methionine marking the 
start of transcription (see Figure II.2).
All DNA primers mentioned in this thesis were purchased from Amersham 
Pharmacia Biotech.
6 8
10 20 30 40 50 60 70 80 90 100
* * * * ★ ★ * * * *
M O S H S M R
■ H a m F
A*020101 ATGGCCGTCATGGCGCCCCGAACCCTCGTCCTGCTACTCTCGGGGGCTCTGGCCCTGACCCAGACCTGGGCGGGCTCTCACTCCATGAGGTATTTCTTCA
A*030101 ________________________1________________■
110 120 130 140 150 160 170 180 190 200
* * * * ★ * * * * *
A * 0 2 0 1 0 1 CATCCGTGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCGCAGTGGGCTACGTGGACGACACGCAGTTCGTGCGGTTCGACAGCGACGCCGCGAGCCA
A * 0 3 0 1 0 1
810 820 830 840 850 860 870 880 890 900
★ * * * * * *  *  *  *
T  L  R W E P
HLA-A*0201 (Bam HI) reverse: 3'-TGGGACTCTACCCTAGGC
A*020101 GTGGGCGGCTGTGGTGGTGCCTTCTGGACAGGAGCAGAGATACACCTGCCATGTGCAGCATGAGGGTTTGCCCAAGCCCCTCACCCTGAGATGGGAGCCG
A * 0 3 0 1 0 1 -----G---- |
910 920 930 940 950 960 970 980 990 1000
* * * * *  * it it it -k
3 3  Q
AGAAGGGTC 5'
A*020101 TCTTCCCAGCCCACCATCCCCATCGTGGGCATCATTGCTGGCCTGGTTCTCTTTGGAGCTGTGATCACTGGAGCTGTGGTCGCTGCTGTGATGTGGAGGA
A*030101
Figure II.2 HLA-A*0201 and HLA-A*0301 alignment and PCR primers
HLA-A*0301 was aligned with HLA-A*0201 as a reference using the alignment tool written by James Robinson for the IGMT/HLA database. The cloned 
sequence included residues 73 to 898 from the 1098 residues encoding the HLA-A*0201 molecule. The restriction enzyme sites included in the primers are 
underlined, the forward and reverse primers are highlighted in blue and yellow respectively, and the single mismatches between the two molecules in the primer 
sequences are highlighted in green.
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Synthesis of complementary strand Deoxyribonucleic acid (cDNA)
cDNA was synthesised from template RNA using the Reverse Transcriptase 
Polymerase Chain Reaction enzyme (RT-PCR, with the Moloney Murine Leukaemia 
Virus Reverse Transcriptase or M-MLV-RT enzyme from Promega). This enzyme is an 
RNA-dependent DNA polymerase that was used to synthesise a first strand cDNA from 
a long messenger RNA template, in this case total cellular RNA. A volume of 10 pi (or 
~ 1 fig) of RNA purified with the RNeasy kit from 5xl06 PBMCs was dispensed in a 
sterile RNase free microcentrifuge tube and 0.5 fig of random primers (Promega) per 
mg of mRNA sample were added in a maximum 15 pi final volume. The RNA was 
annealed to the random primers by heating the tube to 70°C for 5 min in a hot block to 
melt the secondary structure within the template. The tube was cooled immediately on 
ice to prevent the secondary structure from reforming and was then spun down briefly 
to collect all of the solution at the bottom of the tube.
The following components were then added in respective order:
M-MLV 5X Reaction Buffer 5 pi
dATP, 10 mM 1.25 pi
dCTP, 10 mM 1.25 pi
dGTP, 10 mM 1.25 pi
dTTP, 10 mM 1.25 pi
rRNasin® Ribonuclease inhibitor 25 units
M-MLV RT 200 units
Nuclease free water 25 pi
Table II.4 Components of the reverse transcriptase reaction
This table summarises all components of the RT-PCR reaction 
needed to obtain cDNA from purified cellular RNA.
The components of the reaction were mixed gently by flicking the tube. The 
tube was then incubated for 60 min at 37°C. The cDNA fragments obtained were used 
immediately as a template in the PCR reaction.
DNA gel electrophoresis
Agarose gels were used to separate DNA fragments of different size; they were 
prepared by mixing 0.8% electrophoresis grade agarose (Gibco BRL) with 50 ml of tris- 
acetic acid-EDTA (TAE: 0.04M Tris acetate, 1 mM EDTA) buffer (see buffer recipes) 
in a glass bottle (Duran) and melted in a microwave oven. The melted agarose was 
cooled down and poured into a sealed gel tray (Bio Rad). A comb was placed to form
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wells, 5 |il of ethidium bromide (10 mg/ml) was added and the gel was left to solidify. 
A gel was placed in a mini SUB™ DNA cell (Bio Rad) that was then filled with TAE 
buffer. The combs were removed to load the DNA samples previously mixed with 2 pi 
of Orange G buffer (0.29% Orange G, 30% glycerol). A well was kept to load 5 pi of 
1Kb Plus DNA Ladder™ diluted in Orange G (0.1 pg final concentration, Gibco BRL), 
then 200 volts were applied for about 40 min to induce DNA migration towards the 
positive electrode. DNA bands were then visualised in the gel under UV light and a 
digital photograph was taken.
Polymerase Chain Reaction (PCR)
Single stranded cDNA was obtained from a HLA-A*0201 and a HLA-A*0301 
individual, it was however necessary to synthesise the second DNA strand to each 
cDNA sample before the PCR reaction could be performed as a double stranded DNA 
template was needed. This was included as a first cycle of amplification of the PCR 
reaction programme, using a low annealing temperature and identical primers to the 
main PCR reaction (for the primers sequences, see Table n.3).
The annealing temperature for both primers in the main PCR amplification was 
determined after the melting temperature (Tm) for each primer was calculated using the 
following formula:
Tm = 61.2 + 0.41 (%age GC) -  500/L
with %age GC being the percentage of guanosine (G) and cytidine (C) 
bases contained in the primer and L being the length of the primer.
The respective Tm calculated for each primer were (67°C) for the forward primer and 
(64°C) for the reverse primer. The lowest Tm was chosen and nine degrees were 
subtracted (as the primers were not an exact match to the sequence we wanted to 
amplify) to obtain the annealing temperature; therefore the final annealing temperature 
used in the reaction was 55°C.
The PCR reaction was performed using a higher quality DNA polymerase 
enzyme (Platinum Taq DNA polymerase, Invitrogen) as previous attempts with a 
regular DNA polymerase had resulted in coding errors that were detected by sequencing 
of the positive recombinant clones that had been selected. The following components 
were mixed in a sterile PCR tube:
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Platinum DNA polymerase 10X buffer with 1.5 mM MgCl2 10 pi
DNTP mix, 10 mM each 1 pi
Forward primer (6 pmol/pl) 5 pi
Reverse primer (6 pmol/pl) 5 pi
Platinum DNA polymerase 0.5 pi
cDNA template 1 pi
Nuclease free water to a final volume of 100 pi
Table n.5 Components of polymerase chain reaction
This table summarises all components of the PCR reaction needed to 
obtain amplified double stranded DNA from cDNA.
The reaction tubes, including HLA-A*0201, HLA-A*0301 and a negative 
control were then placed in a PCR machine (Primus, MWG-Biotech). The following 
programme was then applied:
Duration Temperature (°C) Effect
5 min 95 Denaturation
f 1 min 94 Denaturation
5 cycles i  1 min 46 Low specificity annealing
1 min 72 extension
r 1 min 94 Denaturation
30 cycles -j 1 min 55 annealing
 ^1 min 72 extension
10 min 72 Final extension
Table n.6 Polymerase chain reaction reaction
This table summarises all steps of the PCR reaction programme used 
to amplify double stranded HLA-A*0201 and HLA-A*0301 DNA.
A 20 pi sample of amplified DNA fragment was tested by gel electrophoresis to 
determine if the reaction had been successful and if the amplification was specific and 
produced a fragment of the expected size (Figure H.3).
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1 2 3 4 5
Size 
(bp)
-  3,000
-  1,600 
-  1,000
-  500
-  100
Figure II.3 HLA-A*0201 and HLA-A*0301 PCR amplification
20 pi samples of the amplified fragments were separated on 0.8% 
agarose gels. The following had been loaded: lane 1, no DNA 
template negative control; lane 2, product of HLA-A*0201 cDNA 
synthesis; lane 3, product of HLA-A*0201 cDNA synthesis, 1:100 
dilution; lane 4, product of HLA-A*0301 cDNA synthesis. Lane 5 
was reserved for the 1 Kb DNA ladder. The bands were sharp and of 
expected size: around 840 base pairs (bp).
D N A  m in i -p r e p a r a tio n  a n d  m a x i-p r e p a r a tio n  
DNA mini-preparation
On average, 10 to 20 single colonies were tested to check whether they contained 
recombinant plasmids.
A single colony was inoculated in 5 ml of liquid culture medium containing the 
appropriate selective agent(s) and incubated overnight at 37°C in a loosely capped 
Universal container (Bibby Sterilin) placed in a shaking incubator. A 1.5 ml sample of 
culture was transferred to a microcentrifuge tube and spun for 1 min at 12,000 g at 4°C 
(the remainder of the culture was kept at 4°C to grow a larger preparation if one of the 
clones was recombinant). The medium was removed by aspiration and all following 
steps were performed on ice. The pellet was resuspended in 100 pi of ice cold Solution I 
(50 mM glucose, 25 mM Tris-Cl pH 8.0, 10 mM EDTA) to lyse the bacteria and 
vortexed vigorously. Then 200 pi of freshly prepared Solution II (0.2 M NaOH, 1% 
(w/v) SDS, mixed immediately prior to use) was added and mixed gently by inversion. 
This was followed by the addition of 150 pi of Solution III (obtained by mixing 60 ml 
of 5M KoAc (potassium acetate), 11.5 ml of glacial acetic acid and 28.5 ml of water and 
obtain a 3M potassium-5M acetate final solution). After thorough mixing, the tube was 
centrifuged at 12,000 g for 2 min at 4°C. The supernatant was transferred to a fresh tube 
and an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1, pH 6/6.8; BDH)
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was added. After vortexing, the tube was centrifuged at 12,000 g for 2 min at 4°C and 
the supernatant was transferred to a fresh tube. The DNA was then precipitated by 
adding two volumes of ethanol to the supernatant at room temperature and vortexed. 
After 2 min of incubation at room temperature or alternatively 10 to 15 min at -20°C, 
the tube was centrifuged at 12,000 g for 5 min at 4°C. The supernatant was aspirated 
totally and the pellet was allowed to drain, before being rinsed with 70% ethanol. It was 
then allowed to air dry before resuspension in 50 |Xl double-distilled water.
DNA midi-preparation
The DNA maxi-preparation was essentially a scaled up version of the DNA mini- 
preparation. It was performed by growing a 50 ml bacterial culture overnight and the 
typical yield for this method was 3 to 5 pg of DNA per millilitre of original bacterial 
culture.
Measuring DNA concentration
DNA concentration was assessed by UV spectrophotometry at 260 nm (6405 UV/vis 
spectrophotometer, Jenway) which allowed a correlation of one optical density (OD) 
unit to 1 mg/ml of DNA.
DNA endonuclease restriction digest
Endonucleases are restriction enzymes that can be isolated from bacteria and cut DNA 
at a specific target site. The following enzymes (Table n.7), all at 10 U/ml (Gibco BRL) 
were used in this project to clone DNA fragments into plasmid vectors and to screen 
clones.
Endonuclease Target sequence
Eco RI 5’-G4-AATT C-3’ 
3’-CTTAATG-5’
Bam HI 5’-GlGATC C-3’ 
3’-C CTAGTG-5’
Nco I 5’-CiCATG G-3’ 
3’-G GTACTC-5’
Bglll 5’-AlGATCT-3’
3’-TCTAGTA-5’
Table n.7 Endonucleases and restriction target sequences
This table summarises all endonucleases used to clone and screen 
positive clones encoding for the extracellular portion of HLA- 
A*0201 and HLA-A*0301 molecules and the bsp insertion in the 
pET 8 vector. Arrows indicate cleavage sites.
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These enzymes were typically used by mixing 1 to 5 pi of DNA (constituting a 
maximum of 1 pg of DNA) with 2 pi of 10X React® 3 buffer (final concentrations: 50 
mM Tris-HCl pH8.0, 10 mM MgCl2, 100 mM NaCl; Gibco BRL) and 1 pi of restriction 
enzyme. The final volume was made up to 20 pi with double-distilled water. This was 
incubated for 1 hr at 37°C and the products of this digestion were separated by gel 
electrophoresis (Figure II.4).
A a 1 2 3 4 5 6
Size T -----------------------------------------
(bp)
6.000 A
4.000 A
2.000 J
1,600 A
1,0 0 0 ^
500 A
B  a 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2
Size 
(bp)
6.000 J
4.000 A
1,600 J  
1,0 0 0 -
5 0 0 -
Figure II.4 Screening of HLA-A*0201 recombinant bacterial 
clones
10 pi samples of DNA mini-preparations were loaded and run on 
0.8% agarose DNA gels after restriction digest with Eco RI (PCR 2.1 
clones, panel A) or Nco I and Bam HI (pET 8 bsp clones, panel B). 
On panel A, two clones were positive for the 840 base pairs (bp) DNA 
fragment of interest; clone 4 was selected for subcloning into pET 8 
bsp. On panel B, all the clones were positive for the Nco I/Bam HI 
840 base pairs cloned fragment. A few positive clones were selected 
and tested for optimal protein expression.
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DNA gel purification
Following endonuclease restriction digest, the DNA fragments that contained the coding 
sequence for the protein of interest (HLA-A*0201 or HLA-A*0301) were separated 
from the unwanted sequences (usually the vector backbone) by gel electrophoresis. The 
DNA was then purified from the agarose gel using the GFX PCR DNA and Gel Band 
Purification kit (Amersham Biosciences). A narrow gel slice containing the DNA band 
of the correct size, as seen under UV lighting, was cut with a sterile scalpel and 
transferred to a 1.5 ml microcentrifuge tube. The tube was weighed to determine the 
weight of the gel slice (the empty tube having been weighed previously and its known 
weight subtracted from the total). The slice was then cut into several smaller parts and 
10 pi of capture buffer for each 10 mg of gel was added. The tube was closed and 
mixed by vortexing vigorously, then it was incubated at 60°C for 5 to 15 min until the 
agarose dissolved completely. The melted sample was transferred to a GFX column 
placed over a collection tube and incubated for 1 min to allow the DNA to bind to the 
glass fibre matrix. The sample was then spun through the column at maximum speed in 
a microcentrifuge and the eluate was discarded. 500 pi of wash buffer was applied to 
the column and the tube was centrifuged a second time. The column was then 
transferred to a fresh sterile 1.5 ml microcentrifuge tube, 50 fil of double-distilled water 
was applied directly to the matrix. The tube was incubated for 1 min at room 
temperature and centrifuged for 1 min at full speed to recover the purified DNA.
Plasmid Vectors and vector modification
Two different vectors, PCR 2.1 and pET 8, were used in our cloning strategy to ensure 
an efficient system and allowed a degree of versatility so that the constructs could be 
utilised in alternative experiments (PCR 2.1 and pET 8 maps can be found in the 
Appendix).
Initially, the products of PCR amplification were ligated into the PCR 2.1 vector 
(TA cloning kit, Promega). The product of PCR amplification of a DNA fragment by 
the enzyme DNA polymerase ends in an overhanging adenosine base at the end of each 
DNA strand. The PCR 2.1 vector has been designed and manufactured as a linear 
double stranded DNA fragment that ends with overhanging thymidine bases that are 
flanked by EcoR I restriction sites to allow for the screening of recombinant bacterial 
clones by single endonuclease digestion. The PCR 2.1 vector encodes for a short gene 
embedded in the poly-cloning site coding for the first segment of the p-Galactosidase
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gene (Lac Z) that can complement the carboxy-terminal part of the enzyme encoded by 
E.coli to form an enzymatically functional protein. Addition of isopropylthio-p-D- 
galactoside (IPTG, Sigma) in the medium can trigger protein transcription by inducing 
the T7 promoter. If the Lac Z gene is not interrupted by a cloned DNA fragment, the 
bacteria will be able to process 5-bromo-4-chloro-3indolyl-p-D-galactoside (X-gal) and 
form colonies coloured by its blue degradation product. Consequently, the ligation of 
PCR fragments in PCR 2.1 was very efficient and after transformation in E.coli XL IB, 
allowed the production of large quantities of plasmid DNA that were tested by 
endonuclease digestion. This plasmid DNA was kept as stock and because the PCR 2.1 
vector contained a cloning cassette with a range of restriction sites, this offered different 
sub-cloning options if needed for later projects.
The DNA fragment of interest was then subcloned into a modified protein 
expression vector pET 8 (Kind gift of Dr F.W Studier, now available commercially 
from Novagen under the name pET 3d). The DNA transcription and translation of genes 
ligated in pET vectors are placed under the control of strong bacteriophage T7 signals. 
The pET 8 plasmid vector had been modified by Chrissy Zamoyska in the laboratory. 
This involved a consensus biotinylation substrate peptide (bsp2) tag (chosen from a 
panel of candidate peptides described by Schatz in 1993) that was inserted at the end of 
the cloning cassette using DNA linkers (see Figure H.5). After ligation of the HLA 
coding fragment in this modified vector and verification by DNA sequencing, the 
encoded molecule was transcribed all the way through to the bsp tag and the 
transcription was ended by a stop codon. The biotinylation substrate peptide then 
became part of the translated protein.
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Linker A
!0 I overhang
U g atcggat cc c g g ct c c g gc t c c c tg c a t ca t a t tt t t g a ag
D P G S G S L H H I F E Linker C
CTAGCCTAGGGCCGAGGCCGAGGGACGTAGT
Bam HI site | A Q  I E W R H R  Stop
CACAG TTGAATGGCGCCATCGTTAAA
ATAAAAACTTCGTGTCTTTTAACTTACCGCGGTAGG
Linker B
Bgl II overhang
Linker D
Figure II.5 Bsp tag: linkers sequences
The four complementary oligo-nucleotide linkers (A,B,C and D) 
were made to anneal and were then ligated into a Nco I/BamHI 
purified restriction fragment of the pET 8 vector (Bam HI and Bgl II 
overhang fragments are complementary, this also cancels this end 
Bam HI site from the pET 8 vector; see ). Nco I and Bgl II 
overhangs are highlighted in blue and pink respectively. The bsp tag 
coded for the biotinylation substrate sequence (in bold blue letters) 
containing a lysine residue that was to be biotinylated ( • )  and was 
terminated by a stop codon (—•).
The (3-2 microglobulin molecule was cloned into the pHN 1 ampicillin resistant 
vector, transformed into E.coli (strain XA90 f  Laclql) and was kindly donated to our 
laboratory by Professor Don Wiley (Garboczi et al, 1992).
D N A  L ig a tio n , t r a n s fo r m a t io n  in to  E .c o l i  
DNA Ligation
Ligations of the original HLA-A*0201 and HLA-A*0301 PCR fragments into the PCR
2.1 vector were performed using the TA cloning® kit (Invitrogen). A volume of 1 to 
5 pi of freshly amplified PCR fragment (~ 10 ng) was added to 2 pi of PCR® 2.1 vector 
(25 ng/pl), 1 pi of T4 DNA ligase (5 U/pl) and 2 pi of lOx Ligation Buffer in a 
microcentrifuge tube. The total volume was made up to 20 pi with sterile water and the 
tube was incubated overnight in a waterbath at 15°C. Some of the ligated DNA product 
was then used to transform competent bacteria and the remnants were kept frozen at -
HLA-A*0201 and HLA-A*0301 purified Nco I/Bam HI restriction fragments (5 
to 10 pi) were ligated into the bsp2 modified and Nco I/Bam HI purified pET 8 vector
20°C.
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fragment with T4 DNA ligase and Ligation Buffer (both from Boehringer Mannheim) 
using an identical protocol.
Transformation of Escherichia coli (E. coli)
Competent E. coli bacterial strains XL 1-Blue and BL21(DE3)pLys S were prepared 
following a classical calcium chloride membrane permeabilisation protocol and kept in 
aliquots at -80°C.
The XL 1-Blue strain was transformed with the PCR 2.1 constructs to allow for 
the colour selection of recombinant colonies (see below). It was subsequently 
transformed with the bsp2 modified pET 8 constructs to produce sufficient amounts of 
plasmid DNA for the selection of recombinant colonies and the sequencing of the 
selected clones.
The BL21(DE3)pLys S strain was transformed with plasmid DNA from selected 
bsp modified pET 8 HLA-A*0201 or HLA-A*0301 constructs to express the 
extracellular portion of these proteins.
The competent cells were thawed slowly on ice, and a sterile 1.5 ml Eppendorf 
tube was cooled down on ice simultaneously. A volume of 200 jLil of competent cells 
was gently mixed by inversion with 5 jllI of ligated DNA mix. The competent cells and 
DNA were incubated on ice for 30 min, then heat shocked at 42°C for 3 min. 1 ml of 
bacterial liquid culture medium was added to the transformed competent cells and the 
tube was incubated at 37°C for an hour. Two different volumes (usually 50 and 200 Jil) 
were then overlaid on Petri dishes containing selective culture medium with agarose.
Bacterial culture
Liquid bacterial culture medium
Liquid 2xYT culture medium for E.coli bacteria was prepared by solubilising 16 g of 
Peptone (Gibco BRL), 10 g of Yeast extract (Oxoid) and 5 g of Sodium Chloride (NaCl, 
BDH) in a litre of double distilled water (Select Bio water filter, Purite). The solution 
was sterilised by autoclaving before use.
Solid bacterial culture medium
Solid 2xYT bacterial culture medium was prepared in an identical fashion to the liquid 
culture medium, with the difference that 16 g of bacterial agar (Select Agar, Gibco 
BRL) per litre of medium was added before autoclaving. The solution was cooled down 
to 50°C, appropriate selection agents were added (if applicable) before it was poured
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into sterile Petri dishes (Falcon Ten-twenty-nine™ Petri Dish, BD) and left to set before 
use or storage for up to two weeks at 4°C.
Bacterial plasmids and bacterial selection
Most recombinant plasmids encode for a gene that confers specific antibiotic resistance, 
so inclusion of the relevant antibiotic allows the recombinant colonies to be resistant, 
thus preventing other contaminating bacteria, which are antibiotic sensitive, from 
growing. The PCR 2.1 plasmid (Invitrogen) and the pET 8 plasmid both encode for an 
ampicillin resistance gene (Appendix VII and VIII). Thus, the bacteria following 
transformation with one of these recombinant plasmids were grown in medium 
containing a final concentration of 50 |ig/ml of Ampicillin (Sigma).
To screen for recombinant PCR 2.1 colonies, 40|il of IPTG (20|ig/ml) and 40 |il 
of X-gal (20|ig/ml (Sigma) in dimethylformamide) were mixed, overlaid on bacterial 
agarose medium and left to dry before the product of the bacterial transformation was 
spread onto the agarose. After overnight incubation at 37°C, recombinant white 
colonies were selected to set up DNA mini-preparations and checked for recombination 
by endonuclease digestion (non-recombinant colonies were able to process X-gal and as 
a result appeared blue).
The BL21(DE3)pLysS E.coli strain was a constitutive host of the pLysS plasmid 
that provided an inhibitor of the T7 RNA polymerase enzyme. This prevented the 
transcription of the pET 8 plasmid encoded protein during the initial period of bacterial 
growth and also encoded for an ampicillin resistance gene. The BL21 strain also 
contained a chloramphenicol resistance gene. Therefore, the selection of positive 
recombinant bacterial clones in this strain was performed in medium containing both 
Ampicillin and Chloramphenicol (at a final concentration of 34 pg/ml, Merck). The 
BL21 host strain contains a chromosomal copy of the T7 RNA polymerase gene, and 
the DE3 lysogen encodes for the Lac repressor gene that represses the transcription of 
T7 RNA polymerase and the transcription of the target gene. Additionally, these 
bacteria contain the pLysS plasmid that encodes for the low-level expression of T7 
lysosyme, which binds to T7 RNA polymerase and inhibits transcription. The two types 
of T7 RNA polymerase repression are counteracted by the addition of IPTG to the 
bacterial culture, which results in high transcription levels of the T7 RNA polymerase 
and target genes.
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DNA sequencing
A few clones testing positive for the HL A-A *0201 or HLA-A*0301 DNA inserts after 
restriction digest and gel electrophoresis were sequenced to confirm that no mistakes 
had occurred during the PCR amplification and or cloning steps. Oligo nucleotide 
primers were designed to bind to the external section of the pET 8 vector cloning 
cassette (Amersham Pharmacia Biotech). The respective primer sequences are described 
in the following table:
PRIMER SEQUENCES: pET 8 sequencing
Forward oligo primer (5’-3’): 20 mers Reverse oligo primer (5’-3’): 20 mers
GGAGACCACAACGGTTTCCC TGCTAGTTATTGCTCAGCGG
Table H.8 pET 8 primers for Sequencing
Forward and reverse primers used to sequence pET 8 plasmid DNA 
clones.
DNA purified by the DNA miniprep protocol (described previously) was sent to 
the HLA and Bio-informatics group at the ANRI, where the sequencing analysis for the 
selected clones was carried out. The sequencing reaction was performed in both 
directions by ABI-Prism big dye terminator chemistry and was run on an ABI 377 
automated DNA sequencer. The resulting sequences were aligned with the Sequence 
Navigator Software and showed to be identical to the established HLA sequence for 
these antigens and was also in frame for translation in the pET 8 vector.
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Synthetic peptides
C h o ic e  o f  p e p t i d e s  
Control peptides
Two control peptides were selected. The first control peptide was the influenza matrix 
(58-66) HLA-A*0201 specific peptide (amino-acid sequence: GILGFVFTL), shown to 
bind HLA-A*0201 with high affinity (Morrison et al, 1992). This specific peptide was 
used as a positive reference for the refolding and synthesis of the HLA-peptide 
complexes. The second control peptide, selected for its HLA-A*0201 binding properties 
was the minor antigen HA-1 HLA-A*0201 specific peptide (amino-acid sequence: 
VLHDDLLEA; Ren et al, 2000). Specific T cell responses restricted to this peptide are 
only observed in HA-1 mismatched patients (Mutis et al, 1999) and therefore would not 
have induced a T cell response in healthy individuals. It was used as a negative 
HLA/peptide tetramer control staining.
CMV study
Three peptides from the immunodominant pp65 protein were selected for this study. 
They were synthesised by fluorenylmethoxycarbonyl (F-moc) chemistry and purified by 
high performance liquid chromatography (HPLC) before being dessicated and stored at 
-20°C. They were all shown to bind the HLA-A*0201 molecule and could therefore be 
potentially presented to T cells. The peptide sequences are summarised in the following 
Table:
Peptide Amino acid sequence pp 65 fragment (amino acids)
AE 42 nI v pm v a t! 495-503
AE 44 vI gpisghI 14-22
AE 45 m b n i p s i n | 120-128
Table II.9 Cytomegalovirus pp 65 specific peptide sequences
This table summarises the three peptides that were selected to be 
refolded with HLA-A*0201 and be made into HLA/peptide 
tetrameric complexes. The leucine (L) and valine (V) anchoring 
residues are highlighted at positions 2 and 9 of the HLA-A*0201 
molecule peptide binding groove.
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CML study
A single peptide from the BCR/ABL b3a2 junction peptide was predicted as a potential 
binder to the HLA-A*0301 molecule. The amino-acid sequence of the predicted peptide 
was KQSSKALQR. It was solubilised in RPMI 1640 at 1 mg/ml and stored at -20°C.
Solubilisation of peptides
Dessicated peptide stocks were kept at -20°C, and were solubilised in a 50% 
dimethylsulfoxide (DMSO) solution. A quantity sufficient for each HLA refolding was 
dissolved immediately before use in a total volume of 1 ml of 50% DMSO and peptide 
used in cell stimulation experiments was dissolved in 50% DMSO at 1 mg/ml, and 
stored at +4°C.
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Biochemistry
Protein expression and maxi-preparation
A single colony, or a scraping from a frozen glycerol stock, was inoculated into 10 ml 
of liquid bacterial culture medium with the relevant antibiotic selection and incubated 
overnight in a shaking incubator at 37°C.
The overnight culture was then inoculated into one litre of autoclaved bacterial 
culture medium containing the appropriate selection and was placed in a shaking 
incubator at 37°C until the culture was in exponential growth and had reached an optical 
density of 0.4 as measured by spectrophotometry at 550 nm. Protein expression was 
then induced by adding IPTG to the culture at a final concentration of 1 mg/ml. After 4 
hrs of further incubation, the bacteria were harvested and transferred to a one litre 
centrifuge bottle and centrifuged at maximum speed for 30 minutes at +4°C (Beckman 
JB-6). The supernatant was disinfected and discarded and the pellet was resuspended in 
10 ml of Bacterial Lysis buffer (50 mM Tris-Cl pH 8.0, 1 mM EDTA, 25% (w/v) 
sucrose, filter sterilised) and transferred to a fresh 50 ml Falcon tube (BD). From this 
point, all steps were performed on ice. The tube was centrifuged at 4000 g for 10 min at 
4°C to remove any remaining medium and the supernatant was discarded. The pellet 
was resuspended with 10 ml of B-PER® Bacterial Protein Extraction Reagent (Pierce) 
and 2.5 ml of lysosyme (10 mg/ml freshly prepared stock, Sigma) was added. The tube 
was then frozen, thawed to fully lyse the bacteria and sonicated (five 15 seconds bursts 
of sonication at 45 seconds intervals) on ice. The sample was spun at 10,000 g at 4°C 
for 10 min. The insoluble proteins recovered as inclusion bodies were washed once in 
10 ml of detergent buffer (0.2 M NaCl, 1 % (w/v) deoxycholic acid, 1 % (v/v) Nodinet 
P 40, 20 mM Tris-Cl pH 7.5, 2 mM EDTA pH 8.0, filter sterilised) with 
phenylmethylsulphoxyde (PMSF) at a final concentration of 1 mM. They were then 
washed three to four times with 10 ml of Triton wash buffer (0.5 % (v/v) Triton X 100, 
50 mM Tris-Cl pH 8.0, 100 mM NaCl, 1 mM EDTA pH 8.0) until a milky white pellet 
was obtained. After the final wash the supernatant was discarded and the pellet 
resuspended in 5 ml of the following buffer: 50 mM Tris and 1 mM EDTA, 1 mM of 
PMSF and 2 mM dithiothreitol (DTT). The inclusion bodies were then stored at -20°C 
or solubilised in deionised 8 M urea buffer (8 M deionised urea with lOmM Tris and 
150 mM NaCl) before use in a refolding solution. The 8 M urea solution was deionised
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by incubating 5 g of Amberlite ion exchanger (Merck) overnight in 200 ml of solution, 
then the beads were removed by filtration.
P r o te in  g e l  e l e c t r o p h o r e s i s
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
The size of the expressed proteins was checked by SDS-PAGE. The theoretical 
molecular weight of the expressed proteins was determined by submitting the full amino 
acid sequence to the Biopolymer Calculator Results v4.1.1 software, which can be 
accessed freely at the following web address: http://paris.chem.yale.edu/cgi- 
bin/extinct.pl. For the cloned HLA-A*0201 or HLA-A*0301 extracellular portion with 
bsp, the molecular weight was estimated at around 35,000 Dalton (Da). The full 
sequence of the human (3-2 microglobulin molecule was cloned (gift from Don Wiley) 
and its molecular weight was estimated to be 12,000 Da, as reported by Garboczi et al, 
1992.
Fifteen percent acrylamide gels were prepared in a Mighty Small multi-gel 
caster (Hoefer scientific Instruments) and were composed of a separating gel matrix that 
allowed separation of the proteins according to their size; butan-2-ol was laid over the 
separating gel until it set to create an even surface). When the gel was set, a stacking gel 
layer was poured above it and loading wells were created by insertion of a gel comb. 
Both gels were made by mixing the relevant upper gel buffer (0.4 % (w/v) SDS, 0.5 M 
Tris-Cl, adjust the pH at 6.8, filter sterilised and kept at 4°C) or lower gel buffer (0.4% 
(w/v) SDS, 1.5 M Tris-Cl, pH adjusted to 8.8, filter sterilised and kept at 4°C) with the 
following components (sufficient for four gels):
Separating gel Stacking gel
Upper gel buffer - 2.5 ml
Lower gel buffer 7.5 ml -
30% acrylamide-0.8% Bisacrylamide 15 ml 1.5 ml
(Protogel, National Diagnostics)
double distilled water 7.5 ml 6 ml
Table 11.10 Composition of SDS-PAGE gels
This table summarises the volumes of the different components 
mixed to cast four 15% acrylamide SDS-PAGE gels in a Mighty 
Small multi-gel caster (Hoefer Scientific Instruments). The 
following solutions were added to polymerise both gel layers: 10 pi 
of N-N-N’-N’ tetramethylethylene diamine (TEMED, BDH) and 100 
pi of 10% ammonium persulphate (APS, BDH).
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The samples to be tested were transferred to 1.5 ml microcentrifuge tubes and 
mixed with 5 pi of SDS sample buffer (2% (w/v) SDS, 0.0625 M Tris-Cl, 10% (v/v) 
Glycerol, 5% 2-mercaptoethanol, 0.01% (w/v) bromophenol blue). The lids were 
pierced and the samples were denatured by incubation at 100°C for 5 min. The samples 
were then loaded into the wells of the pre-cast gels with one lane being used to load 5 pi 
of BenchMark™ pre-stained protein ladder (9,300 to 172,600 apparent molecular weight 
range, Gibco BRL). The gels were run in a Mighty Small II gel tank (Hoefer Scientific 
Instruments) in SDS-PAGE buffer (0.1 % (w/v) SDS, 0.025 M Tris-Cl, 0.192 M 
Glycine, filter sterilised) for 30 to 40 min at 30 mA. They were consequently stained 
with Coomassie brilliant blue, vacuum dried on Whatman paper and photographed or 
scanned (Figure II.6).
H 0 o | Apparent
molecular 
weight (Da)
-  61,300
-  36,400
-  24,700
-  19,200
-  13,100
-  9,300
Figure II.6 SDS-PAGE analysis of large scale protein expression
Inclusion body preparation aliquots (20 pi) of human p-2 
microglobulin (lane 1) and HLA-A*0201(lane 2) were dissolved in 8 
M urea, and after the aggregated elements were discarded, were run 
on a 15% acrylamide SDS-PAGE gel. The apparent molecular 
weight of the molecules was compared to a pre-stained marker in 
lane 3 (size indicated in Dalton).
Moreover, this assay allowed for a qualitative assessment of the purity of the 
protein preparation by checking for contaminating bands on the SDS-PAGE gel. This 
was necessary to ensure that the contaminating proteins (usually encoded in the E.coli 
genome or in the plasmid vector) were present in small enough amount so that they 
would not interfere in the refolding reaction.
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Native protein gel electrophoresis
This was performed after the synthesis of HLA-peptide complexes and their 
biotinylation (see below). Identical gel casting units and tanks were used for the native 
gels as for the SDS-PAGE gels. Native gels were composed of separating and stacking 
layers that was prepared using the following recipe:
Separating gel Stacking gel
1.5 M Tris-HCl, pH 8.8 7.5 ml -
1 M Tris-HCl, pH 6.8 - 1.25 ml
30% acrylamide-0.8% Bisacrylamide 8 ml 1.7 ml
(Protogel, National Diagnostics)
double distilled water 14.5 ml 6.8 ml
Table 11.11 SDS-PAGE gel recipe
This table summarises the volumes of the different components 
mixed to cast two 8% acrylamide native gels in a Mighty Small gel 
caster (Hoefer Scientific Instruments).
As mentioned previously, 100 pi of APS and 10 pi of TEMED were added to 
induce gel polymerisation. The gels were pre-run in native gel electrophoresis buffer 
(24.8 mM Tris, 192 mM Glycine) at 150 volts for 30 min to remove any excess salt that 
could influence the separation. The samples were mixed with 5 pi of native gel sample 
buffer (50 mM Tris-Cl pH 6.8, 10% Glycerol, 0.01% (w/v) bromophenol blue) and were 
run in native electrophoresis gel buffer at 200 Volts until the bromophenol blue dye 
reached the end of the gel. The gels were then stained with Coomassie brilliant blue.
1 2 3
m*
Figure II.7 Native gel shift assay
HLA-A*0201/CMV/biotin was incubated at a 4:1 molar ratio with 
streptavidin for an hour on ice. A native gel shift analysis was 
performed to confirm the level of biotinylation of the complexes: 
lane 1, HLA-A*0201/CMV/biotin alone; lane 2, streptavidin alone; 
lane 3, HLA-A*0201/CMV/biotin complexed with streptavidin. In 
lane 3, an 80 to 90% shift of the refolded HLA band to the level of 
the strepatvidin band is observed.
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By mixing a sample of refolded and biotinylated HLA-peptide complex with the 
respective 4:1 molar ratio of streptavidin, the level of biotinylation of the complexes 
could be assessed and therefore taken into account when calculating how much 
fluorescently labelled streptavidin to be added.
Coomassie brilliant blue staining
SDS-PAGE and native protein gels were stained for 20 mins with gentle shaking in 
Coomassie blue staining solution (50% methanol (v/v), 10% glacial acetic acid (v/v), 
0.25% (w/v) Coomassie brilliant blue G 250 in water). The gels were then destained in 
Coomassie destain solution (16.5% (v/v) methanol, 5% glacial acetic acid in water) that 
was changed frequently over 4 to 8 hrs. Destained gels were then photographed and 
dried on 3 mm chromatography paper (Whatman) using a Bio Rad gel drier (model 
583).
HLA class /  refolding
The refolding of the extracellular portion of HLA-A*0201 and HLA-A*0301 with 
peptide and p-2-microglubulin was performed using a dilution protocol. A dilution 
refolding buffer was prepared by combining the following in a final volume of 200 ml: 
lOOmM Tris-HCl pH8.0, 400 mM L-arginine-HCl, 2mM EDTA, 5 mM reduced 
Glutathione, 0.5 mM oxydised Glutathione and 0.5 mM PMSF. The pH was adjusted to
8.0 and the buffer was cooled down to 4°C before adding the solubilised HLA and P-2- 
microglobulin chains and peptide at the following concentrations:
Solubilised protein Final concentration
HLA-A*0201 or HLA-A*0301 1 mM
p-2-microglobulin 2 |xM
Peptide 10 pM
Table 11.12 Components of dilution refolding
This table summarises the concentration of the different components 
mixed in the dilution refolding for HLA class I molecules.
The solubilised HLA-class I heavy chain, P-2 microglobulin and peptide were added 
separately and drop-wise to the buffer while stirring simultaneously. The refolding mix 
was incubated with stirring at 4°C for 48 hrs. The product of the refolding was then 
transferred to 50 ml sterile Falcon tubes and centrifuged at 2,000 g for 15 min at 4°C to 
pellet any aggregated material. The supernatants were then transferred to an 
ultrafiltration stirred cell (8400 model, Amicon) and concentrated down to 20 ml 
through a microfiltration membrane of 10,000 molecular weight cut off (YM 10, 10,000
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MWCO, Millipore) by applying gas pressure. The product of the refolding mix was then 
transferred to a Vivaspin 20 ml concentrator (10,000 MWCO, Vivascience) and further 
concentrated down to 1 ml or less by centrifugation (2,000 g at 4°C).
The refolded and concentrated product was kept at 4°C and purified by fast 
protein liquid chromatography (FPLC) gel filtration within 12 to 24 hrs.
Biotinylation reaction
Biotinylation of the biotin substrate peptide target sequence expressed at the C-terminal 
portion of the HLA class I molecules was performed using in-house bacterially 
expressed Bir A enzyme. This enzyme catalyses the formation of biotinyl-5’-adenylate 
from adenosine tri-phosphate (ATP) and biotin, and in E.coli, it transfers the biotin from 
the biotinyl-5’-adenylate to a particular lysine residue in only one protein. This allowed 
targeted biotinylation of the HLA molecules. The biotinylation carried out with the in- 
house Bir A was comparable in efficiency to commercially available enzyme (Avidity). 
The pure fraction containing correctly refolded HLA (in a 20 mM Tris, 5 mM NaCl, pH
8.0 buffer) was concentrated down to 200 pi. The reaction mix consisted of 8 parts of 
refolded HLA solution, one part of Biomix A buffer (0.5 M bicine, pH 8.3), one part of 
Biomix B buffer (100 mM ATP, 100 mM MgOAc, 400 mM biotin) as well as 10 pi of 
Bir A enzyme (1 mg/ml). An appropriate amount of Complete™ protease inhibitor 
cocktail (Boehringer Mannheim) was added to the mix. The reaction was incubated 
overnight at RT, and the refolded and biotinylated product was purified from the excess 
biotin by FPLC gel filtration immediately thereafter.
FPLC gel filtration purification
Purification of refolded HLA molecules and refolded/biotinylated molecules was 
performed by FPLC gel filtration on an Akta purifier instrument using a XK 16/70 
column packed with 100 ml of Superdex™ 75 matrix (composed of dextran covalently 
linked to highly cross-linked agarose, Pharmacia). This system allowed the separation 
of proteins depending on their molecular weight. The column was equilibrated with 
buffer before the sample was loaded, a maximum pressure of 0.5 MPa was set on the 
instrument, and the pump was set to run at 1 ml/min. All samples were filtered by 
centrifugation through a 0.2 pm mini-filter (Vivaspin 0.5 ml, Vivascience) before 
loading in the injection loop. The elution of the proteins was programmed using the 
IBM operating system 2 (OS 2) to run the Unicom 3.10 software and was carried out 
over one and a half column volumes. At the end of the column, the UV absorbance was
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measured to determine where the proteins were eluted and 3 ml fractions were collected 
(Figure II.8). Prior to biotinylation, the refolded product was purified in a buffer 
containing a low level of salt (20 mM Tris, 5 mM NaCl, pH 8.0) in order to combine a 
buffer exchange to the purification procedure. This was necessary as the Bir A enzyme 
is inhibited by high salt concentrations. However the refolded product after 
biotinylation was purified in a buffer with physiological levels of salt (20 mM Tris, 150 
mM NaCl, pH 8.0) as it would become the final storage buffer for refolded/biotinylated 
HLA molecules.
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Figure II.8 FPLC purification traces: after refolding and after 
biotinylation
FPLC purification traces: after refolding of HLA-A*0201 with (3-2 
microglobulin and CMV peptide AE42, — curve; after biotinylation 
of a third of the refolded product from the second green peak 
(labelled p2, — curve. Fractions of 3 ml were collected (—) and the 
relative absorbance (milli-absorbance units, mAU) was measured at 
280 nm to detect proteins throughout the run as they were leaving the 
separation matrix (— and — curves). The peak resolution was 
compared to the resolution of standard proteins separated with the 
same protocole ( B ..J standard markers): A, blue dextran, 2xl06 Da; 
B, Albumin, 66,000 Da; C, carbonic anhydrase, 29,000 Da; D, 
cytochrome C, 12,400 Da. This allowed the determination of the peaks 
composition: purification after refolding —: pi, aggregated material; 
p2, refolded HLA; p3, (3-2 microglobulin alone; p4, Arginine (present 
in refolding mix and absorbing at 280 nm); p5, remaining peptide; 
purification after biotinylation —: pi, refolded and biotinylated HLA 
molecule; p2, remaining biotin.
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Measurement of protein concentration
Protein concentration in solution was measured using the Micro BCA protein assay 
reagent kit (Pierce) that uses bicinchoninic acid (BCA) as the detection reagent for 
reduced copper ions formed by the reaction of proteins with copper. One cuprous ion 
(Cu+1) chelates two molecules of BCA and produces a purple water soluble complex 
characterised by a strong absorbance at 562 nm that is linear with increasing protein 
concentrations.
Briefly, serially diluted standards of bovine serum albumin (BSA) were prepared 
as well as diluted samples from the solutions to be tested. 500 pi of each standard 
dilution or unknown sample were dispensed in labelled tubes (5 ml round bottom tubes, 
Thermo Life Science), a 500 pi blank consisting of double distilled water was also 
prepared. Then 500 pi of mixed working reagent (containing the copper and BCA 
solutions, Pierce) was added to each test tube. After incubating for 1 hour at 37°C, the 
tubes were left to cool at room temperature and the absorbance was measured by 
transferring the contents of each tube to a plastic cuvette (1 ml plastic cuvettes, Jencons 
PLS) and reading the absorbance at 562 nm. The reading from the blank tube was 
subtracted from all other readings and the BSA standard curve was plotted against its 
concentration using the KaleidaGraph™ 3.0 Software. Finally, the protein concentration 
of the samples (refolded and biotinylated HLA molecule for example) was determined 
using the standard curve to establish the corresponding concentration.
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HLA-Tetramer complexes
Avidin/Biotin interaction, tetramerisation
The biotin molecule has the ability to form a strong non-covalent interaction with the 
avidin molecule has four binding sub-units thus forming a tetramer. When a given 
molecule is tagged with a biotin molecule, the former can then be tetramerised by 
incubation with avidin or streptavidin at a molecular ratio of four to one respectively. 
The extracellular portions of the HLA-A*0201 and HLA-A*0301 molecules were 
produced and refolded with specific nine mer peptides and p-2-microglobulin as 
described previously. These monomeric molecules were then biotinylated and tested by 
Dot-Blot and/or ELISA as described below to confirm the correct refolding and 
biotinylation of the complexes. They were then tetramerised by adding labelled 
streptavidin and formed a reagent that could specifically bind its T cell receptor ligand. 
Streptavidin (avidin purified from the microorganism Streptomyces avidinii) conjugated 
to the fluorescent markers phycoerythrin (PE) or alternatively allophycocyanin (APC) 
was purchased from Biogenesis and used to tetramerise HLA/peptide molecules (See 
Figure II.9, next page). Tetramerisation of these molecules was necessary to increase 
the avidity of the complexes for the T cell receptor and establish a relatively long lasting 
and stable interaction. This allowed the visualisation of these complexes and the 
detection of T cells specific for a particular HLA/peptide combination by fluorescence 
microscopy or flow cytometry.
93
Chapter II
CMV Peptide
(3-2-microglobulin 
Biotin
Figure II.9 HLA/peptide tetramer molecule composition
HLA/peptide tetramer molecules are composed of four biotinylated 
HLA molecules refolded with a peptide and p-2-microglobulin.
These can bind streptavidin conjugated to a fluorescent label at 4:1 
molar ratio.
H L A  c l a s s  I m o n o m e r  a n d  te t r a m e r  r e a g e n t  s to r a g e
HLA class I monomeric and tetrameric complexes (in alO mM Tris, 150 mM NaCl, pH
8.0 buffer) were mixed with 10% (v/v) of sterile glycerol. Aliquots were stored at 
-20°C.
HLA/peptide monomers were defrosted and tetramerised on ice by adding the 
conjugated streptavidin in small volumes over a couple of hours to favour the formation 
of tetramers. The tetramers were then aliquoted to be frozen and stored or they were 
used as a 4°C working stock.
HLA heavy chain
Phycoerythrin 
fluorescent label
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Immuno-assays
Immuno-assays are all based on using specific immunoglobulins (or antibodies) and 
immunoglobulin combinations to detect a specific protein (or antigen) present in a 
biological sample. Immunoglobulins can be raised against a specific human protein by 
immunising an animal (often a mouse) with the molecule that is to be targeted. The 
purified antibodies can then be either conjugated to a labelled molecular marker or 
immobilised on a solid surface (nitro-cellulose membrane or immuno-plate) and will 
allow the detection and quantification of their specific antigen on the cell surface.
Characterisation of cell surface markers with fluorescent antibodies
The surface of cells is characterised by the presence of a high numbers of trans­
membrane molecules that can bind to receptors on the surface of neighbouring cells or 
tissues.
The different fluorescent conjugates and antibodies to various lymphocyte cell surface 
molecules are summarised in the following tables:
name Full name emission colour, peak (nm)
FITC fluorescein isothiocyanate green, 520
PE phycoerythrin yellow, 576
PerCP peridinin chlorophyl protein red, 677
PerCP-Cy5.5 PerCP- cyanin 5.5 long red, 695
APC allophycocyanin red, 660
Table 11.13 Antibody fluorescent conjugates
This table summarises the emission peak of different fluorescent 
components conjugated to antibodies (emission peaks obtained after 
excitation by an argon ion laser emitting light at 488 nm (or a red ion 
laser for APC)).
Directly conjugated antibodies were purchased from BD-Pharmingen and were used to 
stain cells at the recommended concentration for 30 min at 4°C in staining medium. Up 
to four different colours were detected simultaneously at the surface of a single cell. The 
unbound antibodies were washed off by addition of RPMI and centrifugation at 1,000 g. 
Samples were then re-suspended in fixative prior to analysis by flow cytometry. The 
specificity of the different antibodies used in this study are described in the following 
table:
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Name Protein target Positive population phenotype
CD3 T cell receptor complex T cells
CD8 T cell co-receptor cytotoxic T cells
CD25 Interleukin 2 receptor Activated T cells
CD27 T cell surface receptor Activated T cells subset
CD95 Fas “death domain” Activated T cells
CD45 RO Leucocyte common antigen, 
RO isoform
Memory T cells subset
CD69 T cell surface molecule Recently activated T cells
CCR7 CC chemokine receptor 7 T cells
Table 11.14 Antibodies to lymphocyte surface molecules
This table summarises the different mouse-anti-human cell surface 
marker antibodies used to characterise different subset of T cells by 
flow cytometry.
Cross-linking and delivery of a specific co-signal
Biotinylated antibodies were purchased from BD-Pharmingen (mouse anti-human CD3, 
CD28 and CD95) or R&D systems (goat anti-human CD40L and 4-IBB) and were used 
to make HLA/peptide-antibody chimera tetramers or chimeramers. This consisted of 
first synthesising biotinylated monomeric HLA/peptide molecules as described in the 
previous section then in mixing these at 4°C with a co-stimulatory biotinylated antibody 
of choice at a respective three to one molecular ratio. The mix was then tetramerised as 
described in the HLA/peptide tetramer complexes paragraph.
The specificity of the different biotinylated antibodies used in these assays are 
described in the following table:
Name Protein target
CD3 T cell receptor complex
CD28 T cell co-receptor, activation
CD40L (CD 154) T cell co-receptor, activation
4-1BB (CD 137) T cell surface receptor, survival
CD95 Fas “death domain”
Table 11.15 Biotinylated antibodies to T lymphocyte surface molecules
This table summarises the different biotinylated anti-human cell 
surface marker antibodies (mouse or goat) used to synthesise HLA- 
peptide/antibody chimera tetramers or chimeramers.
These chimeramer complexes were used as an antigen specific stimulus and co-stimulus 
in cell culture assays at a concentration of lpg/ml of culture medium for 2xl06 PBMCs.
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Assessment of cellular apoptosis
The assessment of cellular apoptosis in cellular activation or cytotoxicity assays was 
performed with the intracellular caspase detection kit Apostat (R&D systems).
A group of caspase enzymes are part of a signalling cascade in the cell that can 
be triggered through different pathways, and once activated mediates programmed cell 
death or apoptosis. The substrate preferences and specificities of caspases have been 
exploited for the development of cell permeable peptides (conjugated to a fluorescent 
molecule, here FITC) that compete for caspase binding and therefore allow for the 
detection of active caspases by flow cytometry.
Cells were stained directly during the last 30 min of culture at 37°C prior to the 
assessment of apoptosis by adding 10 pi of Apostat reagent per 1 ml of culture medium. 
Any unbound reagent diffused out of the cells. The cells were then transferred to a 
sterile tube and washed with 4 ml of PBS to remove any unbound reagent. The cells 
were then resuspended in PBS and analysed by flow cytometry.
Protein Dot-Blot
After protein refolding and purification, several peaks were eluted from the Superdex 
column and were tested by immuno-labelling to confirm which fraction contained the 
correctly refolded HLA molecule. This was done using either by protein dot-blot or 
ELISA analysis.
Triplicate 50 pi samples were taken from each the FPLC elution peaks and were 
deposited onto a pre-wet labelled (with distilled water, then with PBS) Hybond™ ECL 
nitrocellulose membrane (Amersham Life Science) using a vacuum dot-blotter (Hybri- 
dot Manifold, Bethesda Research Laboratories). Each protein dot was washed twice 
with 200 pi of PBS before the membrane was transferred to a 50 ml Falcon tube (BD) 
filled with blocking buffer (PBS, 0.05% (v/v) Tween 20, 1% (w/v) BSA). This was 
incubated on a rolling cylinder overnight at 4°C. The membrane was then washed three 
times for 15 mins in PBS-T buffer (PBS with 0.05% (v/v) Tween 20). The triplicate 
samples were then cut into three identical membrane strips to be incubated with 5 pg/ml 
of different primary antibodies (either W6/32 or BB7.2 were used for HLA-A0201 
while only W6/32 could be used for HLA-A0301) in 15 ml of PBS-T. The tubes were 
incubated for an hour at RT on a rolling cylinder. The antibodies used to test the blots 
and their role are described in the following Table:
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Name Specificity
Normal mouse serum Negative control
W6/32 Conformational HLA class I
BB7.2 HLA-A2
Gap-A3 HLA-A3
BBM1 or ME-1 (3-2 microglobulin
Table 11.16 Dot blot: control and test antibodies
This table summarises the control and specific antibodies used to test 
the FPLC eluted fractions for refolding of the HLA molecules.
The samples were washed three times in PBS-T for 15 min at RT and they were 
incubated for an hour with a second layer goat-anti mouse antibody conjugated to the 
peroxidase enzyme (1:2,500 dilution, Sigma) in PBS-T. The strips were then washed 
three times for 15 min with PBS-T at RT, and the presence of the peroxidase on the blot 
was revealed by incubating the membrane in ECL™ chemi-luminescent reagent for 45 
sec (ECL™ reagent kit, Amersham Pharmacia Biotech). The nitrocellulose membrane 
was then wrapped and exposed to X-ray photographic film (MXB film, GRI 
autoradiography blue sensitive, Kodak). A typical dot-blot film is represented on 
Figure 11.10.
Biotinylation was checked in a similar way, with just a one step antibody 
incubation of the blot with Streptavidin coupled to the peroxidase enzyme.
Although good results were obtained with the dot-blot technique, it was quite 
time consuming, occasionally failed and required to be repeated. As any delay before 
storage or tetramerisation of the monomers might impair the quality of the resulting 
tetramer reagent, we decided to modify the dot-blot test for an ELISA approach, which 
would be a faster and more reliable method to test for refolding and biotinylation.
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Figure 11.10 Dot Blot analysis of peaks post refolding and post 
biotinylation
After refolding of the HLA-A*0201 molecule with p-2 
microglobulin and the AE44 peptide, FPLC purification peaks 
(panel A, p i, p2 and p3, — ) were blotted on a nitrocellulose 
membrane (see Chapter II). After blocking the membrane, the 
samples were probed with (panel A): W6/32 HLA class I 
conformation specific antibody, lane 1; BBM 1 p-2 microglobulin 
specific antibody, lane 2; BB7.2 HLA-A2 specific antibody, lane 3; 
normal mouse serum control, lane 4. Samples from p2 are positive 
for all antibodies and negative for the control confirming correct 
refolding of the HLA molecule. After biotinylation (panel B), a 
sample from the refolded and biotinylated peak was tested against a 
sample from p2 prior to biotinylation. Both samples and a negative 
control were probed with streptavidin-peroxydase: 1, normal mouse 
serum negative control; 2, p2 prior to biotinylation; 3, refolded and 
biotinylated peak. It can be noted that a small level of biotinylation is 
detectable in the second peak sample prior to the biotinyation 
reaction. This is likely to be due to biotinylation occuring at the time 
of bacterial expression, as the Bir A enzyme is constitutive of E.coli 
bacteria.
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ELISA
The ELISA method was developed by one of the laboratory personnel as a more reliable 
and faster way to test FPLC eluted fractions for correct refolding and biotinylation of 
HLA-peptide monomers.
Briefly, on the day prior to the purification of a refolded and biotinylated HLA 
preparation, a Maxisorb immuno-plate (Nunc) was coated with W6/32 antibody at 5 
|Xg/ml (100 jil per well). After incubating the plate for two hours at 37°C, the antibody 
solution was discarded and replaced by 100 pi of blocking buffer. This was incubated 
overnight at 4°C, then the blocking buffer was discarded and the plate was rinsed four 
to five times with PBS. Samples were then added (5 to 20 pi in a final volume of 100 pi 
of PBS) and serial dilutions performed, keeping a blank well (negative control) at he 
beginning of each row of samples. The plate was incubated at RT for an hour and 
washed five times with PBS. A second antibody layer consisting of 100 pi of rabbit 
anti-human |3-2 microglobulin (1:5,000 in PBS, Dako) was then applied. It was 
incubated at RT for 20 min and then the unbound antibodies were washed off. A goat 
anti-rabbit antibody conjugated to the alkaline phosphatase enzyme was then applied 
(1:5,000 in PBS, Sigma) and incubated at RT for 20 min. After another washing step, 
the alkaline phosphatase substrate (p-nitrophenyl phosphate (pNPP), Sigma) was added 
and incubated for 10 to 30 min at RT until a yellow colour developed. The result was 
measured by spectrophotometry at 405 nm using a Titertek Multiscan MCC/340 
(Labsystems) plate reader; a positive reaction confirmed that the protein had been 
correctly refolded. The coloured reagent was then washed off and the plate was probed 
with Streptavidin coupled to the enzyme horseradish peroxidase for 20 min at RT. The 
excess antibody was washed off; the enzyme substrate was added (O-phenylenediamine 
dihydrochloride, Sigma) and incubated for 10 to 15 min at RT. A yellow colour 
developed and the result was measured by spectrophotometry at 492 nm. A positive 
result confirmed that the HLA molecules had been correctly biotinylated.
Modified ELISA for chimeramer complexes
HLA-peptide biotinylated monomers used to prepare the chimeramer complexes were 
tested as described previously. Tetramerised Chimeramer complexes were also tested 
using a modified version of the previously described ELISA assay to confirm the 
presence of the antibody molecule in the complex.
The modification included involved a different capture antibody used in the first 
step that would confirm the presence of the co-stimulatory antibody in the complexes.
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This capture antibody, being a goat anti-mouse antibody or a mouse anti-goat antibody 
at 5 |ig/ml (both from sigma) was incubated on the Maxisorb immuno-plate (Nunc) as 
described previously. After incubating the samples to be tested, an additional step 
incubating diluted normal goat serum (100 pi of a 1:100 dilution per well, Sigma) was 
added to block any remaining free anti-goat antibody in the case of the mouse anti-goat 
ELISA first layer. This was necessary to prevent the goat anti-rabbit antibody 
conjugated to the alkaline phosphatase enzyme at the last layer from binding directly to 
the capture antibody (see
Figure II. 11). The following steps were identical to the ELISA method described 
previously for the detection of correctly refolded HLA-peptide molecules.
Immunoplate, coated with Goat anti-mouse Ig
Figure 11.11 Modified ELISA assay to test chimeramer complexes
HLA-peptide/antibody chimeramers are captured on an immunoplate 
pre-coated with a goat anti-mouse or mouse anti-goat (as applicable) 
antibody. The bound complexes are then probed with an anti-human 
(3-2 microglobulin antibody to test for the presence of refolded HLA, 
and the reaction is developed.
iuorescently la belle 
tetramer chimera
alkaline phosphatase 
Substrate
goat anti-rabbit Ig* 
alkaline phosphatase
Rabbit anti-beta2 
microglobulin
v v  Y
Mouse biotinylated
antibody
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IFN gamma ELIspot
The ELIspot assay consists in a modified version of the ELISA method, and allows the 
capture of proteins secreted by cells under specific culture settings. In the case of this 
study, the secretion of the cytokine interferon-y (IFN-y) by PBMCs upon peptide 
specific stimulation was measured. As the production of IFN-y has an important role in 
T cell proliferation and activation, this was used as an in-vitro test for the functionality 
of these cells.
On the first day of the ELIspot assay, PBMCs were plated in round bottomed 
96-well plates (BD) in two triplicate series of 100,000 cells or 50,000 cells per well. 
They were stimulated overnight with either PBS (negative and background release 
control), with PHA at 1 |ig/ml (positive control) or with 10 pg/ml of antigen specific 
peptide and incubated overnight at 37°C in a water-saturated 5% COz incubator. On the 
same day, a 96-well filtration plate (Multiscreen® Immobilon™-P filtration 
nitrocellulose plates, MAIP N45 10, Millipore) was coated with 15 Jig/ml of 
monoclonal mouse anti-human IFN-y antibody (1-D1K, ELIspot for human IFN-y Kit, 
Mabtech) in PBS and incubated overnight at 4°C.
On the second day, any unbound anti-human IFN-y antibody was washed from 
the Multiscreen plate extensively with sterile filtered PBS (0.45fxm). The cells cultured 
the previous day were then transferred to this capture plate and incubated for 24 hrs at 
37°C in a humidified 5% COz incubator.
On the third day, the cells were removed from the capture plate. Each well of the 
Multiscreen plate was then washed six times with PBS. IFN-y secreted by the cells 
following stimulation was captured by the monoclonal antibody and then detected by 
incubating with 1 jig/ml of biotinylated goat anti-mouse antibody (7-B6-1-biotin, 
ELIspot for human IFN-y Kit, Mabtech) in filtered PBS with 0.5% (v/v) FCS. This was 
incubated for 2 hrs at RT and the plate was then washed six times with PBS. A 1:1,000 
dilution of streptavidin-alkaline phosphatase (ELIspot for human IFN-y Kit, Mabtech) 
in PBS with 5% FCS was then added and incubated for 1 hr at RT. After washing (6x 
PBS), the plate was finally incubated with 100 |il/well of alkaline phosphatase substrate 
(Alkaline phosphatase substrate package, composed of nitroblue tetrazolium chloride 
(NBT) and 5-bromo-4-chloro-3-indolylphosphate p-toluidine(BCIP), Gibco BRL) until 
dark blue spots emerged. The colour development was then stopped by washing with 
water, and after the plate was left to air-dry, the spots were enumerated under a
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dissection microscope (x 20 magnification) and the samples were scored according to 
the number of spots counted per 100,000 or 50,000 cells.
A 
B
C
Figure 11.12 IFN-y ELIspot assay
Triplicate samples of 100,000 or 50,000 cells (in RPMI 1640 with 
10% human AB serum) were incubated overnight with either: lane 
A, not stimulated (to control for the background release); lane B, 
stimulated with a potent mitogen (positive control: PH A at 1 pg/ml); 
or lane C, incubated with CMV peptide (here NLVPMVATV, 10 
pg/ml). They were then transferred onto a sterile IFN-y antibody 
coated plate and incubated for a further 24 hr. The cells were then 
discarded and the IFN-y captured on the plate revealed. The number 
of spot forming units (sfu) was counted using a dissection 
microscope (x 20).
M a g n e t ic  b e a d  s e le c t i o n
Tetramer positive T cells were purified after staining by magnetic separation. First, 
PBMCs were isolated from whole blood and specific staining with PE fluorescently 
labelled tetramer was performed as described previously. Labelled PBMCs were kept at 
4°C during the whole purification procedure.
A two step purification protocol was used to first select CD8+ T cells by mean of 
negative selection, then to purify the PE+ cells by positive selection. The first step 
consisted in depleting B cells, monocytes, NK cells, T helper cells, dendritic cells, early 
erythroid cells, platelets and basophils from PBMCs resuspended in 80 pi of buffer 
(PBS, 0.5% bovine serum albumin and 2 mM EDTA, cooled at 4°C) by adding 20 pi of 
a cocktail of CD19, CD16, CD56, CD4, CD llb and CD36 antibodies coupled to an 
anti-hapten antibody per 107 total cells (CD8+ T cell isolation Kit, Miltenyi Biotec). 
After 10 minutes of incubation, centrifugation and removal of the supernatant, 20 pi of 
Macs Microbeads were then added per 107 total cells. After a further 15 minutes of 
incubation, the cells were washed, resuspended in 500 pi of buffer (same as above) and 
loaded onto a MiniMacs column (Miltenyi Biotec) placed in the magnetic field of a
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Macs separator. The cells labelled for depletion were then trapped in the column while 
CD8+ T cells could be eluted freely from the column by gravity with the addition of 
buffer (same as above). Purified CD8+ T cells were resuspended in 80 |il of buffer and 
then incubated with an anti-PE antibody coupled to an anti-hapten antibody in order to 
separate CD8+ Tet+ T cells from CD8+ Tet' T cells by positive selection. A similar 
procedure to that described previously was used to wash off any unbound reagent and 
add magnetic microbeads. The cells were then loaded onto a fresh MiniMacs column, 
and the fraction eluted with the buffer flow-through consisted of non-magnetically 
labelled CD8+ Tet' cells. After washing with several ml of buffer, the positive fraction 
of pure CD8+ Tet+ T cells were pushed through the column with a plunger into a tube 
containing 500 pi of warm RPMI culture medium for use in experiments.
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Determination of Cytomegalovirus DNA viral load
The number of CMV genomes in the blood of patients was first measured by 
quantitative competitive PCR, then by an alternative method of real time PCR when the 
technique was updated in the Department of Virology at the RFH.
DNA extraction
Briefly, DNA was extracted from whole blood (200pL) using commercially available 
DNA extraction columns (Qiagen, Crawley, UK). All qualitative and quantitative PCR 
analyses were performed on 5pL aliquots (about 40 ng DNA, 6000 cell equivalent) 
derived from the 200 (iL final whole blood DNA extract.
Quantitative-Competitive PCR method
A standard PCR reaction was set up with 1 unit of DNA polymerase Amplitaq Gold 
(Perkin Elmer, Warrington, UK), lx PCR buffer II, 2mM MgCl2, 100 ng each of 
glycoprotein B (gB) forward, gBl and reverse, gB2 CMV primers (see Table 11.17).
PRIMER SEQUENCES: CMV PCR
gB 1 oligo primer (5’-3’): 25 mers gB 2 oligo primer (5’-3’): 25 mers
GAGGACAACGAAATCCTGTTGGGCA GTCGACGGTGGAGATACTGCTGAGG
Table 11.17 glycoprotein B CMV specific primers
Forward and reverse glycoprotein B primers used to amplify CMV 
DNA by competitive-quantitative or real time PCR reactions.
The following program was then run:
Duration Temperature (°C) Effect
12 min 95 denaturation
f30 sec 94 denaturation
40 cycles l 30 sec 60 annealing
^ 0  sec 72 extension
10 min 72 denaturation
Table EL18 CMV specific PCR
This table summarises all steps of the PCR reaction programme used 
to amplify double stranded gB CMV DNA isolated from patient 
samples.
A mutated internal control sequence of known copy number was included in 
each reaction, which can be differentiated from target amplicons after PCR
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amplification by digestion with Hpa 1 and separation on a 12% acrylamide gel. Gels 
were stained in ethidium bromide (0.15 pg/ml) and the viral load was calculated by 
comparing the intensity of the target band to the intensity of the control band using the 
NIH image analysis program. The data was expressed as log10 genomes/ml of whole 
blood.
Real time PCR method
Real time PCR reactions were performed in 96 well optical reaction plates (ABI Prism). 
The following components were added in the PCR mix (per tube): 1 unit of Hotstar Taq 
DNA polymerase (Qiagen), lx PCR buffer, 2 mM MgCl2, 100 ng of each of the gB 
primers (see Table 11.17). Additionally, 100 ng of gB DNA probe labelled with the 
FAM-TAMRA fluorescent reporter complex (5(6)-Carboxyfluorescein or FAM; 5(6)- 
Carboxy-tetramethylrhodamine or TAMRA) were added. The specific probe annealed 
to the gB DNA between the forward gBl and the reverse gB2 primers. Its sequence was 
as follows: 5’-FAM-CAATCATGCGTTTGAAGAGGTAGTCCACG-TAMRA-3’).
As the PCR amplification occurs, the advance of the Taq polymerase 
exonuclease activity will induce the cleavage of the FAM-TAMRA complex, 
interrupting the transfer of energy to the fluorescent quencher TAMRA, allowing the 
TAM molecule to fluoresce. Therefore, the measured TAM fluorescence in the tube is 
directly proportional to the number of DNA copies amplified in each tube. The total 
volume of the PCR mix was 20 pi per well, to which 5 pi whole gB DNA positive 
control from 1 to 105 copies per well with 50 ng/(il of Salmon Sperm to facilitate 
amplification (Virology stock at 107 DNA copies/ 2 pi) was added. Similarly, 5 pi of 
negative control (50ng/ml Salmon sperm (Sigma) in Elution buffer (EB from the 
Qiagen DNA extraction kit) or EB alone), or 5 pi of patient DNA sample was added to 
20 pi of PCR mix in the remaining wells. All positive control serial dilutions were 
tested in triplicate, a few negative controls were scattered throughout the plate, and all 
patient samples were tested in duplicate to ensure accurate and reproducible results. The 
Plate was then placed in a Taqman real time PCR machine 7700 sequence detector (ABI 
Prism), and the following program was run:
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Duration Temperature (°C) Effect
2 min 50 Enzyme hot start
10 min 95 Denaturation
rl5 sec 95 Denaturation
50 cycles L 1 min 50 Annealing and extension
Table 11.19 Real time Polymerase chain reaction
This table summarises all steps of the PCR reaction programme used 
to amplify gB cytomegalovirus DNA from patient samples with the 
7700 sequence detector (ABI Prism).
The fluorescence in each well was measured 4 times every minute while the 
program was running. Data were analysed with the sequence detector v 1.7a software 
(ABI Prism) that plotted the level of fluorescence detected in each well as a function of 
the cycle number. This allowed to verify that the amplification had occurred, and to set 
a minimum threshold of detection. Negative controls were also checked.
Am plification -  bmt2
— Samples
0 FAM -  A1 □
0 FAM -  A2 □
0 FAM -  A3 □
0 FAM -  A4 □
0 FAM -  A5 □
0 FAM -  AS ■
0 FAM -  A?
0  FAM -  A3
0 FAM -  A9 n
Viewer: f aRn (B... »1
0 2 4 6 8 10 14 18 20 24 28 30 34 38 40 44 48 50 Reporter: ( FAM
C ycle
Figure 11.13 Taqman PCR amplification for CMV viral load
The level of fluorescence (ARn) in each tube was plotted as a 
function of the cycle number and allowed to verify that each 
standard and sample had amplified correctly. It was also used to set 
the threshold of detection for the assay (—) so that the background 
fluorescence could be discounted from the analysis.
A standard curve was then produced and confirmed whether the reaction had 
worked with satisfying reliability (with a slope value close to the theoretical -3.5 and a 
correlation coefficient close to 1). The software assessed the amplification of the 
samples by determining the Ct value being the cycle number at which the PCR
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amplification becomes detectable above the set threshold (typically the Ct value for one 
CMV copy number was 41 cycles).
Standard Curve -  bmt260.00 '■ ■ ■■■ ■■■■ ■■■"  «****
50.00
2  40.00
«
"3 30.00
|  20.00 
i
£ 10.00 
0.00 
- 10.00
Figure n.14 Taqman PCR for CMV viral load: standard curve
A standard curve of the Ct results from the amplifications of the 
triplicate positive controls (•): from 1 to 105 copies of CMV DNA/ml 
of blood was plotted on a log scale graph. The slope at around -3.5 
and a good correlation coefficient confirmed that the assay was 
reliable. This was used to plot the Ct of the samples tested ( • )  and to 
calculate their respective CMV copy numbers.
To calculate the number of CMV genomes in an unknown sample, the software 
placed the Ct of the sample on the standard curve and calculated the corresponding 
quantitative value.
The mean of duplicate values was taken for each 5 jil DNA sample tested and 
the result was expressed as log10 genomes/ml of whole blood.
Unknowns
Trrri
10*610 *  1 10*3 10*4 10*5
□
-3.566
43.009
0.969
S ta r t in f Quantity
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Flow Cytometry
Flow cytometry allows the visualisation of single cell events and the simultaneous 
collection of a series of characteristics particular to that same single cell. It renders 
possible the collection of data characterising the size of the cell, its granularity and up to 
three or four cellular markers (in the case of the instruments available in the laboratory), 
labelled with fluorescent antibodies binding to cell surface molecules.
Instruments
Flow cytometric acquisition of stained cellular samples was performed on the Facscan 
Instrument, which comprised an argon-ion laser for three colours fluorescence 
detection. The instrument was upgraded to a Facscalibur Instrument, which was 
composed of both an argon ion laser and a red diode laser in early 2002 that allowed 
four colours fluorescence detection). Both instruments were purchased from Becton 
Dickinson, who calibrated and maintained both instruments.
Acquisition and/or Analysis
Acquisition and analysis on the flow cytometers were performed using the CellQuest 
version 3.3 software (BD). This was used to visualise the cellular events as they were 
being acquired by the instrument, to set the compensation (and time delay calibration 
for four colour calibration on Facscalibur) for the fluorescence detection and later, to 
analyse the samples.
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Statistical analyses
The statistical tests used to assess the data reported in the following chapters were 
carried out using the Prism 3 Software (GraphPad) package.
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Chapter III 
Detection of Antigen Specific 
Immune Responses
Introduction
Prior to the discovery of HLA/peptide tetramer complexes, the standard methods for 
detection and quantification of antigen specific T lymphocyte responses were based on 
the proliferative capacity of these cells (limiting dilution analysis) or their activation 
and response following antigen specific stimulation and assessment by interferon-y 
ELIspot. Although these tests constitute good markers of activation and effector 
function, their drawback resides in the fact that all cells specific for the same antigen are 
unlikely to give a 100% response to an in vitro (and perhaps sub-optimal) stimulus and 
proliferate at a given time. Therefore these techniques have the disadvantage of 
underestimating the true number of antigen specific T cells present in peripheral blood.
The first report of the use of HLA/peptide tetramer complexes in 1996 by 
Altman et al revolutionised the field of immunology by describing a new method that 
allowed the detection of antigen specific T lymphocytes specifically using their receptor 
specificity. This was achieved by detecting T lymphocytes with a fluorescent complex 
of their specific natural ligand directed at the T cell receptor: the HLA/peptide 
molecular complex. The fast dissociation rate of the HLA/peptide molecule from the 
TCR was compensated for by the formation of a tetramer of HLA/peptide molecules, 
which resulted in an increased avidity of the complex for the TCR. This permitted the 
detection and phenotyping of antigen specific T lymphocytes by flow cytometry. This 
method is described in further detail in Chapter II.
At the start of the work described in this thesis in 1999, this was the main 
reference describing the synthesis of HLA/peptide tetramer complexes. They had been 
used successfully for the detection of specific CD8+ T cells in the context of several 
human viral infections: human immunodeficiency virus (Altman et alt 1996; Ogg et al,
1998), influenza (Dunbar et al, 1998) and Epstein-Barr virus (Callan et al, 1998).
I l l
Chapter III
As these complexes were not available commercially at the time, the first objective of 
this PhD project was to set up a reliable method to make HLA/peptide tetramer 
complexes at the ANRI to enable the application of the most sensitive method to date 
for studying peptide specific cytotoxic T cell responses. The focus of this chapter is to 
outline the steps that were taken to apply this technology and to detect antigen specific 
T cell responses of relevance to the treatment of haematological malignancies and viral 
pathology occurring in patients receiving SCT.
CMV
The CMV study was initially focused on the HLA-A*0201 molecule, because it is the 
most common HLA subtype in many ethnic groups, with an antigen frequency of up to 
42.8% in the Caucasoid population (Marsh et al, 2000). Hence, it was chosen for 
cloning and preparing HLA/peptide tetramers in order to maximise the number of 
individuals that could be tested.
In SCT recipients, the CTL component of the immune response to CMV was 
shown to be essential for their recovery from viral reactivation (Quinnan et al, 1982, 
1984; Borysiewicz, 1988; Riddell et al, 1991). Furthermore, the adoptive transfer of 
CD8 specific T cell clones and the transfusion of leucocytes was used successfully and 
proven to be sufficient to resolve CMV reactivation post transplantation (Walter et al, 
1995; Riddell et al, 1997; Witt et al, 1998). The antigenic targets for the CTL 
component of the immune response were demonstrated by several research groups and 
were mainly directed against the following proteins: IE-1 (or pp72, UL123), ppl50 
(UL32), pp65 (UL83) and gB (UL55) (Borysiewicz et al, 1988; Wills et al, 1996; Kern 
et al, 1999; Gyulai et al, 2000; for a review on potential vaccination targets, see Plotkin, 
2002). Although the total CTL response has several components directed towards a 
range of targets, the pp65 protein was found to be a major target and shown to be 
immuno-dominant in the context of HLA-A*0201 (McLaughlin-Taylor et al, 1994; 
Wills et al, 1996; Diamond et al, 1997).
Previous work at the ANRI defined seventeen CMV pp65 candidate peptides 
selected using a computer algorithm, which tested for the presence of HLA-A*0201 
specific anchoring residues and for potential binding capacity of these peptides to HLA- 
A*0201. Subsequently, actual binding affinity was shown with both a T2 binding assay 
(or ability of the pulsed peptide to stabilise HLA expression at the surface of T2 cells) 
and a peptide competitive binding assay (competitive binding of the test CMV peptide 
to displace and bind in place of a control peptide, which was used to give 100%
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binding) by Solache et al (1999). Three of these 17 peptides, AE42, AE44 and AE45 
(see Chapter II) could bind HLA-A*0201 molecules with high or intermediate affinity. 
These peptides were used to stimulate T cells: the cells were stimulated twice with 
peptide pulsed autologous PHA blasts, followed by two rounds of stimulation with 
peptide pulsed T2 cells to raise CMV specific lines. Only the cell lines generated 
against AE42, AE44 and AE45 could kill peptide pulsed T2 targets, CMV infected cells 
and cells infected with an adenoviral construct coding for the pp65 antigen. None of the 
other peptide tested generated any CMV specific T cells after stimulation.
The fact that CMV reactivation remains a major concern post SCT was 
highlighted in Chapter I. Prior to embarking on the study of CMV specific immune 
recovery in HLA-A*0201 positive SCT recipients, it was first necessary to establish that 
CMV specific CTL responses could be reliably detected in samples from healthy CMV 
seropositive donors and from SCT recipients using the tetramer technology.
Based on these results, HLA-A*0201/peptide complexes specific for these three 
CMV peptides were generated to test whether CMV seropositive individuals possessed 
peripheral blood T cells that are specific for any of these HLA/peptide combinations. 
This would confirm whether these peptides are processed, and presented on the surface 
of CMV infected cells and are able to elicit a specific T cell response. The synthesised 
complexes detecting a positive response would then be used for the detection, 
quantification and characterisation of CMV specific responses.
CML
The success of donor leucocyte infusions for CML patients with relapsed disease after 
SCT triggered the search for the immunological component of the response that was 
observed clinically. A number of potential targets for an immune response were 
envisaged: mismatched minor histocompatibility antigens, leukaemia reactive antigens 
that are highly expressed in leukaemia positive cells but also present in normal cells, 
and leukaemia specific antigens that only exist in leukaemia positive cells (for a review, 
see Falkenburg et al, 1997).
As part of a collaborative study between three research centres (ANRI, 
Nottingham Trent University and University of Liverpool) we set out to determine 
whether leukaemia specific T cells could be identified in the blood of CML patients, 
thus helping to resolve the question of the potential leukaemia specific immunogenicity 
of CML cells. Focus was put on the BCR/ABL b3a2 leukaemia specific fusion protein 
in HLA-A*0301 positive patients. This combination was chosen for investigating the
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presence of fusion peptide specific T cells in patients and their immune potential, as a 
number of reports had previously demonstrated the intermediate affinity of the 
KQSSKALQR peptide spanning the b3a2 BCR/ABL fusion region for the HLA- 
A*0301 molecule (Bocchia et al, 1995; Buzyn et al, 1997; Berke et al, 2000). 
Additionally, a retrospective analysis of the HLA allele frequencies observed in CML 
patients revealed that HLA-A3 and particularly HLA-A3 associated with HLA-B8 were 
linked with a reduced risk of developing CML malignancy. Furthermore, the 
KQSSKALQR peptide was shown to be able to induce HLA-A*0301 restricted in vitro 
cytotoxic activity in PBMC samples from healthy donors and from patients, which 
suggested that triggering of anti-leukaemia specific T cells was a distinct possibility 
(Bocchia et al, 1996; Norbury et al, 2000).
PBMCs were isolated from blood samples obtained from CML patients and 
were tested for the presence of HLA-A*0301/KQSSKALQR specific T cells. HLA- 
A*0301/peptide tetramer complexes prepared with the KQSSKALQR peptide (or HLA- 
A*0301/CML tetramer) were used to determine whether CML specific T cells could be 
detected in the peripheral blood of HLA-A*0301 CML patients. They were prepared 
with the assistance of Audrey Bourdon, an undergraduate student at the ANRI.
Results
CMV specific immune T ceil responses 
Flow cytometry analysis of HLA/tetramer stainings
HLA/peptide tetramer complexes were composed of fluorescently labelled streptavidin 
molecule that allowed their detection (see Chapter II). Following the binding of 
tetramers to their specific TCR ligand on the T cell surface and removal of any unbound 
reagent by washing, the fluorescently marked cells were then detected by flow 
cytometry.
After isolating PBMCs from freshly drawn blood, they were first stained with 
HLA/peptide tetramer, followed by stainings with two CD markers. The first was the 
CD3 marker specifically binding to T cells, and the second was the CD8 marker 
specifically binding to the cytotoxic T cell subset. These were visualised using a 
Facscan instrument, which allowed the simultaneous detection of 3 fluorescent colours. 
Sequential gating of CD3+ T cells (panels A and B, Figure III.l), then of CD3+CD8+T 
cells (panel C) was used to ensure the specificity of the cytotoxic T cell population of
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interest. This gating strategy was necessary for the accurate detection of tetramer 
positive (Tet+) T cells, for monocytes as well as apoptotic or necrotic cells can also bind 
tetramer reagents in a non specific fashion and need to be discounted from the analysis. 
The quantification of tetramer positive cells in the samples was expressed as a 
percentage of CD8+ T cells (panel E, as reported in most references using the tetramer 
methodology), or as a percentage of CD3+ T cells (panel D). This facilitated the 
subsequent calculation of the absolute number of Tet+ T cells per ml of blood. In 
addition, this gating strategy proved to be useful with tests on SCT recipient samples, 
particularly at early times post transplant, or when cytotoxic drugs were administered to 
the patient when analysis could be difficult due to low cell number and/or cell lysis.
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Figure III.l Tetramer analysis and gating strategy
Triple staining of an HLA-A*0201 CMV+ healthy individual with 
HLA-A*0201/AE42 CMV specific tetramer, CD3 and CD8 antibodies 
are represented. All detection experiments were performed in a similar 
manner. First CD3+ T cells were gated on the forward and side scatter 
panels (A and B), then the CD8+ fraction of these CD3+ cells were 
gated (panel C). The tetramer positive events were gated thereafter 
and their numbers expressed as a percentage value of CD3+ or 
CD3+CD8+ T cells as indicated on panel D and panel E respectively.
Determination of CMV pp65 antigenic peptide targets
A preliminary study assessing the CMV specific CTL responses of a selection of 
healthy individuals and SCT recipients was conducted. The three CMV peptides 
previously discussed were tested to determine which ones would be relevant markers
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for CMV specific CTL responses. Therefore CMV specific tetramer complexes were 
prepared with these three pp65 peptides (AE42, AE44 and AE45) and tested to answer 
this question. PBMC stainings and analyses were performed as indicated in the previous 
paragraph, with representative results shown in Table III. 1 and illustrated in Figure 
m.2. Additionally, HLA-A*0201/HA-1 minor antigen specific tetramer reagents were 
used in some cases as an additional negative reagent control.
Sample HLA type CMVb
HLA-A*0201 Tetramer staining, 
%age of CD8+
AE42 AE44 AE45 HA-1
HDa 1 A*0201 + 0.60 0.02 0.03 0.02
HD 2 A*0201 - 0.04 0.01 001 nd
HD 3 A*30/A*31 + 0.02 0.01 0.02 nd
Patient 4 A*0201 +/+ 11.17 0.02 0.02 0.01
Patient 9 A*0201 -/- 0.02 0.01 0.03 0
Table m .1 Results of representative CMV specific tetramer 
stainings
a HD, healthy donor; b CMV, cytomegalovirus serostatus and 
patient/donor serostatus when applicable.
Responses to three CMV epitopes (AE42, AE44 and AE45) were 
measured by HLA-A*0201/peptide tetramer staining. T cells specific 
for the HLA-A*0201/AE42 tetramer were only detected in CMV 
seropositive individuals as seen for HD 1 and Patient 4. HD 1 is 
representative of 8/9 healthy CMV+ donors, Patients 4 and 9 are 
representative of 12 SCT recipients tested over a 4 months period.
HD 2 is representative of 5 CMV' healthy donors tested.
As can be deduced from the representative samples reported in Table III. 1, none 
of the individuals tested showed CTL populations specific for the HLA-A*0201/AE44 
or the HLA-A*0201/AE45 tetramers. Neither the HLA-A*0201' CMV+ (one healthy 
individual tested), nor the HLA-A*0201+ CMV* samples tested (representative of 5 
healthy individuals and 5 SCT recipients tested) stained with any of the tetramer 
reagents. The HLA-A*0201/AE42 tetramer was the only one that stained consistently 
showing a discrete population of CTLs in all but one of the HLA-A*0201 CMV 
seropositive individuals. The sample from donor HD 1 (0.60% of CD8+ T cells) is 
representative of 8 healthy individuals tested, and the sample from Patient 4(11.17% of 
CD8+ T cells) is representative of 12 SCT recipients tested in this preliminary study. 
The only healthy CMV+ volunteer that did not have any HLA-A*0201/AE42 specific T 
cells was later shown to respond to the CMV IE-1 antigen by another student in the
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laboratory. The patients were therefore tested in a longitudinal study to determine if 
CMV reactivation would trigger the emergence of HLA-A*0201/AE44 or HLA- 
A*0201/AE45 specific T cells. All tetramer stainings performed in this context were 
negative. Although no HLA-A*0201/AE44 nor HLA-A*0201/AE45 specific T cells 
could be detected in samples from healthy individuals or SCT patients, there was still a 
possibility that these cells may be present at a level below the detection limit of the 
assay. A specific antigenic stimulation should result in the proliferation of these cells, 
which should bring them above the detection limit. CTL responses to HLA- 
A*0201/AE42, HLA-A*0201/AE44 and HLA-A*0201/AE45 were examined in the 
context of CMV reactivation after SCT. The result obtained from representative 
samples of a CMV+ SCT recipient (patient 4) are represented on Figure III.2, together 
with a sample from a healthy CMV+ donor sample. The data presented clearly 
demonstrate the fact that only T cells specific for the HLA-A*0201/AE42 combination 
proliferated in response to an “in vivo” CMV antigenic stimulus that could be detected 
by tetramer staining. By contrast, no T cells specific for HLA-A*0201/AE44 or HLA- 
A*0201/AE45 could be seen above the detection level of the assay. This further 
confirmed that no T cells specific for HLA-A*0201/AE44 or HLA-A*0201/AE45 are 
present in the peripheral blood from CMV+ healthy individuals or SCT recipients.
The HLA-A*0201/AE42 was therefore chosen for the identification of CMV 
pp65 specific T cells in PBMC samples. This tetramer complex will be referred to as 
CMV tetramer in the following paragraphs.
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Figure III.2 CMV tetramer specific staining
Representative stainings with HLA/peptide CMV specific tetramer 
reagents prepared with the peptides: AE42 (■), AE44 (■  ) and 
AE45 (■). 4 individual samples are shown: one from a healthy CMV+ 
donor (HD1) and 3 from a CMV+ recipient of a CMV+ graft (patient 4) 
before and after occurrence of CMV infection after SCT (panel A), 
with the section from 0 to 0.5% CDS^eC cells magnified (panel B).
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CMV tetramer staining specificity 
Staining temperature
The issue of staining specificity for tetramers is essential for the accurate detection of 
antigen specific T cells. Whelan et al (1999) demonstrated that the specificity of 
tetramer staining was temperature dependent and that the highest specificity was 
obtained by staining at 37°C, with some degree of cross reactivity and that additional 
non specific staining was observed at lower temperatures. Tests on the staining 
specificity of CMV tetramers were performed on samples from healthy CMV 
seropositive individuals at both 4°C and 37°C. Results were concordant with the data 
generated by Whelan et al (data not shown). Accordingly, and as mentioned in Chapter 
II, all subsequent HLA/peptide tetramer stainings were performed at 37°C for 30 
minutes.
Competitive block of CD3 binding
As described previously, HLA/peptide tetramer complexes bind to their natural ligand 
on the T cell: the TCR. The CD3 molecule is part of the TCR complex and therefore 
lies in close proximity to the a  and P chains of the TCR molecules on the cell surface. 
As a consequence, the binding of tetramer complexes to the a/p TCR might prevent to 
some degree the subsequent staining with anti-CD3 antibodies. However, non-specific 
and/or low affinity binding of the tetramer to its ligand would not prevent the binding of 
the anti-CD3 antibody. This phenomenon was confirmed by Hoffmann et al (2000) and 
can be used as a test of specificity for the binding of HLA tetramers to their respective 
TCR. This can be visualised by comparing the geometric mean of CD3 fluorescence 
intensity in the lymphocyte population, to the geometric mean CD3 fluorescence 
intensity in the CDS^ef1' cell population. The ligand specificity is confirmed if the level 
of CD3 antigen visualised on the Tet+ T cell surface is lower as compared to the 
expression on the general T lymphocyte population.
This procedure was applied to CMV specific stainings (see Figure III.3), which 
were characterised by high affinity of the peptide for the HLA-A*0201 molecule and 
relatively high T cell frequencies in peripheral blood. Figure III.3 shows two 
representative samples from HD1 and patient 6 respectively, where live lymphocytes 
were gated, as well as CD3+ cells and the CD8+ Tet+ cells subsequently visualised.
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Figure III.3 Specificity of tetramer staining
Competitive block of CD3 antibody binding following tetramer 
staining.
Two healthy donors are represented. Live lymphocytes were gated 
(panel A, • ) ,  and CDSTeC cells painted in pink (• ) . A histogram 
plot of CD3 staining intensity is shown on panel B with the gated 
CD3+Tet+ population in pink. The respective geometric mean 
fluorescence intensity values of the CD3 marker were: HD 1, CD3+: 
306, CD3+Tet+: 101; patient 6, CD3+: 403, CD3+Tet+: 106. This can 
also be visualised on the dot plot (panel C) representing the gated live 
lymphocyte populations using Paint-a-Gate, and the CD3 expression 
of the whole CD3 T cell population (top half) and the CDS^eC T cell 
population in pink.
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The mean fluorescence intensity of the CD3 marker between the CD3+ Tet' T cell 
population and the CXtt^et* population was measured. This level of fluorescence was 
consistently and significantly lower in the T cells that bound the tetramer reagent prior 
to the incubation with the CD3 antibody, therefore indicating the specific occupancy of 
the ap  TCR on Tet+ cells (CD3 fluorescence intensities of: 101 versus 306 and 106 
versus 403 for HD1 and patient 6 respectively). It proved to be a reliable way to check 
the specificity of tetramer stainings and also particularly useful in testing the 
consistency of the stainings when new batches of tetramer reagents were prepared.
However, this assay may not be suitable for testing all HLA/peptide tetramer 
reagents as Hoffmann et al noted that this test had proven inconclusive in the case of 
rare tetramer positive events.
Correlation of CMV tetramer staining with CMV specific effector function
The release of IFN-y following specific T cells activation has been shown to be 
important in the fight against viral pathogens with its direct anti-viral properties 
involving the prevention of viral replication in previously uninfected cells as well as 
immunoregulatory effects (Guidotti and Chisari, 1996; Biron et al, 1999, 2001; Durbin 
et al, 2000). The other major functions of IFN-y are the recruitment of macrophages to 
the site of infection, their activation, and the up-regulation of the expression of MHC 
molecules and antigen processing components in cells upon binding of the IFN-y 
receptor.
The production of IFN-y following peptide stimulation of freshly isolated PBMCs from 
HLA-A*0201 and CMV+ healthy individuals was examined by ELIspot assay. In 
parallel, CMV tetramer staining was performed to determine the frequency of CMV 
peptide specific T cells. The two analyses were run simultaneously on fresh PBMC 
samples, and the same CMV pp65 specific peptide was used for both techniques. The 
results obtained for three representative healthy CMV+ individuals of six tested are 
represented on Figure III.4 and were compared with the Pearson’s test to establish 
whether the two correlated. The correlation between the two data sets was calculated 
and the resulting Pearson’s coefficient was r=0.99 (p<0.001). This result represented a 
high correlation between CMV specific tetramer staining and IFN-y that was consistent 
with the concept that the CMV Tet+ CTLs were capable of mediating an antiviral 
response in CMV+ healthy individuals.
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Figure III.4 CMV peptide specific effector function
CMV tetramer staining and CMV peptide specific CD8+ T cell IFN-y 
ELIspot assays were performed in parallel on freshly isolated PBMC 
samples from healthy CMV+ individuals. CMV Tet+ T cell frequencies 
are indicated on the dot plots and are expressed as a percentage of 
CD8+ T cells. The number of spot forming units (sfu) per 2xl05 
PBMCs after overnight peptide stimulation (AE42 at 10 pg/ml, ■) in 
ELIspot assays were counted; the background IFN-y release (medium 
alone control, □ ) was subtracted before the degree of correlation 
between the two measurements was assessed.
123
Chapter III
other available option was to use a T cell clone, which would provide good purity of the 
cellular population to be tested. As T cell clones specific for CMV were known to be 
available, colleagues in Leiden were therefore contacted, and they kindly agreed to 
donate a cryopreserved HLA-A*0201/CMV AE42 restricted T cell clone.
An assay measuring the rate of apoptosis (or programmed cell death) by staining 
for intracellular caspases (Apostat) was chosen and was set up rather than using the 
more classic chromium (Cr51) release assay because T cell numbers were limiting. All 
pathways inducing apoptosis lead to the activation of a series of caspase enzymes that 
end with the activation of a DNase that transfers to the cell nucleus and cleaves DNA 
therefore causing cell death. Substrate recognition motifs are conserved between 
caspases and were exploited to develop an irreversible competitive fluorescent peptide 
that can then be detected in cells undergoing apoptosis. This technique was chosen in 
order to reduce the number of cells from the clone used in each experiment. CMV 
pulsed T2 target cells were labelled with the membrane red dye PKH 26 and incubated 
with differing ratios of CMV specific T cells; after 3 hours they were then assessed for 
apoptosis with the Apostat staining reagent (measuring the level of active caspase 
enzymes labelled with the FITC marked peptide). A major problem that was 
encountered in these experiments was that the CMV specific T cell clone lost viability 
rapidly and cultures could not be maintained with over 50% viability. Attempts to 
recover viable cells by density gradient centrifugation were unsuccessful. Staining with 
anti-CD95 antibody revealed a high expression level on the surface of Tet+ cells, 
suggesting a high apoptotic potential for these cells. This resulted in disappointing 
results for the killing assay that could not be reproduced reliably after three attempts 
following short-term in vitro culture with IL7 and IL15.
Despite this unsatisfactory outcome, specific killing was observed using the 
same effector and target system (but with a different labelling combination) by 
fluorescent microscopy as seen in Figure IU.5. Binding of the tetramer labelled T cells 
to the larger peptide pulsed T2 target cells was observed (Figure III.5, C). This 
demonstrated the specific targeting of pulsed T2 cells by the T cell clone and 
subsequent cytotoxic killing as visualised by the apoptotic morphology of the target 
(irregular shape, shrinking cytosol and presence of large granules, Figure HI.5,D).
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Figure III.5 CMV Tetramer+ T cell cytotoxicity
A T cell clone specific for CMV was purified from a HLA-A*0201 
healthy donor, was generated by single cell sorting and subsequent in 
vitro expansion. This clone was stained with HLA-A*0201/CMV 
tetramer and proved to be 96% pure (panel A). T2 cells were labelled 
with the green PKH 67 dye, washed and pulsed with 1 mg/ml CMV 
AE42 peptide for two hours (panel B). Cloned T cells pre-stained with 
tetramer were added to the T2 at a 1:1 ratio and incubated at 37°C. 15 
minutes after mixing the two cell types, attachment of the T cells to 
the T2 targets was observed (panel C). The T cells could later be 
observed still attached to a target, which presents typical apoptotic 
morphology after half an hour to an hour (Panel D).
The synthesis and appropriate testing of HLA/peptide tetramers allowed the 
detection of antigen specific CD8 T cells in healthy individuals. Positive tetramer 
staining could be correlated with effector function upon peptide stimulation and 
together with target specific cytotoxicity. The HLA/peptide tetramer technology was 
therefore applied to the detection of antigen specific responses of potential diagnostic
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and/or therapeutic interest for the treatment of patients with haematological 
malignancies.
CMV specific T cell detection in patients post SCT
Following the generation of HLA-A*0201 restricted tetramers containing the 
immunodominant peptide AE42 from CMV pp65 and the identification a tetramer 
positive population of CD8+ T cells in healthy seropositive individuals, SCT samples 
were obtained after engraftment and were tested for the presence of CMV specific T 
cells.
Patients characteristics are described in Chapter II, in particular the CMV 
serostatus of the patients and that of their donors, which were relevant to the detection 
of CMV specific T cells. It had been previously established (Table ELI and Figure 
IH.2) that only HLA-A*0201 restricted T cell responses to the AE42 CMV peptide were 
detectable in both healthy donors and SCT recipients. All 19 CMV+ SCT recipients 
showed detectable populations of CMV tetramer specific T cells whether they were 
expected to have acquired specific T cell immunity from the graft they received (for the 
patients with CMV+ donors) or not for the CMV+ patients with CMV' donors who 
subsequently had CMV infection following transplant. Representative samples are 
shown on Figure III.6, with HD1 a healthy CMV+ control. As is the case for healthy 
CMV+ donors, CMV specific T cells can be reliably detected in PBMC samples from 
CMV+ patients after SCT using HLA/peptide tetramer reagents. Additionally, CMV 
specific T cells were successfully detected after staining with HLA/peptide tetramer 
reagent in all CMV+ recipients, whether their donor was CMV+ or CMV'. Therefore 
patients with CMV' donors, although having no transferred memory T cell immunity, 
should be able to mount a cytotoxic response to CMV challenge (Figure III.6, patient 1). 
It can be noted that CMV' patients with CMV' donors consistently had negative staining 
with CMV Tet, highlighting an absence of CMV specific T cell immunity in these 
patients and giving further evidence to confirm that these patients had not previously 
contracted CMV. This allowed for the reliable detection and longitudinal study of CMV 
specific T cells in all SCT patients at “risk” of cytomegalovirus reactivation and CMV 
disease post SCT (CMV+/' and CMV+/+). The CMV specific immune recovery of all 
patients recruited in the CMV study will be further examined later in Chapter IV.
The accurate identification of CMV specific Tet+ T cells can be exploited to 
further characterise these cells and their properties.
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Figure III.6 Detection of CMV specific T cells in SCT recipients
Representative CMV tetramer stainings, gating on CD3+ T cells 
(blue), and representing CD3+CD8+ T cells in the upper half of each 
panel, with CD3+CD8+Tet+ T cells in pink. As shown in CMV' 
healthy individuals, no Tet+ T cells were detected in samples from 
CMV' recipients of SCT with a CMV donor. As shown for CMV+ 
healthy individuals (Healthy donor panel), Tet+ discrete T cell 
populations were detected in all CMV+ SCT recipients, regardless of 
their donors’ serostatus (CMV+,Patient 4; CMV',Patient 1).
Phenotypic analysis of CMV specific CD8 T cells
Further phenotypic analysis of CMV specific Tet+ CD8 T cells became possible in the 
later stages of these studies with the acquisition of a Facscalibur flow cytometry 
instrument allowing the simultaneous detection of four distinct fluorescent colour 
emissions, by simultaneously staining for tetramer and antibodies to specific cellular 
molecules that are characteristic for distinct cell populations.
Traditionally, the two distinct isoforms of the transmembrane phosphatase CD45 
were used together with CD8 to separate naive cytotoxic T cells CD45RA+, from 
antigen experienced (or memory) CD45RO+, as the latter form becomes up-regulated
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after activation (Akbar et al, 1988; Merkenschlager and Beverley, 1989). However this 
concept has since been re-evaluated as CD45RA high populations were shown to 
comprise both naive and memory T cell subsets (Wills et al, 1999), and these CD45RA 
high memory T cells were thought to constitute a terminally differentiated T cell 
population or terminal effectors. To characterise tetramer positive T cell populations in 
SCT recipients in whom these responses are likely to be originating from donor T cells 
transfused with the graft (in the cases of CMV+/+ transplants) and therefore to be antigen 
experienced, CD45RO was used as a marker of the memory phenotype.
In addition to characterising the naive or memory phenotype of T cells, it is 
possible to segregate T cells into memory or effector memory cells by staining for the 
CD27 co-stimulatory molecule (respectively CD27+ and CD27\ Hamann et al, 1997), 
which becomes irreversibly downregulated following T cell receptor triggering. 
Therefore CD45RO in combination with CD27 allows the differentiation of naive CTLs 
(CD45RO- CD27+), memory CTLs (CD45RO+ CD27+), effector memory CTLs 
(CD45RO+ CD27 ) and terminal effector CTLs (CD45RO' CD27 ).
A further and more recently available marker of memory T cell differentiation 
was described with the chemokine receptor CCR7. CCR7 is a lymph node homing 
receptor and hence defines a population termed central memory cells, whereas CCR7' 
cells (effector or peripheral memory, to distinguish them from CD27+/) express 
receptors for peripheral circulation and/or migration into inflamed tissues (Sallusto et 
al, 1999).
These three markers, CD45RO, CD27 and CCR7 were used simultaneously with 
CMV tetramer staining or CD8 specific staining (as a reference for the general cytotoxic 
population and a guide for the gating of positive and negative cell subsets) to 
characterise the cytotoxic CMV specific T cell population in SCT recipients.
All patients at risk of CMV reactivation were selected, and staining data 
representative of a healthy donor and two SCT recipients is shown on Figure m.7.
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Figure III.7 Phenotypic characteristics of CMV specific Tet+ T 
cells and CD8+ T cells
Panels are representative of CMV tetramer specific staining and CD8 
specific staining ( • )  A shows staining for a CMV+ HLA-A*0201 
healthy donor (HD1), panels B and C show stainings for two CMV+/+ 
SCT recipients, patients 5 and 6 respectively. Positive events were 
gated and the cells were sub-categorised according to their 
phenotypic or activation marker expression ( • )  with antibodies to 
CD45RO, CD27 and CCR7. The relative percentages of negative and 
positive events for each sub-category are reported in the top right end 
comer.
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This characterisation was performed retrospectively from frozen PBMC 
samples, from 8 SCT patients, at timepoints when no current CMV reactivation was 
detected by PCR screening; the phenotype results for the majority of Tet+ T cells are 
summarised in Table III.2.
CD27
Tet+ cells 
CD45RO CCR7 CD27
CD8+ cells 
CD45RO CCR7
HD1 + + - - - -
1 + + - - - -
2 +/- + - +/- +/- -
4 +/- +/- - - - -
5 - - - +/- - -
6 - + - - - -
7 + + - +/- +/- -
19 + + - - - -
23 + + - +/- - -
Table III.2 Phenotypic characteristics of CMV Tet+ and CD8+ T 
cells in 8 SCT recipients
The analysis of the phenotype and activation status of CMV specific 
Tet+ T cells and CD8+ T cells was examined in 1 healthy CMV+ donor 
and 8 SCT recipients. Tet+ or CD8+ T cells were gated and the 
percentage of CD45RO, CD27 and CCR7 positive and negative T 
cells were determined in each gated population as seen on Figure 111.7 
the phenotype of the majority of gated cells are reported in the above 
table.
From the data reported in Table in.2, the following can be drawn. Firstly, in the 
majority of the patients tested (6/8 high frequencies, 1 heterogeneous, 1 low), CMV 
Tet+ T cells expressed high levels of CD45RO, consistent with memory T cells. It is of 
note that there was a higher proportion of T cells expressing CD45RO in the Tet+ 
population than in the total CD8+ population, indicating that the great majority of CMV 
Tet+ T cells belong to a memory population.
Secondly, the expression of CD27 seemed slightly less conserved in this patient 
group with 4/8 SCT recipients with a high proportion of CD27+ cells, 2 with an 
intermediate proportion and 2 with a low proportion of CD27+ cells. This would suggest 
that CD27 was heterogeneously expressed on Tet+ T cells, highlighting a CMV specific 
memory or effector-memory phenotype CTL population in these SCT recipients. By 
comparison, the total CD8+ pool had a much more differentiated phenotype with mostly 
effector type cells that had already encountered a TCR signal.
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Finally, a large proportion of Tet+ T cells did not express CCR7. This was found 
in all patients, demonstrating that these cells were destined for circulation in the 
peripheral blood and tissues, as did the majority of the CD8+ pool of cells and also 
probably memory type cells inherited from the donor.
The results obtained for patient 5 are somewhat unexpected, as the majority of 
CMV specific T cells appear to consist mainly of terminal effector type cells (CD27' 
CD45RO' CCR7', while there was no evidence of CMV infection after transplant. 
Therefore these cells are likely to be of donor origin, but this also raises the question of 
a possible undetected CMV infection during SCT or early after SCT, or of a possible 
reactivation in the donor prior to the stem cell harvest.
The predominant phenotype of Tet+ T cells tested was found to be CD45RO+ 
CD27+/‘ CCR7", consistent with a peripheral memory or effector memory phenotype. 
This was shown to be true for the majority of the SCT patients analysed. However, it is 
to be noted that some variability was observed with the CD45RO marker and more so 
with CD27 marker expression highlighting a degree of heterogeneity in the level of 
differentiation of Tet+ T cell population that were observed between different patients.
Detection of BCR/ABL specific T celis in CML patients
The following details the work performed as part of this thesis in the detection of CML 
specific T cell responses. These experiments were all performed using HLA tetramers. 
All other data related to the project and the collaborations with other groups will be 
detailed in the text to ensure clarity in the explanations, and the related publication will 
be cited as a reference; however, the raw data will not be reproduced here. This project 
was part of a collaborative study and our contribution at the ANRI consisted in the 
production of transfected K562 cells for epitope identification and in the production and 
use of HLA tetramers to investigate the presence of circulating leukaemia specific T 
cells in these patients.
Elution of KQSSKALQR peptide from the surface of a CML b3a2+ cell line
The work described in this paragraph was performed at the ANRI and in collaboration 
with our colleagues from Nottingham University prior to this PhD project.
The erythroid lineage cell line K562 does not express HLA molecules at its 
surface as a consequence of its early differentiation state. It is however positive for the 
b3a2 BCR/ABL chromosomal translocation found in approximately 40 % of CML 
patients. This translocation gives rise to transcripts encoding for the p210 b3a2 protein
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of BCR/ABL, producing a novel protein in CML patients. The K562 cell line was 
transfected at the ANRI with a plasmid encoding for the full length HLA-A*0301 
molecule. Cell surface expression was confirmed by staining with the HLA-A3 specific 
monoclonal antibody Gap-A3 and with the HLA class I conformational specific 
antibody W6/32. The expression of the HLA-A3 antigen on the cells surface allowed 
the binding and presentation of endogenous peptides at the cell surface specifically in 
the context of the HLA-A*0301 molecules. As no other HLA molecules are present on 
the K562 cells, all peptide presentation would be focused through this HLA antigen. 
Once successfully transfected K562 cells had been obtained and a stable cell line 
established it was then possible to search for the presentation of the KQSSKALQR 
peptide spanning the BCR/ABL junction, which was thought to be present on cells 
bearing the b3a2 translocation and that were also HLA-A3 positive. This transfected 
K562 system resulted in a great simplification of the data obtained for analysis as a very 
large pool of peptides are normally presented by up to six different classical HLA class 
I molecules on the surface of a normal cell. The potential presentation of the 
KQSSKALQR peptide in the context of HLA-A*0301 was investigated by performing 
peptide elutions, followed by the analysis of the amino acid sequence of the eluted 
material by tandem mass spectrometry by our colleagues in Nottingham. As a reference 
for the peptide profile and to account for the cellular background, a control cell line was 
loaded with excess KQSSKALQR peptide and the mass spectrometry profile was 
analysed. Peptide eluate from cultured HLA-A*0301 transfected K562 cell line was 
subsequently analysed, as well as PBMCs isolated from a CML b3a2+ HLA-A*0301 
positive patient and both produced identical peptide profiles on the mass spectrometry 
read-out. This analysis was published in Blood (Clark et al, 2001).
It was therefore concluded that the KQSSKALQR peptide could be presented at 
the surface of CML b3a2+ cells in the context of HLA-A*0301 and consequently was a 
potential target by the immune system, and in particular by CD8+ cytotoxic T cells.
Detection and stimulation of KQSSKALQR specific cytotoxic T cells
In order to test whether a KQSSKALQR peptide specific CD8+ cytotoxic response 
could be detected in HLA-A3+ CML patients, HLA-A*0301/KQSSKALQR tetramers 
were prepared as described in Chapter II.
Representative staining for six CML patients who were b3a2 and HLA-A3 
positive are shown on Figure HI.8. For some of the CML b3a2+ HLA-A3+ patients 
(patients 26 and 27), KQSSKALQR tetramer specific T cells were detected, while in
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others, the staining was negative or below the detection level of the assay. The mean 
frequency detected in CML b3a2+ HLA-A3+ individuals was 0.2% of CD8+ T cells, with 
a range of 0.01 to 1.03%. As expected, the CML b3a2+ HLA-A3' patient did not stain 
with the tetramer, neither did 2 CML'HLA-A3' patients (one of these patients was 
CMV Patient 5, who also had a high frequency of CMV tetramer positive T cells).
For some of the patients selected in this study, expansion of the CML specific T 
cell populations was attempted by our colleagues in Liverpool to assess if these cells 
could be used in immunotherapy protocols. The stimulation was performed using 
KQSSKALQR peptide pulsed autologous PHA blast cells as antigen presenting cells 
(Clark et al, 2001). After one or several rounds of stimulation and subsequent in vitro 
cell culture, two samples were tested by staining with HLA-A*0301/KQSSKALQR 
tetramer (Figure III.8) and showed a significant expansion of the tetramer positive cells. 
It was presumed that patient 28 who acquired tetramer positive T cells after stimulation 
had CML specific T cells present in the freshly stained sample but that were likely 
below the detection level of the assay.
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Figure III.8 Detection of BCR/ABL b3a2 junction peptide specific 
T cells
PBMCs were isolated and stained with HLA-A*0201/AE42 (control reagent and 
gating reference) and HLA-A*0301/KQSSKALQR tetramers. The data presented 
is gated on CD3+ events and Tet+ events are expressed as a percentage of CD8+ T 
cells. Patients 26,27 and 28 are CML b3a2+ and HLA-A3 positive, Patient 29 was 
CML b3a2+ but HLA-A3 negative, and Patient 30 was CML' and HLA-A3 . Also, 
CMV Patient 5 was a further control and was CML', HLA-A3 , but was known to 
have a strong CMV specific T cell response.
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This confirmed that CML KQSSKALQR HLA-A*0301 restricted tetramer 
specific T cells were able to respond to an HLA matched peptide specific stimulus and 
proliferate in vitro.
CML fusion peptide KQSSKALQR specific CD8 T cell cytotoxicity
The cells expanded in vitro as described above were also used in chromium release 
assays to test their specific cytotoxic potential in vitro. For three of the patient samples 
also tested by tetramer staining (patients 26, 27 and 28, Figure III.8), specific killing of 
lymphoblasts pulsed with peptide, of matched lymphoblasts pulsed with peptide, and 
most significantly of autologous CML cells was demonstrated. Control autologous and 
matched lymphoblasts without peptide were not killed in these assays (Clark et al, 
2001).
This demonstrated that CML peptide specific expanded PBMCs are able to kill 
peptide pulsed or autologous CMLb3a2+ cells in an HLA restricted manner, 
highlighting the possibility for the application of a CML tumour specific 
immunotherapeutic approach.
Discussion
The development and wider availability of HLA/peptide tetramer complexes in the past 
few years has led to an explosion in the number and diversity of studies focused on 
antigen specific immune responses. As part of this thesis, HLA-A*0201 and HLA- 
A*0301 recombinant molecules have been successfully prepared and were used to make 
HLA/peptide tetramers, which were used to detect antigen specific responses of 
relevance to haematological malignancies.
Initially, this technology was applied to the detection of CMV specific CD8 T cell 
responses, and pointed to the fact that this response was directed against only one of the 
three pp65 peptide epitopes selected both in healthy CMV seropositive individuals and 
in patients post SCT. While responses can be induced in vitro to peptides AE44 and 
AE45, we saw no evidence of responses ex vivo, even though these peptides were found 
to be better binders of HLA-A*0201 than the AE42 peptide, to which all seropositive 
individuals tested showed a response. In this respect, the data described in this thesis 
suggest a significant caveat in relying on the binding of peptides to MHC molecules as 
the sole basis for epitope prediction. This indicates that the affinity of candidate 
peptides to the chosen HLA molecule cannot be considered solely from peptide epitope 
definition, and that knowledge of the antigen or molecule targeted as well as specific
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antigen restricted detection and function are indispensable to the definition of an 
antigenic peptide. Furthermore the study of immune responses in numerous individuals 
is needed to establish the relative immunodominance of selected antigens in an HLA 
restricted manner to ensure that the response visualised is representative of the total 
cytotoxic immune response.
The staining specificity of tetramer reagents was tested and the detection of 
CMV tetramer specific positive T cells correlated well with peptide specific effector 
function as measured by IFN-y ELIspot. However, it was not possible to directly 
visualise tetramer staining together simultaneously to the peptide specific IFN-y 
production as a flow cytometry instrument allowing the detection of 4 fluorescent 
colours was not available at the time that these experiments were conducted. In 
addition, specific binding and cytotoxicity of CD8+ CMV Tet+ T cells towards HLA 
matched and peptide specific targets could be demonstrated in vitro. Furthermore, CMV 
specific T cells have been shown to produce cytokines following virus specific 
stimulation, even in a CD4 deficient environment (Appay et al, 2000). This fact is of 
particular interest in the context of SCT, as patients often have deficient or abnormally 
distributed cellular immune responses. These findings were a good indication that the 
detection of immunodominant CD8+ CMV specific T cell responses in SCT patients 
could constitute a significant marker of their virus specific immune recovery. CMV 
specific T cells could be reliably detected in all SCT patients at risk of reactivation, 
regardless of their donors’ serostatus, setting the conditions for a longitudinal study of 
CMV specific immune recovery post SCT. Similar CMV specific tetramer detection 
data with samples obtained from healthy CMV seropositive individuals was reported by 
Gillespie et al (2000), which highlighted what seemed to be a degree of functional 
heterogeneity in these cells, with a substantial proportion being cytotoxic. However, this 
data may not be representative of in vivo cytotoxicity as it was generated using a T cell 
clone selected and expanded by in vitro stimulation, processes that may modify the 
properties of these T cells. The correlation between antigen specific tetramer staining 
with effector function and cytotoxic activity has also been demonstrated for other 
viruses i.e. HIV (Goulder et al, 2000), EBV (Burrows et al, 2000) and hepatitis C 
(Lechner et al, 2000). The detection and function of antigen specific T cells was also 
examined in relation to the phenotypic and activation markers in an effort to further 
characterise their nature and properties. The expression of the CD45RO, CD27 and 
CCR7 markers was tested for retrospectively in one healthy CMV seropositive 
individual sample and in 8 SCT recipient samples. The findings confirmed that the
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majority of CMV tetramer positive T cells were of memory phenotype, had a 
heterogeneous expression of the CD27 activation marker (CD27+ memory and CD27 
effector-memory) and were nearly all committed to the peripheral circulation. These 
characteristics were found to vary amongst this group of immunosuppressed SCT 
patients. The heterogeneity of memory CMV specific T cells was also demonstrated in 
healthy CMV seropositive individuals (Gillespie et al, 2000; Vargas et al, 2001) and in 
other groups of immunosuppressed individuals: in renal transplant patients (Gamadia et 
al, 2001) and in HIV patients (Champagne et al, 2001). After considering all these 
results, it becomes difficult to categorise CMV specific T cells in previously infected 
individuals, although a common feature would be a relatively differentiated memory 
peripheral phenotype. The case of patient 5 was surprising as the CD8+ CMV Tet+ T cell 
population that was detected was mainly CD27 and CD45 RO', which indicates a 
terminally differentiated cell population, believed to be short lived terminal effectors. 
This was unexpected, as no CMV replication was ever detected in samples from this 
patient, therefore there was no evidence of the presence of antigen to induce this type of 
differentiation. However it is possible to speculate that such a largely expanded 
differentiated population might have arisen from an expansion from already 
differentiated donor cells, or perhaps from an undetected episode of CMV infection 
after SCT. By contrast to findings with CD27 and CD45RO expression, CCR7 
expression was found to be consistently negative in CD8+ CMV Tet+ T cell populations. 
However, CCR7 expression was shown not to influence immediate effector function or 
cytotoxicity in the context of recall memory responses both in humans (Sallusto et al,
1999) and in mouse models (Unsoeld et al, 2002). However, recent studies investigating 
T cell differentiation pathways have pointed CD27 as being a marker to be investigated 
further. Tomiyama et al (2002) have shown that CMV specific CD8+CD45RA'CD27' T 
cells were producing more cytokines (IFN-y, TNF-a) than CD8+CD45RA'CD27+ cells 
for a comparable cytotoxic capability. Additionally, Campbell et al (2001) have shown 
that in CD4 memory T cells, the ratios of CD27 CCR7* to CD27+CCR7+ cells varies 
from tissue to tissue and may correlate with the number of cells actively engaged in 
antigen recognition within a given tissue. Therefore further investigation of CD27 
expression might clarify further memory differentiation pathways and the assessment of 
the response to active or recurrent infection. Thus most studies of CD8+ Tet+ T cells 
have reported a relatively broad phenotypic distribution amongst CD8 T cell subsets 
that have lost CCR7 expression highlight the fact that an attempt at categorising these 
responsive cell populations in persistent viral infections may be inappropriate (Hislop et
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al, 2001; Appay et al, 2002). However, the focus on the phenotype of antigen specific T 
cells in the context of SCT will probably need further be investigation in order to 
determine the relative proportions and the level of differentiation of cell populations. 
This may lead to insights with respect to their functional potential and/or life span.
The HLA/peptide tetramers were also used to determine if a tumour specific 
BCR/ABL fusion peptide CD8 T cell response could be detected in CML patients. In 
some cases, these T cells were present at very low frequencies compared to those 
observed in a virus specific response, and in other cases they were not detected. Yet, 
some proved to be present at levels below the detection limit of the tetramer staining, 
and appeared to represent very few cells that could subsequently be expanded in vitro. 
Together with the demonstrations that the KQSSKALQR fusion peptide was presented 
at the surface of BCR/ABL HLA-A*0301+ cells, that it stimulated PBMCs from CML 
patients, which subsequently specifically killed BCR/ABL targets in a HLA restricted 
manner, the positive detection of CML specific CD8+ T cells with HLA/peptide 
tetramers provided the first evidence for a truly tumour specific immune response. 
However these low cell numbers make tests constructed to address the question there 
are so few antigen specific T cells very difficult to perform, however ways of enhancing 
these to favour a strong response must be investigated. The reasons for finding such a 
limited T cell response in CML patients are likely to be multi-factorial, and there is 
emerging evidence that the immune system may be affected with for example defects 
detected in antigen processing by dendritic cells (Eisendle et al, 2003). Furthermore, in 
the case of patients treated for established tumours, many mechanisms are thought to 
contribute to tumour immune escape. These include the exhaustion of the immune 
response, the tolerisation of the immune response or simply escape of the tumour by 
lack of HLA class I expression or lack of appropriate co-stimulation on the surface of 
the tumour cells.
Although the present study was restricted in the first instance to HLA-A*0301, 
other HLA class I BCR/ABL fusion peptide specific epitopes have been described: for 
example HLA-A24 and HLA-A2 (Nieda et al, 1998; Yotnda et al, 1998). So tumour 
specific responses could now be investigated using a similar strategy to that described 
above and published by Clark et al in the context of other HLA alleles. However, the 
BCR/ABL fusion peptide or the fusion protein are not the only potential targets in 
CML. The other translocation (b2a2) described in Chapter I as well as the whole 
sequence of b3a2 might be stimulating tumour associated responses. Also, other tumour 
associated immune responses directed towards antigens which expression is highly up-
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regulated in CML have also been reported. For example, Molldrem et al (2000) have 
shown using HLA tetramers that the detection of proteinase 3 (PR1) tetramer specific T 
cells correlated with a positive clinical response. Similar findings were also 
demonstrated in the case of the Wilm’s tumour protein (WT1) with WT1 specific 
cytotoxic T lymphocytes able to kill leukaemic progenitor cells (Gao et al, 2000), and 
WT1 specific peptides described by Bellantuono et al (2002), although WT1 specific 
HLA tetramers haven’t been used to date. A similar approach was attempted in the 
study presented in this chapter, with the search for candidate patients who had received 
SCT and were successfully treated for rejection by DLI. Unfortunately, no HLA- 
A*0301+ patients who fitted these selection criteria were found during the course of this 
project.
One or a combination of peptide epitopes could be selected and assessed in 
immunotherapy protocols with the aim to stimulate and/or transfer tumour specific 
cytotoxic T cells in a manner similar to that described by Falkenburg et al (1999), with 
the transfer of leukaemia reactive T cell lines. They could also be used in a peptide 
vaccination strategy as described by Pinilla-Ibarz et al (2000). The former protocol 
involved a leukaemia reactive line that was raised using HLA haplo-identical donor 
cells stimulated with irradiated tumour cells, and the latter involved the injection of a 
combination of several HLA Class I and Class II restricted peptides. The best 
candidates to benefit from either strategy would be the patients with relatively low 
tumour burden (Olavarria et al, 2001) or the patients responding to treatment with IFN- 
a  or Imatinib Mesylate (Gleevec or STI 571), where the tumour burden is decreased 
substantially therefore leaving more opportunity for an efficient immunotherapeutic 
approach. Consequently, a combination approach with the use of chemotherapy and 
immunotherapy may provide improved treatment options for CML patients. Also the 
application of an alternate strategy is currently being tested with a peptide vaccination 
trial with the KQSSKALQR peptide currently under way at the ANRI with a 
collaborating centre in Liverpool. HLA-A*0301 tetramer will allow us to monitor 
peptide specific T cell responses in the patients who have entered the vaccination trial. 
The progress of patients who received SCT and who are treated for disease relapse by 
donor leucocyte infusion(s) or DLI could also be assessed using CML specific and/or 
associated tumour antigen specific tetramer reagents. This may be the ideal setting to 
investigate the graft versus leukaemia effect and study the contribution of different 
types of stimuli for an effective response, including tumour specific, tumour associated 
and minor histocompatibility antigen specific responses.
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Chapter IV 
Cytomegalovirus Specific Immune 
Reconstitution in Recipients of 
Allogeneic Stem Cell Transplantation
Introduction
In the immunocompetent host, primary CMV infections and viral reactivations are often 
clinically silent. In contrast, in the case of immunocompromised individuals, such as 
those patients who have received immunosuppressive conditioning prior to SCT, 
reactivation of latent CMV or primary infection can lead to potentially life threatening 
disease, particularly viral pneumonia (Rubin et al, 1989). Furthermore, depletion of T 
cells from the stem cell graft to control GvHD also removes the potential capacity to 
control latent or de novo infection. (Milbum et al, 1989; Hertenstein et al, 1995; Couriel 
et al, 1996). This remains the case with the most recent methods of direct or indirect T 
cell depletion with Campath-IH or CD34 selection respectively (Lowdell et al, 1998; 
Holmberg et al, 1999).
Despite the development of potent antiviral drugs, CMV infection is frequent 
post SCT. Prolonged prophylaxis with antiviral drugs, such as Ganciclovir and 
Foscamet, is myelosuppressive and is associated with significant toxicity, morbidity and 
potential mortality due to invasive fungal infection or late CMV disease (Li et al, 1994).
Consequently, the two key parameters directly relating to CMV infection post 
SCT appear to be the virus reactivation status and the anti-CMV specific immune 
recovery. The two most sensitive up to date methods were applied to measure these 
parameters.
Assessment of CMV specific immune reconstitution
On the basis of many studies, the CD8 T cell response has been shown to correlate with 
recovery from CMV infection of patients after SCT (Quinnan et al, 1982, Reusser et al,
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1997; Small et al, 1999). This was also demonstrated with an experimental SCT mouse 
model of murine CMV infection where the reconstitution of CD8 T cells was shown to 
be essential for the prevention of multiple organ CMV pathology, and where post 
transplant T cell depletion lead to lethal disease (Podlech et al, 1998). Therefore, it is 
likely that a CD8 T cell response plays a major role in the control of CMV replication.
However until recently, there was a paucity of studies assessing CMV specific 
CD8 T cell immune recovery post SCT due to the lack of a rapid and accurate direct ex 
vivo method for quantitating CMV specific CD8 T cells. This problem was resolved by 
using HLA/peptide fluorescent tetramer complexes, as described in the previous 
chapter, to detect and quantify CD8 CMV T cells specific for a pp65 immunodominant 
epitope in the context of the HLA-A*0201 molecule. This constitutes the most sensitive 
method to date that allows the assessment of antigen specific immune responses.
CMV viral load monitoring
On the basis of many studies using a variety of methods including cell or shell vial 
culture, pp65 antigenemia assay, or polymerase chain reaction (reviewed by Boeckh and 
Boivin, 1998), the clinical importance of monitoring SCT patients prospectively for 
CMV infection has been clearly demonstrated. A comparative study by Einsele et al 
(1995), showed that PCR detection preceded culture detection of CMV and allowed a 
faster and shorter treatment, leading to a lower incidence of CMV disease, a decreased 
associated mortality and reduced periods of neutropenia induced by anti-viral treatment. 
This made a pre-emptive treatment strategy using anti-viral therapy one of the main 
approaches to the treatment of CMV infection and the prevention of CMV disease post 
SCT.
A similar strategy was applied routinely for the monitoring of the HLA-A*0201 
SCT patient group, as described in Chapter II, to assess CMV reactivation or infection 
by qualitative PCR (Kidd et al, 1993). Although this was a very sensitive method to 
detect CMV reactivation, no information on longitudinal viral load changes could be 
detected by this method. A retrospective analysis of the patient samples by QC-PCR 
and subsequently by real time PCR (Taqman) permitted the accurate assessment of 
CMV viral load in the blood of SCT patients. Both these techniques were found to give 
comparable results when they were tested in parallel on identical samples at the RFH 
department of Virology (Emery et al, unpublished observations). High viral loads 
measured using the QC-PCR technique were associated with subsequent CMV disease 
in SCT recipients (Gor et al, 1998), or with symptomatic CMV infection in another
141
Chapter IV
group of immunosuppressed renal allograft recipients (Hassan-Walker et al, 1999). 
However, the relation between CMV DNA viral load in blood and CMV specific 
immune responses has not been previously examined.
The aim of this chapter is to examine CMV specific immune reconstitution and 
CMV viral load as well as their temporal relationship in a cohort of HLA-A*0201 SCT 
recipients.
142
Chapter IV
Results
CMV specific immune reconstitution in SCT patients
Detection and quantification of CMV tetramer positive T cells in SCT patients
After identifying a population of CD8+ T cells specific for the CMV pp65 AE42 peptide 
in healthy seropositive individuals and in a selection of SCT patients, the cellular 
immune response to CMV was monitored in a group of HLA-A*0201 SCT recipients 
(see Chapter II). Patient 24 was taken out of the analysis because the treatment notes 
were not accessible at the time the data was consulted; this patient died from disease 
relapse after 134 days post transplant, consequently the notes were microfilmed and 
stored in the Haematology department records system. Of the 24 patients remaining in 
the HLA-A*0201 positive group, 19 were considered “at risk” of developing CMV 
infection post transplant with a seropositive (CMV+) patient and/or donor (see 
Chapter I). Thirteen patients were CMV+ with a CMV+ donor, 5 patients were CMV+ 
with a CMV' donor, while only one was CMV' with a CMV+ donor. Five were at low 
risk of developing a primary CMV infection post transplant (with both patient and 
donor seronegative) and were acting as a control population; none developed a primary 
CMV infection during the monitoring period.
Isolated PBMCs were stained with the CMV pp65 AE42 HLA-A*0201 tetramer 
(referred to as CMV tetramer thereafter). As shown in the previous chapter, no 
significant population of CMV specific CD8+ T cells was identified with the AE44 or 
AE45 peptide tetramers. All patients at risk of CMV infection post SCT had detectable 
levels of immunodominant CD8+ CMV tetramer specific T cells (Figure IV. 1). The 
CMV specific T cells were detectable as early as day +21 post transplantation in the 
case of a non T cell depleted HLA matched sibling donor transplant (Figure IV. 1, 
patient 6). None of the 5 CMV' patients with CMV' donors contracted primary CMV 
infection during the monitoring period, and no CMV specific T cells were detected in 
any of the samples from these patients that were analysed. A striking feature of these 
data is that the frequencies and absolute numbers of CD8+ CMV Tet+ T cells observed 
in patients reconstituting their immunity were often higher than those observed in 
healthy control individuals (Figure IV. 1, red hatched area, shows 95% confidence 
interval (Cl) of the mean value).
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Figure IV. 1 Monitoring cytomegalovirus (CMV) 
specific CD8+ T cells in patients after stem cell 
transplantation (SCT)
Levels of CMV tetramer positive (Tet+) CD8+ T cells are 
r ,  expressed as a percentage of CD8+ T cells ( • ) .  Individual
f  patient numbers (see Table II. 1 for further details) are) SO 100 1 SO 200  250  300 3S0 r  v ’
reported in the top right hand comer of each graph.
Patients were grouped depending on whether they reactivated CMV (A,B or C) or not (D and E) 
and sub-grouped depending on the level of T cell depletion (TCD) they received: TCD in vivo 
and of graft (A), TCD in vivo or of the graft (B) or no TCD (C). For panels D and E, respective 
levels TCD for each patient were: patients 5 and 15, TCD in vivo; patient 6, no TCD; patients 
20, 22 and 9, TCD in vivo and of graft. Red hatched areas indicate the 95% confidence interval 
of the mean Tet+ frequencies observed amongst healthy in d iv id u a ls^  indicate periods of 
immunosuppressive treatment with prednisolone. The mean follow up time was 250 days post 
transplant.
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However, of note is the fact that amongst the patients who had CMV infection 
post SCT, heavily T cell depleted transplanted patients were faced with a much longer 
period of immune deficiency before their CMV specific immunity was reconstituted 
(Figure IV. 1, Patients 3, 17 and 19, panel A), with no CD8+ CMV Tet+ T cells detected 
before 100 days after SCT. This is in contrast with what was observed while monitoring 
patients who developed CMV infection after SCT and who received either in vivo TCD 
or received a TCD graft where CD8+ Tet+ T cells. They were found in the majority of 
cases to increase rapidly after SCT with the same levels as the frequencies observed in 
healthy individuals or above (Figure IV. 1, panel B). A similar observation can be made 
for these patients who developed CMV infection after SCT but did not receive any 
TCD, where higher frequencies of CD8+ Tet+ T cells can be observed compared to the 
previous cohort (Figure IV. 1, panel C). By contrast to the two groups described above, 
patients who did not have any detected evidence of CMV infection after SCT appear to 
be subdivided into two groups (Figure IV. 1, panel D). The first group consists of 
patients 5 and 6 who were shown to have high frequencies of CD8+ Tet+ T cells from 
early time-points after SCT and were also long-lasting. These may have arisen from a 
large expansion of these particular cells in the early reconstitution of the peripheral T 
cell pool after SCT, or could be due to an undetected CMV challenge. The high levels 
of CD8+ Tet+ T cells observed in these two patients might be mediating the immune 
protection against CMV infection. The second group, which consisted of patients 15, 20 
and 22 who did not develop CMV infection after SCT, did not have elevated 
frequencies of CD8+ Tet+ T cells (or often below these observed in healthy individuals). 
This might be representative of the absence of any CMV antigenic challenge in these 
patients after SCT during the period of monitoring.
These observations led to the comparison of the frequencies of CD8+ Tet+ T cells 
observed in healthy individuals with these observed in patients after SCT.
A formal analysis of the difference between the frequencies measured in healthy 
individuals and the ones measured post SCT was carried out using the Mann-Whitney 
U test, as the data sets were shown not to have a Gaussian distribution after a Normality 
test was performed (Figure IV.2). The mean frequency of Tet+ T cells in SCT recipients 
was 3.2% (95% Cl, 2.71-3.7%; p=0.0956), or 39.10xl06 Tet+ cells/1 of blood and was 
found not to be different from the mean frequency observed in healthy individuals: 
1.3% (95% Cl, 0.54-2.06%) or a calculated value of 8.7xl06 Tet+ cells/1 of blood (based 
on an average T cell frequency of 0.67xl06 T cells/1 of blood in healthy individuals).
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Figure IV.2 Comparison of cytomegalovirus tetramer positive 
CD8+ T cell frequencies in healthy individuals and in SCT 
recipients
Representation of the CMV Tet+ T cell frequencies observed in a 
control group of healthy individuals (■) and the measurements 
obtained while monitoring 19 SCT patients at risk of CMV infection 
post SCT (A). Bars indicate the mean values. Measurements are 
frequently higher in SCT recipients than in healthy individuals, 
although this is not statistically significant (Mann-Whitney U test).
These high frequencies may be attributable to several distinct phenomena post 
SCT: 1) the re-population of the periphery by haematopoeitic cells, most of which will 
be mainly driven by peripheral expansion; 2) the expansion of antigen specific T cell 
pools upon antigenic stimulation; 3) the non-specific proliferation due to bystander 
activation driven by local inflammation or GvHD; 4) the lack of competition from other 
antigen specific T cell clones; or even a combination of some or all these possible 
causes. Therefore the interpretation of these high frequencies is not straight forward and 
other parameters need to be investigated in parallel with the estimation of the frequency 
of Tet+ CD8 T cells to examine the expansion of specific T cells upon specific antigen 
stimulation in the context of SCT.
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CMV specific CD8 T cell detection and effector function
For 18 out of 19 of the patients at risk of CMV reactivation, PBMC samples were 
cryopreserved at timepoints when Tetramer positive T cells had been detected by fresh 
staining. They were subsequently thawed and put back in culture briefly before 
performing a CMV tetramer staining in parallel with an IFN-y ELIspot assay. This 
allowed the assessment of the relation between the presence of CMV specific T cells 
and peptide specific effector function. The results of this comparison are presented in 
Figure IV.3. There was good positive correlation between the frequency of tetramer 
staining and the CMV peptide specific effector function with a Pearson’s coefficient 
r=0.92. This suggests that in SCT patients as in healthy individuals (see Chapter III), the 
level of CMV Tet+ CD8+ T cells reflects the capacity of CMV antigen specific T cells to 
secrete IFN-y upon specific stimulation in SCT patients.
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Figure IV.3 Correlation between CMV tetramer CD8+ T cell 
frequencies and CMV specific effector function
Retrospective analysis of Tet+ CD8+ T cell frequencies and CMV 
specific effector function assessed by IFN-y release mediated by 
peptide specific stimulation was performed for 18 patients at risk of 
CMV reactivation post SCT (■). Both groups were tested to confirm 
their Gaussian distribution before carrying out a Pearson’s correlation 
test. The data sets showed a good level of correlation with a Pearson’s 
coefficient r=0.92 (95% Cl, 0.78-0.97; p<0.0001) and r^O.84.
To test whether this finding remained constant throughout the immune recovery 
period post SCT, three patients were selected for whom regular samples had been 
cryopreserved. Retrospectively, a time-course analysis of the CMV specific tetramer 
staining and the peptide specific effector function was then performed. The results are
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presented in Figure IV.4. A good correlation between tetramer positive T cell frequency 
and specific effector function was observed over time. Relatively high frequencies of 
CD8+ CMV Tet+ cells and significant IFN-y production were detected before 100 days 
post SCT for patients treated with moderate or no T cell depletion with Campath-IH 
(patients 18 and 23 respectively). This data is consistent with the clinical observation 
that patients who undergo transplants from HLA matched donors (require only low 
levels of T cell depletion for GvHD prophylaxis) and recover immune functions 
relatively early post transplant. However, the recovery of both CD8+Tet+ positive cells 
and IFN-y production were significantly delayed in more heavily T cell depleted 
individuals (patientl9). The frequency of tetramer positive T cells increased after 100 
days post transplant, and the IFN-y specific release remained below 20 spot forming 
units (sfu) per 50,000 cells tested throughout the period of analysis. This finding is 
consistent with clinical observations of late immune recovery seen for recipients of 
grafts from unrelated donors and/or of grafts with some degree of mismatching when 
more intense conditioning and high levels of T cell depletion will be performed.
Together with the correlation obtained for a single time-point assayed in 18 
patients post transplant (Figure IV.3), the data presented highlight the relationship 
between the frequency of CD8+ CMV Tet+ T cells and CMV peptide specific effector 
function, suggesting that both these assays reflect the degree of immunity to CMV.
148
Chapter IV
125—i 7.5
100-
5.0
75-
50-
2.5
25-
0.0
r T T
to
.tr
1 ^  
.£ 8
§ §
2 §
o o ' a  in« i-
4  a
125—| 
100-  
75- 
50- 
25- 
0-
r7.5
-5.0
-2.5
l-O .O
T TT T
125-, r7.5
100-
-5.0
75-
50-
-2.5
25-
0-
25 50 75 100 125 150 175 200 225
o
<
—i
o<D
W
0s
O
ooo
Days post transplant
Figure IV.4 Timecourse analysis of CMV tetramer staining and 
effector function
Simultaneously represented are the Tet+CD 8+ T cell frequencies (■ ,— ) and the 
CMV specific effector function as measured by IFN-y release following overnight 
peptide specific stimulation ( A .  _ )•  Representative patients shown are: patients 18 
and 23 after HLA identical sibling SCT, patient 19 after a single major HLA antigen 
mismatched SCT from an unrelated donor (individual patient numbers are reported 
in the right hand comer). By contrast to the analysis shown on Fig IV. 1 that was 
performed on freshly isolated PBMCs, the data in this figure was generated by 
retrospective analysis of cryopreserved samples that were briefly cultured prior to 
testing. This freeze/thawing process is therefore the cause of the discrepancies that 
can be noted between Fig IV. 1 and Fig IV.4. The data reported on each figure 
represents the accurate measurement of relative percentages of CMV Tet+ T cells in 
each sample tested in separate experiments and therefore cannot be directly 
compared.
The successful detection of functional CD8+ CMV Tet+ T cells in SCT recipients led to 
the examination of the status o f CMV infection post SCT in relation to the type o f treatment 
received, particularly to the degree o f T cell depletion used. This would enable the study of 
the relation between these parameters and their potential influence on each other.
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Assessment of CMV infection post SCT
The occurrence of CMV infection post transplantation was determined by consultation 
with the clinical team treating the patients on a regular basis during the sample 
collection period. Patient records were also accessed to obtain the results of the 
qualitative PCR performed in the routine department of Virology at the RFH. This 
allowed the retrospective analysis of the quantitative CMV viral load determined by real 
time PCR (Taqman, see Chapter II).
As shown previously, of the 5 CMV' patients receiving a CMV* graft, none 
developed primary CMV infection. Amongst the 19 patients “at risk” of CMV infection 
post SCT, 13 (or 68%) had CMV infection during the period of monitoring. The data 
summarising the occurrence of CMV infection and the patient information cited in 
Chapter II were correlated. It was possible to test if this cohort of 24 patients conformed 
to the well established concept whereby CMV+ patients and/or patients with CMV+ 
donors are considered “at risk” of CMV infection after SCT. This would establish that 
the patient cohort studied is representative and that similar results may be obtained from 
studies with the same number, or a larger number of subjects. The data was entered into 
a contingency table where the conditions were set to test if the patient and/or donor 
CMV+ prior to SCT constituted a risk for the occurrence of CMV infection after 
transplant. This was verified using a two-sided Fischer’s exact test and gave a 
significant positive result: p=0.0109. Therefore this confirmed that in this cohort of 24 
patients, patient and/or donor CMV seropositivity was a risk factor for the development 
of CMV infection after SCT, conforming to the clinical consensus and prognosis.
In all 13 cases where CMV infection was detected after SCT, it is probable that 
these infectious episodes reflect the reactivation of latent virus originating from the 
recipient and/or the graft, although re-infection can not be discounted totally. The 
information collected from patients who presented in the clinic with post SCT CMV 
infection are summarised in Table IV. 1. The mean time to the initial detection of CMV 
DNA in this cohort of 13 patients was day 47 post SCT, ranging from day 7 to day 179 
post SCT. On average, the number of infectious episodes per patient was 3. All 4 CMV+ 
SCT recipients with CMV' donors reactivated CMV, while 10/15 (or 66%) of CMV+ 
recipients with CMV+ donors reactivated CMV, indicative of a possible role for the 
transfer of CMV immunity from the donor to the patient. This could in turn influence 
the level and/or rate of replication of the virus. The major factors influencing the 
number of cells transferred to the patient would be the actual frequency of CMV 
specific T cells present in the blood from the donor, and the level of T cell depletion
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applied in the transplant procedure. Unfortunately, it was only possible to assess CD8+ 
CMV Tet+ T cells frequencies in two of the donors from this cohort. The recruitment of 
donors proved difficult and resulted in low consent rate as the only possible times to 
request their participation in the study was at an already demanding time of donation for 
graft preparation or for preparation of donor leucocyte infusions in the clinic. However 
the two donor samples tested had similar CD8+ CMV Tet+ T cell frequencies to the ones 
detected in the cohort of healthy CMV+ individuals mentioned in Chapter III. They were 
1.22% (or 11.6xl06/l blood) and 0.97% (or 8.6xl06/l blood) of CD8+ T cells that were 
CMV Tet+ for the donors of recipients 4 and 5 respectively.
individual
patient
number
patient/donor 
CMV serotype
first PCR+ 
sample post 
SCT
number of 
infectious 
episodesb
Campath-IH 
T cell depletion 
in vivo/in graft
1 + / - 7 7 No/Yes
2 + / + 53 1 None
3 + / + 7 6 Yes/Yes
4 + / + 56 1 None
7 + / + 179 1 No/Yes
12 + / + 13 2 Yes /No
13 + / + 53 1 None
16 + / + 90 2 None
17 + / + 23 3 Yes /Yes
18 + / + 48 1 Yes/No
19 + / - 9 8 Yes/Yes
21 + / - 43 4 No/Yes
25 + / - 49 2 No/Yes
Table IV.l CMV infection post stem cell transplantation
This table summarises the characteristics of 13/19 “at risk” patients 
who developed CMV infection post transplant. 
a indicates the day when CMV DNA was first detected post transplant 
(with the transplant day being day 0); b indicates the number of 
infectious episodes defined by periods of consecutive CMV DNA 
PCR+ results.
The main common factor that we examined in the cohort of 13 patients who had 
CMV infection post SCT was the level of Campath-IH T cell depletion. This allowed to 
determine whether this factor had an influence on viral replication or the occurrence of 
multiple infectious episodes. Because of the low number of individual patients (13) that 
were studied with respect to the level of viral replication and the frequency of infectious 
episodes, the accumulated data is an indicator of experiments that would be of interest 
for larger cohorts of patient. However one of the first characteristics that can be noticed 
about the 13 patients who had CMV infection after SCT, was that all patients with
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CMV' donors had without exception repetitive occurrence of CMV infection after SCT 
compared to patients with CMV+ donors (Table IV. 1). This was analysed by grouping 
the data in two contingency tables and assessing the likelihood of CMV+ patients with 
CMV' donors to develop more than 2 productive CMV infections after SCT. It was 
found to be a significant risk factor for developing more than 2 episodes of CMV 
infection after SCT (n=13, two-sided Fischer’s exact test: p=0.021). This result might 
suggest that in the CMV+/' patient subgroup there seems to be a failure of immune 
protection or of durable immune protection against CMV infection.
Secondly, the level of CMV replication was examined in samples from patients 
whom had CMV infection post SCT by real time PCR. DNA viral load quantification 
was performed on 140 samples, 94 of which were PCR+ by routine qualitative PCR 
assay. The mean viral load measured was 3.61 log 10 CMV genomes/ml of blood, with a 
maximum load of 5.9 log 10 CMV genomes/ml of blood. The results obtained in this 
cohort of SCT patients were comparable to results obtained by quantitative-competitive 
PCR in a separate cohort of SCT patients studied earlier at the RFH Department of 
Virology (Gor et al, 1998; Emery et al, 2000). The CMV DNA viral load was measured 
in the samples by real time PCR and all positive results were plotted against the level of 
TCD. The results of that analysis are presented in Figure IV.5. Both data sets were 
found to have a Gaussian distribution, and there was no significant difference between 
the mean CMV viral load measured in samples from TCD (3.57; 95% Cl: 3.38-3.76; 
Student’s t test: p=0.49) or non-TCD transplants (3.81; 95% Cl: 2.83-4.80). There was 
also no difference between the peak CMV DNA viral load detected in samples from 
TCD or non-TCD transplants (data not shown). Although this data is only indicative 
due to the small number of patients studied, it highlights the fact that T cell depletion 
probably does not contribute significantly to the extent of virus replication during active 
CMV infection. This is likely due to the frequent viral load monitoring (up to 4 times a 
week) and prompt treatment with antiviral agents (Ganciclovir and/or Foscamet). These 
drugs are very efficient and achieve suppression of viral replication very rapidly. 
Consequently, the rise in viral load detected during the course of CMV infection is 
rapidly curtailed by the treatment (see Figure IV.8); however higher viral loads would 
probably be observed without appropriate treatment or in the rare case of resistant 
mutant virus. This might be exacerbated in the case of TCD patients and might lead to
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higher CMV related mortality, as was the case prior to efficient CMV control (see 
Chapter I).
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Figure IV.5 CMV DNA viral load measurements in SCT patients 
with CMV infection
CMV DNA viral load was measured retrospectively for 13 patients 
who developed CMV infection post SCT. The results were separated 
depending on T cell depletion (TCD) with Campath-IH (TCD,B; no 
TCD,■). The 2 data sets had a Gaussian distribution. No correlation 
was found between the two variables (Student’s t test). Bars indicate 
mean values.
However, it is likely that despite adequate treatment with anti-viral agents, productive 
CMV infection will reoccur until adequate immune protection has been reached. As 
immune recovery was found to be slower for patients who received T cell depletion, the 
actual number of CMV infection episodes could be higher post SCT. This was analysed 
for the cohort of 13 patients who reactivated CMV. Recipients of T cell depleted 
transplants tend to have more episodes of CMV infection post SCT than recipients of a 
non-T cell depleted transplant (Figure IV.6, panel A). The number of non-TCD patients 
in this group was to small to carry out a Normality test, so a Gaussian distribution was 
assumed to carry out a Student’s t test and compare the mean number of infectious 
episodes. There is a tendency for these patients to have more infectious episodes even if 
this does not reach statistical significance (Student’s t test: p=0.089).
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Figure IV.6 Comparison of the number of CMV infection episodes 
post SCT with the level of T cell depletion
13 patients who had CMV infection post SCT are shown. They were 
segregated into patients who received T cell depleted transplants with 
Campath-IH (in vivo and/or graft, ■) or not (■ , A), and between 
patients who received a T cell depleted graft only (■) or no T cell 
depletion (■, B).
Nevertheless, when T cell depletion of the graft only was considered without taking in 
vivo T cell depletion into account, it was possible to see a difference between patients 
who received a T cell depleted graft treated with Campath-IH and patients who 
received an untreated graft (Student’s t test: p=0.017, Figure IV.6, panel B). The mean 
number of CMV infection episodes was 4.43 episodes (95% Cl: 1.99-6.86) for T cell 
depleted graft recipients, whereas it was 1.33 episodes (95% Cl: 0.79-1.87) for 
untreated graft recipients. This was also in accordance with the results of the analysis 
of the data using contingency tables and assessing whether a TCD graft was a risk factor 
for developing more than 1 or more than 2 CMV episodes in the 13 patient who had 
CMV infection after SCT. A similar test was carried out to determine the relative risk of
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multiple CMV infection for patients who received in vivo TCD. Although the results 
were not statistically significant, either for a TCD graft (two-sided Fischer’s exact test: 
p=0.1026) or for in vivo TCD (p=0.5649) in the case of more than 1 CMV episode after 
SCT, they seemed to point to a greater impact of a TCD graft than in vivo TCD. This 
was confirmed when the factor “more than 2 CMV episodes” was tested in a similar 
way, and a significant risk of having more than 2 CMV episodes after SCT was found 
for patients who received TCD grafts (n=13; two-sided Fischer’s exact test: p=0.0210), 
but was not a risk factor for in vivo TCD (p=0.2939).
This further indicates that the level of T cell depletion received in the transplant 
procedure may influence the re-occurrence of infection post transplantation. The 
differences were detected even in a very small patient population highlighting the fact 
that these parameters should be investigated in larger patient cohorts.
Both CMV specific T cell immunity and CMV replication were studied in the 
cohort of 19 patients “at risk” of developing CMV post SCT to assess if immune and 
viral monitoring could point out the dynamics of these variables and contribute to the 
development of new treatment strategies.
Relationship between the detection of CD8* CMV Tet T cells and CMV 
DNAemia
Initially, the relationship between the detection of CMV Tet+ CD8+ T cells and CMV 
DNA in peripheral blood was examined. After the last patient sample was tested, 
analysis of CMV tetramer and positive CMV DNAemia measured simultaneously on 
the same day was only available for 24 individual blood samples for 6 of 13 patients 
who developed CMV infection post SCT, as detected by high level CMV replication 
(>200 CMV genomes/ml of blood). This was in part due to the treatment strategy that 
was applied, which consisted of viral monitoring up to four times a week, prompt 
treatment with anti-viral agents following two consecutive positive results, and an 
immunological assessment with CMV tetramers that was restricted to once a week. 
Treatment with immunosuppressive drugs to prevent GvHD could also impact on the 
number of CD8+ CMV Tet+ T cells, which made univariate analyses of this data 
inappropriate.
However, the relationship between the absolute quantity of CD8+ CMV Tet+ T 
cells in the presence or absence of CMV DNA in the blood of patients “at risk” of CMV 
infection post SCT was investigated. Patients were divided into 2 groups for this 
analysis. The first group consisted of patients who had evidence of CMV infection; the
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second consisted of patients who were “at risk” of CMV infection but had no evidence 
of CMV DNAemia after SCT (Patients 5,6,15,20 and 22). In addition, the number of 
CD8+ CMV Tet+ T cells in patients who had CMV infection post SCT was analysed 
separately during episodes of DNAemia and when no viral DNA could be detected by 
routine and/or real time PCR. The results of these analyses are shown in
Figure IV.7. The data sets did not have Gaussian distributions, so the difference 
between sets was assessed using the non-parametric Mann-Whitney U test. The number 
of CD8+ CMV Tet+ T cells was the lowest in patients with concurrent CMV DNAemia 
(mean, 8.8xl06/l; 95% Cl: 3.36-14.25); whereas in the same group of 13 patients, the 
number of CD8+ CMV Tet+ T cells was significantly higher when CMV DNAemia was 
not detectable (mean, 23.8xl06/l; 95% Cl: 18.95-28.79; p=0.004). In the cases of 
patients for whom no CMV infection could be detected on the basis of PCR positivity in 
blood, the number of CD8+ CMV Tet+ T cells was 55.5xl06/l (95% Cl: 34.62-76.46). 
This value was significantly higher than the level detected in patients with CMV 
DNAemia, either during episodes of high CMV loads (p<0.0001) or during PCR 
negative periods (p=0.041).
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Figure IV.7 Comparison between the number of CD8+ CMV Tet+
T cells and the CMV infection status in SCT recipients
Levels of CD8+ CMV Tet+ T cells in SCT recipients who had CMV 
infection post SCT, at time-points when CMV DNA was detected by 
PCR assay ( • )  or when the PCR result was negative (A), respectively 
indicating an active or latent phase of infection at the time of the CMV 
Tet measurement. These were also compared to the Tet measurements 
obtained while monitoring patients who did not have active CMV 
infection post SCT (♦ ) .  All data sets are statistically different as 
determined by the Mann-Whitney U test.
These results suggest that the number of CD8+ CMV Tet+ T cells detected in the 
blood is representative of the level of immunity to CMV. Although a direct comparison 
of the number of CD8+ CMV Tet+ T cells and CMV DNAemia was not possible, a 
longitudinal analysis of these parameters was carried out for patients with CMV 
infection post SCT.
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Monitoring CD8* CMV Tet T ceils and CMV DNAemia post SCT
Overall, in 15 of 19 patients “at risk” of CMV infection, a similar response pattern was 
observed with an increase in CMV specific CD8+ T cells after SCT. This correlated in 
most cases with an increase in CMV load. Three patient cases were chosen to illustrate 
the dynamics of these two variables post SCT and their relation to each other as well as 
to the type of transplant and the treatments received.
In the first example, (Figure IV.8, patient 4), the donor had 11.6xl06 (or 1.22%) 
peripheral CD8+ T cells/1 of blood staining positive with the CMV Tet. Since the SCT 
procedure for this patient did not involve any T cell depletion with Campath-IH, a 
proportion of these cells would have been infused into the patient together with the 
graft. Nevertheless, CMV still reactivated, with CD8+ CMV Tet+ T cells present at 
5.5xl06 T cells/1 (1.59% of CD8+ cells) at day +45 and increasing sharply, to reach 
15.5xl06 T cells/1 (1.69% of CD8+cells) at day +63 post SCT, after CMV infection 
occurred from days +56 to +67. In subsequent blood samples from this patient, the 
CD8+ CMV Tet+ T cells continued to increase, peaking at 86x106 T cells/1 at day +86 
(8.27% of CD8+ T cells), and then slowly decreased, to stabilise at around 35xl06 T 
cells/1 (5% of CD8+ T cells) from day +134. This is representative of CMV+ patients 
with CMV+ sibling donors, with no or mild T cell depletion and for whom CMV 
infection post SCT stimulates an adequate immune response rapidly restoring viral 
latency.
In the case of a single HLA-C allele mismatched transplant from an unrelated 
donor (Figure IV.8, patient 3), a considerable delay in specific CD8+ CMV Tet+ T cell 
recovery post transplant was observed. This transplant required more intensive 
conditioning as well as both in vitro and in vivo T cell depletion with Campath-IH. 
Despite multiple periods of CMV reactivation from day 0 to day +96 post 
transplantation, no CD8+ CMV Tet+ cells were detected in this patient at day +102 when 
the patient entered the study. This was thought to be due to a combining effect of the 
type of transplant, the intensive T cell depletion and also to the steroids administered 
from day +53 to day +128 for treatment of acute GvHD.
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Figure IV.8 Monitoring of CMV specific T cell immunity and 
CMV viral load
The absolute number of CMV Tet+ CD8+ T cells (xl06/l of blood, • )  
and the quantitation of CMV viral load (log10 genomes/ml of 
blood, • )  are represented as a function of time post SCT. 
Representative patients are shown (individual patient numbers are 
reported in the right hand comer of each graph): patient 4 after a HLA 
identical sibling peripheral blood stem cell transplant; patient 3 after a 
single allele mismatch (HLA-C) unrelated donor bone marrow 
transplant; patient 1 after a sex mismatched HLA identical sibling 
peripheral blood stem cell transplant. Also mentioned on the graphs: 
CMV Ig, administration of CMV immunoglobulin;* G/F: periods of 
treatment with antiviral agents Ganciclovir and/or Foscarnet; 
*  periods of treatment with Valaciclovir; □periods of treatment 
with prednisolone.
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Nevertheless, CMV specific CD8+ T cells numbers recovered from day +145 and were 
maintained at high levels thereafter (>20 x 106 cells/1 or 4% of CD8+ T cells) and the 
patient was protected against further reactivation without need for antiviral help. CMV 
did not reactivate again after the last reported episode. This illustrates well the 
significantly delayed recovery of CMV specific T cells after unrelated donor transplants 
to patients “at risk” of CMV infection post SCT. These cases require extreme clinical 
vigilance as CMV infection remains a major concern until adequate immune protection 
is re-established.
In the case of a CMV seropositive patient with a CMV seronegative donor, no 
antiviral treatment was administered, as the patient never had two consecutive CMV 
PCR positive results during the early three episodes of reactivation. Each of these 
increases in viral load was associated with transient elevations of CD8+ Tet+ T cells, 
although in each case the levels returned essentially to baseline on clearance of the 
virus. It is likely that the response measured at that time represented a primary response 
to CMV mediated by naive donor CD8+ CMV specific T cells (Figure IV.8, patient 1). 
Confirmation that the CD8+ Tet+ T cells were of donor origin was obtained by referring 
to the results of the in situ Y chromosome hybridisation of peripheral blood 
mononuclear cells. The test was performed to establish the degree of chimerism in this 
male patient who received a transplant from a female donor and the responding cells 
were found to be predominantly female. At later time-points after SCT, prolonged 
treatment with prednisolone led to a fall in CMV specific CD8+ T cells over a course of 
3 months. At the end of this period, steroid treatment was maintained and the levels of 
CMV specific CD8+ T cells were insufficient to control the virus and reactivation (at 
day + 147 post transplant) was no longer associated with an increase in CMV specific T 
cells. As subsequent episodes of CMV infection occurred, and as no significant increase 
in CD8+ Tet+ T cells was observed, repeated antiviral treatment was needed. This 
particular example illustrates well the lack of persistent CMV specific T cell responses 
in CMV+ patients with CMV' donors. Although CD8+ CMV Tet+ T cells appear to 
respond appropriately to antigenic stimulus, these responses fail to maintain in 
peripheral blood, with decreasing levels associated with recurrent CMV infection.
Additionally, the evaluation of the number of CD8+ CMV Tet+ T cells at later 
times post transplant could allow for the prediction of late CMV infection. Late CMV 
infection or CMV infection that occurred after 100 days post SCT affected 7 of 19 
patients “at risk” (37%) of developing CMV infection post SCT; the observations 
related to these late infection episodes are summarised in Table IV.2.
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individual 
patient number
patient/donor 
CMV serotype
known
mismatch
chronic GvHD 
steroid treatment
1 + / - sex Yes
3 + / + 1 M HLA“ Yes
7 + / + no Yes
16 + / + no Yes
19 + / - no Yes
21 + / - 1 M HLA Yes
23 + / + no Yes
Table IV.2 Late CMV infection post SCT
7 patients presenting with late CMV infection post SCT are mentioned 
in this table. Also shown: the patient and donor CMV serotype prior to 
transplant, the occurrence of chronic GvHD as well as any known 
mismatches that could be the cause of the clinically diagnosed GvHD. 
“Indicates a single major HLA allele mismatched transplant
The common feature amongst all patients who developed late CMV infection 
resided in the facts that they all developed chronic GvHD, that this condition was 
treated with high dose steroid drugs (prednisolone or methylprednisolone) for prolonged 
periods of time. This factor was considered for all 19 patients “at risk” of CMV 
infection after SCT to test if long term steroid treatment was a risk factor for the 
development of late CMV infection. Data was summarised in a contingency table and a 
two-sided Fischer’s exact test gave a highly significant result: p=0.004. Therefore this 
indicated that in this cohort of patients, long term treatment with steroids was a 
significant risk factor for the development of late CMV infection. Patient monitoring 
also highlighted decreasing numbers of both T cell counts and CD8+ CMV Tet+ T cells 
numbers. After a period that varied depending on the number of CD8+ CMV Tet+ T 
cells previously present and the dose and duration of steroid treatment, this led to CMV 
infection in all 7 patients without exception. Therefore a longitudinal study of CD8+ 
CMV Tet+ T cells could be initiated to predict late CMV infection in patients treated 
with steroids.
Taken together, these examples illustrate the fact that together with accurate 
detection of CMV DNAemia, the detection of CMV specific T cell responses using 
HLA tetramers specific for immunodominant epitopes can provide useful information 
about CMV specific immune reconstitution. The results of this direct ex vivo study
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(illustrated with the three cases presented above) confirms the association between 
rising CMV antigenemia and the subsequent rise in the number of CD8+ CMV Tet+ T 
cells and is representative of the immune response to CMV. Based on the patient cases 
studied, a guideline level was deduced that would constitute a protective level of CD8+ 
CMV Tet+ T cells in the blood of patients “at risk” of developing CMV infection post 
SCT. This was set at 20x106 Tet+ T cells/1 of blood and is represented graphically by an 
interrupted black line on Figure IV.8. This indicative level was deduced from the study 
presented above, but a more accurate number could be established with the statistical 
analysis of a much larger patient cohort.
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Discussion
From the study of a group of healthy individuals, the detection of CMV tetramer 
positive T cells was shown to be consistent with the mediation of an antiviral response, 
confirming previous findings (Gillespie et al, 2000; Wills et al, 1999). From our panel 
of healthy CMV+ individuals, who are asymptomatic, the absolute number of CMV 
specific CD8+ T cells can be estimated to be in the range of 1.87 to 10.67xl06 cells/1. 
These values are based on the median frequency of CMV specific CD8+ T cells 
(0.935%) and the average absolute CD8+ T cell count in healthy individuals (0.2 to 
1.14xl09 cells/1). This seems to account for a larger proportion of the cytotoxic T cell 
pool being restricted to a single CMV epitope than might otherwise be expected, but 
this data has also been confirmed by other groups (Gillespie et al, 2000). This 
observation also appears to be in accordance with immune responses directed against 
other persistent viruses from the herpesviridae family, such as Epstein-Barr virus 
(Callan et al, 1998). The study of 25 SCT recipients presented in this chapter 
highlighted similar if not higher frequencies and absolute numbers of CMV specific T 
cells. A number of other studies also showed high frequencies of CD8+ CMV Tet+ T 
cells in recipients of SCT (Gratama et al, 2001; Cwynarski et al, 2001) but also in the 
context of multiple viral infections in non transplanted HIV+ patients (Jin et al, 2000). 
This finding in SCT recipients may reflect the requirement for more CMV specific T 
cells to control CMV infection after SCT, but could also be due to an inflation of the 
representation of CMV specific T cell clones. These cells might be amongst the first 
stimulated in the case of CMV reactivation at a time when the peripheral pool starts to 
reconstitute after SCT, which could be at the origin of these high frequencies. Similarly 
to the findings for healthy CMV+ donors as described in Chapter III, a defined 
correlation between the detection of CD8+ Tet+ T cells and CMV peptide specific 
effector function was established in SCT patients “at risk” of CMV infection. Despite 
the fact that the measurement of IFN-y release requires in vitro stimulation and only 
detects a fraction of HLA peptide restricted T cells, it can be utilised to demonstrate the 
peptide specificity of responses by ELIspot or intracellular staining/flow cytometry as 
shown by Hebart et al (2002). Simultaneous tetramer and IFN-y release can now be 
performed on a single cell basis by flow cytometry, this should lead to a better 
understanding of the antigen specific T cell population dynamics and activation 
requirements with respect to a specific peptide stimulus.
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CMV specific CD8+ T cells can be detected at relatively early times post SCT 
and are associated with the control of viral replication when levels of CD8+ Tet+ T cells 
of at least 20x106/l are reached and maintained. Furthermore the onset of viral 
replication was found to be associated with low CMV specific CD8+ T cell counts. This 
implies that the number of CMV Tet+ T cells may be used to predict episodes of viral 
replication when they are lower than 20x106/l or lower. The impact of the level of T cell 
depletion on CMV reactivation was examined in the patients at risk. A difference in 
relation to the frequency of occurrence of CMV infection was found when the recipients 
were T cell depleted with Campath-IH in vivo and/or received an ex vivo T cell depleted 
graft. Graft TCD was found to have more impact on the occurrence of CMV infection, 
especially as it was found to be a significant risk factor for developing multiple 
reactivation episodes. No impact on the CMV viral load or the peak viral load was 
detected by comparing each group for the 25 SCT patients studied in this chapter. 
However the number of patient studied was small and this point should be examined 
with the study of a larger group of patients. These findings have been confirmed by 
Supamo et al (2002) and Chakrabarti et al (2002), who demonstrated a high incidence 
of CMV reactivation after SCT with an unrelated donor transplant as being a significant 
risk factor for CMV recurrence and highlighted the potential role of Campath-IH in 
delaying CMV specific immune reconstitution. Additionally, a study by Qamruddin et 
al (2001) also pointed to the role of Campath-IH when used in the conditioning 
regimen of transplant procedures and the link to subsequent CMV reactivation post 
SCT. The study presented in this chapter also pointed to the fact that long term 
treatment with steroids depletes CD8+ CMV Tet+ T cells and constitutes a very 
significant risk factor for the development of late CMV disease.
The majority of active CMV infections observed in patients after SCT are due to 
reactivation of a latent infection (Pillay et al, 1992). It has been suggested that donor 
marrow from seropositive donors may provide cellular immunity to the recipient thus 
accounting for the lower incidence of CMV disease in these patients (Grob et al, 1987; 
Gor et al, 1998). Data from our study provides further evidence in the support of these 
observations: with CMV specific responses observed early after SCT in all seropositive 
patients before de novo lymphopoiesis could have occurred. To date, this study provides 
the first and only formal evidence of an inverse correlation between active CMV 
infection and the number of CD8+ CMV Tet+ T cells in patients post SCT. Further, this 
data demonstrates the benefits of using CMV tetramers to monitor the absolute number 
of CMV specific T cells in recipients of SCT. Regular CMV tetramer staining allowed
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the assessment of CMV immune reconstitution in patients after SCT with levels of 
20x106 CMV specific cells per litre of blood (whether the patients have previously 
become positive or not by PCR) being a good indicator of CMV immunity that could be 
utilised functionally in a clinical setting. The absolute number of CMV specific T cells 
was chosen as an indicator of specific immunity rather than the percentage values 
because the latter can be misleading in the context of SCT as lymphocyte numbers tend 
to be low and tend to fluctuate substantially, especially in the first six months after 
transplant. Similarly to the findings for the cohort of 25 SCT patients presented above, a 
separate study by Cwynarski et al (2001) monitoring HLA-A2 and HLA-B7 restricted 
immunodominant pp65 specific T cell responses as well as pp65 antigenemia associated 
lOxlO6 CD8+ CMV Tet+ cells/1 with protection from CMV disease. The protective 
levels deduced from both this study and the study described in this chapter are of the 
same order, which supports the concept of the ability to predict CMV infection. The 
difference between the two figures can be explained in part by the facts that tetramer 
analyses were performed on freshly isolated PBMC samples in the present study versus 
cryopreserved PBMC samples in the study by Cwynarski.
Previous studies have shown that the greatest risk of CMV disease is associated 
with transplantation of a CMV seronegative marrow into a seropositive patient (Grob et 
al, 1987; Winston et al, 1985). Furthermore a recent study (Nichols et al, 2002) showed 
that SCT CMV+ recipients with CMV+ or CMV' donors remain at a higher mortality risk 
than SCT CMV* patients with CMV+ donors despite the improvements in antiviral 
treatment. This study also pointed to a trend to an increase incidence of CMV disease 
for CMV+ patients with CMV' donors, compared to CMV+ patients with CMV+ donors, 
and pointed to a higher risk of death due to bacterial or fungal infection in the former 
group of patients. The findings presented in this chapter provide further evidence that 
this might be the case as we have observed a transient increase in CMV/AE42 specific 
cells seen in CMV+ recipients who received a transplant from a seronegative donor. 
This contrasts with the response from patients with CMV+ donors, where the levels of 
CMV/AE42 specific T cells remained elevated following virus clearance. These results 
imply that patients with CMV seronegative donors, although they are able to respond to 
increases in viral levels, do not seem able to sustain these responses, which would 
therefore make them more susceptible to recurrent infection. However, we need to study 
more cases to confirm this point, as the complicating factor in interpreting the failure to 
maintain elevated levels of CMV specific T cells is that patient 1 developed chronic 
GvHD, requiring immunosuppressive treatment with prednisolone. Monitoring patients
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“at risk” of CMV infection post SCT also established that steroid treatment can deprive 
patients of effective anti-CMV responses and this may be associated with both recurrent 
and/or late CMV infection. This fact was also highlighted by a study showing that 
steroid treatment was the primary risk for rising pp65 antigenemia in SCT patients 
(Nichols et al, 2001). In the cases of patients with CMV donors and/or on long term 
steroid treatment especially, tetramer monitoring has proven to be an important 
parameter for clinical follow up.
It has been established that the development of GvHD after SCT is associated 
with CMV infection (Wu et al, 1975; Grundy et al, 1985), and a synergy between 
GvHD and CMV infection resulting in catastrophic lung pathology (interstitial 
pneumonitis, IP) has been postulated. Two mechanisms of pathogenesis in the lung 
have been proposed: 1) due to uncontrolled viral replication in the lung caused by the 
absence of CMV specific immune response (Reusser et al, 1991; Greenberg et al, 
1991); 2) due to an immunopathological reaction whereby the immune system might 
lead to pathology triggered by CMV infection (Grundy et al al, 1987; Grundy et al, 
1988). With the use of potent antiviral agents in prophylactic or pre-emptive treatment 
strategies, the occurrence of CMV-IP has been reduced very significantly. None of the 
25 SCT recipients studied in this chapter developed CMV-IP. However the debate over 
the relation between GvHD and CMV (i.e. whether GvHD causes CMV infection or 
vice versa and their relation to the development of CMV-IP) remains. Evidence from 
this study supports the first hypothesis, as it was shown that high frequencies of CMV 
specific T cells correlated with recovery from CMV infection and protection from 
further episodes without any evidence of GvHD or IP. The use of pre-emptive 
Ganciclovir and/or Foscamet treatment did not appear to impair immune recovery, 
despite the fact that Ganciclovir was shown not to affect the down-regulation of HLA 
class I expression on cells infected by CMV (Grundy et al, 1998). Additionally, all the 
patients who developed chronic GvHD and were treated with steroid 
immunosuppressive drugs contracted late CMV infection, which would also suggest 
that the absence of a CMV specific cytotoxic immune response (or its decline) is 
responsible for CMV reactivation. However, supporting the second hypothesis, there is 
also firm evidence that CMV has many pro-inflammatory properties including the 
induction of cytokines (IFN-|3, IL6, TGF-P), chemokines (IL8) and adhesion molecules 
(ICAM-1, LFA-3) that could all contribute to triggering or aggravating GvHD (for a 
review, see Grundy et al, 1998); therefore CMV could be the source of the GvHD 
reaction in the lung and of subsequent immunopathology resulting in IP. As there was
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no evidence of CMV IP in the present study, it is only possible to speculate that in the 
case of uncontrolled CMV infection in the lung, local viral cytopathogenicity and 
inflammation may contribute to enhance the number of functional CMV and GvH 
specific T cells that might both contribute to tissue destruction. However, as CMV IP 
has become less frequent due to efficient CMV treatment, this hypothesis might not be 
tested. Despite the significant progress in CMV treatment after SCT, the overall 
survival of SCT recipients “at risk” of developing CMV infection has not improved 
significantly. Therefore the need for improved antiviral agents with less toxicity and 
side effects and/or alternative cellular therapies such as CMV specific T cell transfer 
remain important areas that warrant further research.
Thus, as seen in this chapter, systematic tetramer monitoring of patients post 
transplant and correlation with the viral load will allow the design of more efficient 
strategies for the prevention of CMV infection and/or reactivation. The establishment of 
a sufficient level of CMV specific CD8+ T cells following SCT will avoid the need for 
regular screening, unless a sudden drop in total lymphocyte numbers is observed (as is 
often the case following the initiation of steroid therapy for the treatment of GvHD). 
This will also help to define a balance between the early use of antiviral drugs, which 
might prevent disease but also impair bone marrow causing neutropenia, and possibly 
induce resistance and late disease in the case of prolonged treatment (Li et al, 1994; 
Goodrich et al, 1991; Knox et al, 1994; Emery et al, 2000; Emery et al, 2000).
Furthermore, it is now possible to isolate specific T cells from the seropositive 
stem cell donor for adoptive transfer into the patient at the time of transplant or soon 
thereafter. Leukocyte transfusion and adoptive transfer of CMV immunity by infusion 
of specific CD8+ T cells has been used with success (Walter et al, 1995; Riddel et al, 
1997; Witt et al, 1998; Einsele et al, 2002). The use of the tetramers to specifically 
isolate CMV effector cells directly from the donor’s PBMCs whilst avoiding unwanted 
CD8+ T cells with other antigenic specificity is clearly feasible and highlights this as a 
fast and efficient means of obtaining effector cells with reduced handling and minimal 
culture periods. In addition this may prevent the onset of GvHD which often occurs 
following the transfer of unselected lymphocytes populations (Papadopoulos et al, 
1994). Therefore, adoptive transfer should be considered for use in the case of unrelated 
and haplo-identical transplants as these patients display delayed engraftment and 
immune reconstitution, and in all patients after cessation of steroid therapy, during 
which time they require active protection against CMV. Finally, CMV/AE42 tetramer 
monitoring may also be considered valuable in the investigation of poor graft survival
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and post transplant complications in the solid organ transplant setting. In these cases 
also, adoptive transfer of CMV specific CD8+ T cells will find clinically relevant 
applications.
168
Chapter V
Chapter V 
Modulation of antigen specific 
immune responses
Introduction
The successful detection and quantification of antigen specific CD8+ T cells using 
HLA/peptide tetramer complexes was described in the previous chapters. The specific 
and stable interaction between HLA/peptide tetramers and their specific TCR can be 
further exploited to modulate antigen specific immune responses by transferring 
purified and/or enriched T cells from an immune donor (adoptive transfer), or by 
directly influencing the antigen specific immune response. This can be achieved by 
using positive tetramer staining as a selection marker to purify CD8+ Tet+ cells. 
Purification methods need to be tested for the establishment of standardised protocols in 
order to achieve safe T cell adoptive transfer in the context of SCT. Additionally, the 
specific interaction between HLA/peptide complexes and the TCR in specific immune 
recognition and activation processes can be exploited to mimic the role of antigen 
presenting cells with HLA/peptide tetramers. Presenting PBMCs with soluble 
HLA/peptide tetramers could induce antigen specific TCR oligomerisation and 
therefore could potentially induce stimulation and/or proliferation if this signal proved 
sufficient. The possibility of applying HLA/peptide tetramers to the stimulation of 
antigen specific T cell responses was examined in vitro.
HLA tetramers and adoptive transfer
The fact that antigen specific CD8+ T cells bind tetramer reagents leads to the 
possibility that tetramer binding may initiate the formation of TCR oligomers and lead 
to signal transduction through the TCR followed by stimulation of the T cell response 
(Reich et al, 1997; Boniface et al, 1998). This might constitute a barrier to the clinical 
application of tetramer purified antigen specific T cells, as unwanted activation induced 
cell death might be triggered, which would diminish the efficacy of the T cells.
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Additionally, some of the tetramer molecules would be present at the cell surface and/or 
internalised by the T cell. Consequently the components of the HLA/peptide tetramer 
may still be present at the cell surface and may constitute an immunogenic target 
themselves, therefore jeopardising repeat treatment. This is likely to be a significant 
concern as streptavidin (or avidin) is a well described immunogen that induces an 
antibody mediated immune response. Furthermore, the impact of the in vivo transfer of 
tetramer sorted cells has not yet been assessed in human patients. Consequently, a 
system using a biotin analogue, 2-iminobiotin, was tested to make tetramer complexes 
because of its lower affinity for streptavidin compared to biotin. This is aimed at 
generating tetramer complexes that could be dissociated from Streptavidin after the 
purification had occurred, using a simple biotin competition wash, therefore releasing 
HLA/peptide monomers and disrupting HLA/peptide-TCR oligomerisation by 
decreasing the interaction. This could prevent T cell activation by the tetramer reagent 
used in the staining and purification of the antigen specific T cell population of interest, 
as well as allowing for the tetramer reagent to be washed away from the T cells.
In vitro modulation of antigen specific immune responses
Most antigen specific responses that have been described so far are generally 
characterised by low number of specific cells in peripheral blood. They can even in 
some instances be below the detection limit of the most sensitive techniques available, 
especially in cases of tumour specific immune responses (see Chapter III). Therefore 
whether the targeted T cell population involves low numbers of T cells or the generation 
of a primary immune response, adoptive transfer of T cells is preceded by a period of in 
vitro stimulation and expansion. This can be achieved by single cell cloning and antigen 
non-specific stimulation by cross-linking of the CD3 and CD28 molecules on the cell 
surface (Dunbar et al, 1999), or by using natural antigen presenting cells, dendritic cells, 
loaded with the specific antigen (Oelke et al, 2000; Szmania et al, 2001). This is 
followed by a period of expansion in culture. Both methods have been successfully 
applied to the generation of virus or tumour specific T cell responses, and dendritic cell 
stimulated CMV specific T cells were used for in vivo adoptive transfer in a study of 
SCT recipients “at risk” of CMV reactivation (Peggs et al, 2002).
However, both methods have significant downfalls. The first strategy targeting 
CD3 and CD28 for the stimulation of the T cells is not antigen specific, and therefore 
requires prior single cell sorting. This can be a limitation as the efficiency of flow 
cytometry sorting is good but not absolute (two cells could end in the one well or could
170
Chapter V
be discarded if they pass the detector simultaneously), and few centres possess this 
facility. The second strategy involving the generation of dendritic cells is both labour 
intensive and time consuming and requires the availability of bone marrow or more 
commonly of a large volume of blood. Additionally, the number and quality of dendritic 
cells generated varies considerably on an individual sample basis, and it is not possible 
to control for any other antigen that might be presented by these dendritic cells despite 
loading them with an excess of the specific antigen. Other molecules can also be 
considered for the targeted modulation of antigen specific T cell responses. For 
example, the induction and maintenance of antigen specific T cell responses could be 
achieved with TCR signalling with simultaneous cross-linking of co-stimulatory 
molecules. These can be CD28 as mentioned above, CD40 ligand (or CD40L; 
Lefrancois et al, 2000), which is thought to contribute to the stimulation of primary T 
cell responses or 4-1BB (Shuford et al, 1997; Takahashi et al, 1999), which is a novel 
cell surface molecule thought to be involved in T cell survival mechanisms. 
Additionally, antigen specific T cells could be targeted for deletion through CD95 to 
suppress unwanted T cell responses.
In recent years, strategies have been devised in an attempt to replace natural 
antigen presenting cells with so-called artificial antigen presenting cells that can be used 
in vitro to stimulate antigen specific T cell responses. For example, mouse fibroblasts 
can be retrovirally transduced with a single HLA/peptide complex, along with the 
human accessory molecules CD80 (B7.1), ICAM-1 and LFA-3. These artificial antigen 
presenting cells elicited strong stimulation and expansion of HLA restricted CTLs, 
specific for viral antigens or tumour associated antigens (Latouche and Sadelain, 2000). 
This method appeared to be very reliable for the generation of memory and primary 
CTL responses, but the main drawback would be that a new artificial antigen presenting 
cell line would have to be produced for each HLA/peptide combination wanted. 
Furthermore, the use of a mouse derived cell line might restrict potential applications. A 
more versatile cell based strategy was described with the use of K562 cells, which 
belong to the erythroid lineage, therefore do not express HLA molecules at their cell 
surface, but do express ICAM-1 and LFA-3. These were transfected with the human 
CD32 Fey receptor to allow binding of anti-CD3 and anti-CD28 antibodies to provide a 
TCR signal and with 4-IBB ligand (Maus et al, 2002). These artificial antigen 
presenting cells were shown to activate and rapidly expand polyclonal or tetramer 
sorted populations. However the use of a tumour cell line “vehicle” may restrict their
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use. Consequently, the possibility of exploiting the specific avidity and properties of 
HLA/peptide multimers to target antigen specific T cells with the addition of co­
stimulation for the activation and proliferation of these cells was examined. This would 
constitute a simpler and more versatile non-cellular “vehicle” compared to these 
described above.
In an attempt to create a system that would allow efficient antigen specific 
stimulation with the possibility of simultaneous co-stimulation, HLA/peptide-antibody 
chimeramer complexes were tested as a form of “minimalist” artificial antigen 
presenting system. These complexes basically consisted of a modified HLA/peptide 
tetramer composed of three biotinylated HLA/peptide monomers and one biotinylated 
antibody molecule bound to streptavidin. The synthesis and testing of these complexes 
was described in Chapter II. The ratio of 3 HLA/peptide complexes to 1 antibody 
molecule was chosen so that specific binding to the TCR would be retained and would 
be more avid than that of the antibody molecule component, therefore specifically 
targeting antigen specific T cells for stimulation and co-stimulation. Similar complexes 
were used previously in a different context aiming at redirecting viral specific T cell 
responses to tumours that were characterised by the presence of a specific antigenic 
marker that was targeted by the antibody (Ogg et al, 2000; Robert et al, 2000). This 
required constructing virus specific HLA/peptide-antibody complexes (chosen because 
of a strong antiviral CTL response) in a similar way to that described previously and in 
Chapter II, but to use an antibody that would specifically target the tumour cell, 
therefore coating it temporarily with HLA/peptide complexes and mimicking a virus 
infected cell. Consequently virus specific CTLs would be redirected to destroy marked 
tumour cells. Antigen specific TCR engagement and virus specific cytotoxicity were 
maintained in these studies, using tumour cell lines as targets, which represented an 
alternative approach to tumour immunotherapy. However this system was not described 
in a more physiological context where both antigen specific T cells and tumour cells 
were present or in an in vivo model, therefore it is not known if this strategy would 
work in vivo.
Successful modulation of in vivo immune specific T cell responses has been 
achieved in mouse models (Maile et al, 2001) using transfer of soluble HLA/peptide 
tetramers. The confirmation that antigen specific immune modulation can be achieved 
in vitro using HLA/peptide tetramer or chimeramer reagents would provide the first 
evidence that they might be used for in vivo applications as part of the purification
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and/or vaccination protocols. Consequently, the possible use of HLA/peptide 
chimeramers to stimulate antigen specific T cell responses was examined in vitro in the 
present study.
The aim of this chapter is to investigate the possible uses for HLA/peptide 
tetramer and chimeramer complexes in the modulation of antigen specific T cell 
responses for the adoptive transfer of selected cells or the direct application of these 
complexes.
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Results
HLA/peptide tetramers and adoptive transfer 
Purification of CD8+ Tet+ T cells
The enrichment of CD8+ Tet+ T cells can be achieved by selecting tetramer positive 
cells by flow cytometry or magnetic bead sorting (Keenan et al, 2001; Szmania et al, 
2001). The highest purity (>90%) can be attained by flow cytometry cell sorting, but 
alternative purification techniques were investigated as sorting by flow cytometry was 
time consuming and not easily accessible because there were no onsite facilities 
available. Magnetic bead sorting was therefore tested as a rapid alternative method that 
could be carried out under sterile conditions on site, therefore maximising the survival 
of sorted cells by minimising the delay between cells sorting and subsequent 
experiments.
Purification trials with direct one step labelling of tetramer-PE stained PBMCs 
with anti-PE beads resulted in poor recovery and purity of the selected cells. The 
reasons for that observation were likely to be two fold: firstly the columns used for bead 
purification were small making it less likely that all beads could be retained amongst a 
much greater majority of unstained cells; secondly, dead cells and monocytes were able 
to bind the tetramer reagent non-specifically and resulted in decreased purity of the 
selected fraction. Rather than opting for using two consecutive larger columns, which 
would have required a significant investment, a two step purification protocol was 
tested. Initially, CD8+ T cells were purified from the total PBMCs by using a negative 
selection Kit (labelling and retaining all cells but CD8+ cells), resulting in pure “bead 
free” CD8+ cells being eluted from the column (Figure V.l, panels A and B). Then, the 
CD8+ T cells were stained with CMV Tet-PE, and positively selected with anti-PE 
beads, and subsequently loaded onto a second small column.
Satisfying purity was obtained using this method: 84% of non gated total events 
acquired in the flow cytometry analysis of the purified population were Tet+ in the case 
of a PBMC sample from Patient 1 (Figure V.l, panel C). This method was used to 
purify CMV specific T cells for Vp repertoire analysis and comparing spectratyping 
analysis to a newly developed reference strand conformational analysis (RSCA, method 
allowing the hybridisation of the amplified Vp DNA fragment to a control template and 
able to show a 1 base pair mismatch between the two) and showing the predominance
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and profound expansion of a limited number of T cell clones (McGreavey et al, 
unpublished observations).
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Figure V.l Enrichment of CD8+ Tet+ T cells
Two step magnetic bead purification of antigen specific CD8+ Tet+ T 
cells. Stepwise enrichment of CD8+ Tet+ cells from a PBMC sample 
from Patient 1 shown with: Total PBMCs (panel A), CD8 negatively 
selected cells (panel B), and phycoerythrin (or Tet+) positively 
selected CD8+ cells.
The enrichment of high purity antigen specific T cells can be achieved by flow 
cytometry or magnetic bead sorting. However purified cells would still be bound to the 
tetramer reagent and to the antibody/bead complex in the case of magnetic sorting, even 
after the recommended washes. Although clinically approved bead selection is possible 
(i.e. CD34 selection), there is no reagent currently available that would allow Tet+ 
positive cell selection. Furthermore, HLA/peptide tetramers are bacterial products, are 
not sterile unless filtered, and would need throughout testing before they can have a 
clinical use. A possible solution to this problem that could also prevent T cell activation 
would consist of removing the tetramer reagent from the cell surface after the sorting 
procedure.
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2-iminobiotin HLA/peptide tetramers
2-iminobiotin was selected as an alternative to biotin in the preparation of HLA/peptide 
tetramers because of its low affinity for streptavidin at acidic pH compared to biotin. As 
the biotinylation reaction and the subsequent tetramerisation of the HLA/peptide 
monomers is performed at pH 8, the preparation of tetramer reagents with 2-iminobiotin 
was performed as described in Chapter II. Subsequent staining was identical to that 
performed with tetramer prepared with biotin (Figure V.2), except all steps were carried 
out at 4°C to avoid activation and internalisation of the complexes, and was visualised 
by flow cytometry. PBMCs stained with 2-iminobiotin CMV tetramer were then 
incubated for 10 min in PBS at pH 4.5 at 4°C with excess competing biotin to test if the 
tetramer binding could be disrupted at the surface of CMV specific T cells. Partial 
disruption of tetramer binding can be visualised with a lower Tet staining fluorescence 
intensity, indicating that fewer TCRs were bound per Tet+ T cell (Figure V.2, panels B 
and D). This phenomenon was found to be reversible if the PBMCs were subsequently 
stained again with CMV Tet, confirming that the T cell surface remained intact after 
this acidic treatment (panel C). As described above, 2-iminobiotin tetramer staining and 
subsequent acid wash was not sufficient to remove some of these reagents completely 
from the cell surface. This clearly demonstrated that this approach to reversible 
HLA/peptide tetramer staining could give a satisfactory result, but that it needed to be 
improved to remove the tetramer reagents totally. In this system, the only parameters 
that could be modified to improve tetramer disruption would be to incubate the cells in a 
buffer at lower pH and/or for longer periods of time. However, due to lack of time at the 
end of this PhD thesis, these experiments could not be attempted. Moreover, although 
such drastic treatment would most likely remove more tetramer molecules from the cell 
surface, it might also be very toxic to the cells therefore reducing their viability and 
impair their possible use in subsequent adoptive transfer protocols.
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Figure V.2 2-iminobiotin HLA/peptide tetramer staining
Test stainings with 2-iminobiotin CMV tetramer. The CD8 versus 
Tet staining of the CD3+ gated population is represented (panel A).
Panel B represents the same PBMC sample labelled with 2- 
iminobiotin tetramer and 10 min washing in pH 4.5 buffer with 
competing biotin (competitive acid wash). The same sample was 
again the same sample after 2-iminobiotin tetramer staining, 
competitive acid wash and secondary staining with CMV Tet (panel 
C). Panel D represents the Tet staining histogram for each circled 
CD8+ population (panels A, B and C).
A similar system was then described that allowed the removal of HLA/peptide 
tetramers after binding to antigen specific T cells by direct competition without 
requiring any modification of the pH conditions. This method required the encoding of 
a specific peptide residue, Streptagll, at the end of the HLA class I molecule (instead of 
the bsp2 tag as a target for subsequent biotinylation). The Streptagll peptide could bind 
streptavidin or StrepTactin (a mutated streptavidin molecule forming a polymer, Voss et 
al, 1997) with lower affinity than d-biotin. Therefore, incubating with a buffer 
containing free biotin could easily compete out Streptagll and cause the dissociation of 
the HLA/peptide polymer complex. The downside of this method was that both HLA 
class I and b2-microglobulin needed to be expressed with the Streptagll peptide and to 
be both bound to StrepTactin in order to obtain stable molecules (Knabel et al, 2002). 
This represented a better alternative to removing HLA/peptide tetramer reagents that
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may be possible with 2-iminobiotin tetramers. Additionally, a new biotin analogue is 
now commercially available (DSB-X Biotin, Molecular Probes), can be used as an 
alternative to 2-iminobiotin and can be competed out by biotin without the requirement 
for an acidic pH. This would provide a reversible staining option that could be adapted 
to any established HLA/peptide tetramer synthesis protocol.
Although both these approaches have been designed to avoid TCR triggering, 
the specific ligand interaction of HLA/peptide tetramers with the TCR could be 
exploited to induce T cell activation and/or proliferation.
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In vitro modulation of antigen specific T cell responses 
HLA/peptide-antibody chimeramer specificity
The preparation and testing of HLA/peptide chimeramers was described in Chapter II. 
This demonstrated that these complexes were composed of successfully refolded 
HLA/peptide complexes and of mouse (or rat) antibodies. A series of HLA/peptide 
chimeramers were prepared in parallel to regular HLA/peptide tetramers diluted at 
equivalent volume to the chimeramers to take the added volume of the antibody into 
account, and were made simultaneously from the same batch of HLA/peptide 
monomers. This was done to ensure that tetramer and chimeramer reagents should 
represent the same number of HLA/peptide complexes for a given volume of reagent. 
The only difference between the chimeramer complexes therefore resides solely in the 
presence of the antibody.
The ligand specificity of these complexes was tested to verify that the high 
avidity to the TCR would be conserved without significant interference from the 
presence of the antibody molecule. CMV HLA/peptide tetramer, chimeramer and 
antibody stainings were performed on separate aliquots from the same PBMC sample. 
Representative stainings from patients 5 and 6 are shown on Figure V.3 (panel A) and 
were performed identically to regular stainings as described in Chapter II. The 
difference observed between tetramer and chimeramer stainings were found to be 
minimal, and control staining with the antibody alone demonstrated that the difference 
should have been very pronounced had the antibody interference been substantial. 
Triplicate stainings were carried out with tetramers and different chimeramers to further 
analyse this difference and determine if the antibody would interfere with the 
HLA/peptide-TCR specificity. A control chimeramer complex was prepared with an 
antibody to a mouse cell surface marker (anti-mouse CD8, gift from Dr. Zamoyska) 
which does not cross-react with the human molecule and therefore should not bind to 
human cells. It was added to the panel of chimeramers tested in this experiment. Parallel 
comparisons of sample stainings with high (Figure V.3, patient 6, blue) or average 
frequencies (HD1, red) of CMV Tet+ T cells did not show significant differences. 
Additionally, PBMC samples from patient 6 were also stained simultaneously with both 
regular CMV Tet labelled with APC and with one of the following chimeramers 
labelled with PE: CMV Tet/28, CMV Tet/40L, CMV Tet/4-lBB, CMV Tet/95 and 
CMV Tet/3.
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Figure V.3 HLA/peptide-antibody chimeramer staining
Panel A: Representative comparative stainings on two patients with HLA/peptide 
tetramer ( • ) ,  HLA/peptide-anti-CD28 chimeramer (CMV Tet/28, • )  and anti- 
CD28 antibody alone ( • ) .  The percentage of gated CD8+ cells is indicated at the 
bottom right of each dot-plot (patient 5,upper row; patient 6, bottom row).
Panel B: independent experiments comparing parallel triplicate stainings of PBMC 
samples from donors with high (patient 6, blue symbols) or average (healthy donor 
1, HD1, red symbols) Tet+ frequencies. Stainings were performed with CMV 
tetramer and the following CMV chimeramers complexes: CMV Tet/28, CMV 
Tet/95 with anti-CD95 antibody and CMV Tet/mCD8 with anti-mouse CD8 
antibody; with mean Tet+ frequencies and the standard deviation represented.
Panel C: representative stainings of PBMC samples from a single donor (patient 6) 
labelled with: 1, no label; 2, CMV Tet-APC; 3, CMV Tet-PE; 4,CMV Tet-APC 
and CMV Tet-PE; 5, CMV Tet-APC and CMV Tet/28-PE.
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As seen on representative stainings on Figure V.3 (panel C), both reagents were able to 
bind to antigen specific T cells and no unspecific staining could be detected staining 
with the chimeramer alone (Figure V.3, panel 5). This result was consistent with all the 
chimeramer reagents tested, and separate comparative triplicate stainings with both 
CMV Tet-APC the different chimeramer reagents showed no difference in the 
frequency of antigen specific T cells that were stained by either reagent respectively. 
These results jointly indicated that the chimeramer reagents conserve their specificity 
for the TCR despite the presence of the antibody molecule. The capacity of theses 
complexes to activate antigen specific T cells was examined next to establish if they 
could be used for in vitro stimulation.
Activation of antigen specific T cells by HLA/peptide tetramer and chimeramer 
complexes
Upon triggering of the TCR, and during T cells activation, a signalling cascade is 
induced that results in the up-regulated expression of specific proteins. Some of these 
proteins, such as CD69 and CD25 are expressed at the cell surface and see their 
expression being up-regulated at relatively short time-points post activation. The up- 
regulation of the expression of both these activation markers was examined 24 hr after 
stimulation with tetramer or chimeramer reagents. Triplicate PBMC samples from a 
healthy CMV+ individual were left unstimulated (no Tet control), stimulated with 
soluble CMV AE42 peptide, or stimulated with CMV tetramers or chimeramers. 
Chimeramer complexes were used individually (CMV Tet/28, CMV Tet/40L and CMV 
Tet/4-lBB) or in combinations consisting of equal parts with mixes of the following 
chimeramers: CMV Tet/28/40L, CMV Tet/28/4-lBB, CMV Tet 28/40L/4-1BB. The 
same volume of reagent was added for all stimulation experiments, which implied that 
the same level of TCR interaction with HLA/peptide molecules was applied, with 
different additional cross-linking of co-stimulatory molecules or combinations of 
molecules.
Tetramer and chimeramer reagents used for stimulation were composed of 
fluorescent-PE streptavidin. They were presumably internalised and degraded rapidly 
by T cell and/or PBMCs in culture as no residual fluorescence could be detected 24 hr 
after stimulation. Nevertheless, to discount any possible influence of remaining reagent 
in culture or of using tetramer complexes labelled with the same fluorescent molecule, 
subsequent stainings were performed with allophycocyanin labelled tetramer reagent 
(Tet-APC). Gated CD8+ Tet+ T cells were tested for their expression levels of CD69 and
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CD25 respectively, and the proportion of Tet+ T cells expressing high levels of these 
markers of activation was assessed (Figure V.4, panels A and C). Triplicate 
measurements for each stimulation condition were then plotted on bar graphs (Figure 
V.4, panels B and D) and indicated that the incubation of PBMCs with HLA/peptide 
tetramer or chimeramer reagents induced the up-regulation of both CD69 and CD25 
expression at the surface of CD8+ Tet+ T cells. This confirmed that the stimulation of 
antigen specific T cells with HLA/peptide tetramer or chimeramer reagents resulted in 
the activation of the majority of these cells. For all stimulation conditions that were 
tested, the increase in expression of these activation markers was comparable. The 
presence of the antibody molecule on chimeramer complexes did not appear to impair 
their T cell activation properties.
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Figure V.4 In vitro stimulation with HLA/peptide tetramer and 
chimeramer complexes: expression of activation markers
Measurement of the up-regulation of CD69 and CD25 activation 
markers 24 hr after antigen specific stimulation. Panels A and C 
represent selected examples of measurements with no stimulation 
control (— ), and the superimposed histograms for stimulated 
samples (— ) graphs. Panels B and D represent the mean of triplicate 
tests (bars indicate the standard deviation) for control (no 
stimulation, ■ ), peptide pulsing (□), and each tetramer or 
chimeramer stimulation tested ( ■ ).
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Slightly more pronounced differences were observed for CD25 expression than 
for CD69 expression, but this was difficult to interpret for several reasons: 1) in a repeat 
experiment, increases in CD25 expression were observed, yet the pattern of expression 
when comparing each stimulation condition could not be reproduced; 2) although the 
same number of PBMCs were plated in each well, this did not guarantee that the 
number of CD8+Tet+ T cells was the same between replicate wells. This might therefore 
result in a higher stimulus in wells with relatively less CD8+ Tet+ cells than in these with 
relatively more CD8+ Tet+ T cells per well; 3) the kinetics of CD69 and CD25 up- 
regulation upon T cell activation are different with the peak CD69 expression occurring 
earlier than the peak CD25 expression. As both CD69 and CD25 expression were 
measured at the same time-point post stimulation, the results presented here are 
indicative of up-regulated expression but do not necessarily represent a maximal 
response.
In order to compare the impact of the different stimuli on T cell activation 
more thoroughly, tetramer purified cells should be used to perform time-course 
measurements of activation markers. Another way of demonstrating the efficacy of 
cross-linking alternate receptors simultaneously to TCR triggering to specifically 
deplete Tet+ cells by activating the programmed cell death pathway through the cross- 
linking of CD95. This would be in contrast to attempts at increasing and improving 
activation, but would provide evidence for antigen specific targeting together with 
inhibitory function.
Selective apoptosis of antigen specific T cells with anti-CD95 chimeramer reagent
Activated T cells express higher levels of the CD95 cell surface molecule than resting T 
cells. Subsequent interaction of CD95 ligand or anti-CD95 antibody with CD95 induces 
a cascade of signalling events that lead to programmed cell death or apoptosis.
As part of the assessment of the capacity of HLA/peptide chimeramer reagents 
to induce a targeted CD8+ Tet+ T cell co-signal, CMV Tet/95 chimeramers were 
prepared. An experimental protocol was established that allowed the measurement of 
the expression of the early enzyme markers of apoptosis: caspases (Apostat, as 
described in Chapter II). In an attempt to use a simplified experimental setting 
compared to using a PBMC sample from a healthy CMV+ donor, a specific T cell line 
was obtained from colleagues in Leiden.
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Two experiments were planned using these purified T cells: 1) the first 
experiment consisted of incubating the CMV specific T cells overnight alone, with 
CMV tetramer, with CMV Tet/95 chimeramer or with anti-CD95 antibody alone, then 
to assess the level of apoptosis after 24 hr in culture. This was to establish whether the 
CMV Tet/95 chimeramer complexes could be used to selectively deplete antigen 
specific T cell responses; 2) the second experiment involved using the same conditions 
as in the previous experiment, but adding the complexes to the CMV specific T cell line 
an hour prior to mixing them with fluorescently labelled and CMV peptide pulsed T2 
targets, or adding them simultaneously by mixing with the target cells. The level of 
apoptosis would then have been measured in the CMV specific T cells as well as in the 
target population to establish if the use of CMV Tet/95 chimeramer complexes could 
specifically deplete CMV specific T cells and/or protect T2 cells from antigen specific 
T cell cytotoxicity.
However, only preparative experiments were completed (cell labelling and 
assessment of apoptosis) as the cell line that was obtained constitutively expressed high 
levels of CD95, high levels of caspases and showed poor viability in culture (~ 50%). 
These characteristics which made the experiments described above impossible, as the 
viability was not sufficient to carry out reliable tests. Despite the inability to 
demonstrate targeted apoptosis through binding of HLA/peptide molecules and cross- 
linking of CD95 molecules with HLA/peptide chimeramers in this particular 
experimental setting, the co-stimulatory effect induced together with the stimulation of 
antigen specific T cells with chimeramers could be assessed. This was achieved by 
testing the capacity of these molecules to induce specific proliferation of antigen 
specific T cells.
Proliferation of antigen specific T cells upon stimulation with HLA/peptide 
tetramer and chimeramer reagents
Upon TCR triggering and receipt of an appropriate agonist signal, a proportion of 
antigen specific T cells will undergo cell division. A similar experiment to that 
described previously with the activation of antigen specific T cells, stimulating the same 
number of PBMCs from a healthy CMV+ individual in triplicate per stimulation 
condition, and assessing the proliferation of CD8+ Tet+ T cells in relation to CD8+ T 
cells. To ensure that the proliferation observed in these assays was truly antigen specific 
and not somewhat influenced by any residual reagent present in culture, PBMCs were
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stimulated with CMV tetramer and chimeramer reagents composed of streptavidin-PE, 
whereas stainings were performed with CMV tetramers prepared with 
streptavidin-APC. However as mentioned previously, no residual PE fluorescence could 
be observed in the PBMC samples 24 hr after stimulation.
The relative frequency of CD8+ Tet+ T cells was measured on day 0 (stimulation day, 
this acted as the baseline control) and after 7 days in culture following stimulation 
(Figure V.5, panels A and B). The results obtained after all stimulation settings were 
plotted and compared to a control where PBMCs only received identical amounts of IL7 
and IL15 cytokines at the same time-points as stimulated samples (Figure V.5, 
panel C). After 7 days in culture, the relative frequency of CD8+ Tet+ T cells decreased 
in the control sample, whereas a vigorous increase could be observed in all stimulated 
samples. This data is representative of two independent experiments carried out with 
PBMCs isolated from the same CMV+ healthy donor. The highest increase was 
observed by stimulating PBMCs with CMV Tet/28 with a mean difference of 5.5% 
between the frequencies measured on day 0 and 7 days after stimulation. Interestingly, 
all samples stimulated with HLA/peptide chimeramer complexes showed more 
pronounced increases than the samples stimulated with HLA/peptide tetramer 
complexes. In this experimental setting, it was not possible to strictly compare each 
different stimulation condition as the initial number of CD8+ Tet+ T cells may not have 
been identical in each individual well tested, as suggested by the high standard 
deviation values. However, the mean frequency increase was found to be consistently 
higher in all samples stimulated with HLA/peptide chimeramer reagents compared to 
these stimulated with HLA/peptide tetramer reagents, which supports the idea that 
cross-linking of cell surface co-stimulatory molecules had occurred and had promoted 
antigen specific CD8+ Tet+ T cell proliferation.
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Figure V.5 In vitro stimulation with HLA/peptide tetramer and 
chimeramer reagents: proliferation of antigen specific CD8+ T 
cells
PBMCs from a healthy CMV+ healthy donor (HD1) were plated in 
triplicate and samples were stimulated with (■) CMV tetramer or 
chimeramer reagents or not stimulated (■). Assessment of the 
relative proliferation was assessed after 7 days in culture. The light 
bars represent day 0 and the dark bars represent day 7 after 
stimulation; error bars represent the standard deviation between 
triplicate samples.
The samples were further stimulated in vitro to establish whether they could be further 
expanded, but after 3 rounds of stimulation under the same conditions as described 
previously, all cells from the samples stimulated with chimeramer reagents prepared 
with the anti-CD28 antibody had died (CMV Tet/28, CMV Tet/28/40L, CMV Tet28/4- 
1BB and CMV Tet/28/40L/4-lBB) while all other samples had mean frequencies very 
similar to the original control sample (Figure V.5, panel C, light blue bar). The
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frequencies measured in the samples that retained viability were: no Tet, 0.6%; CMV 
Tet, 0.8%; CMV Tet/40L, 1.19%; CMV Tet/4-lBB, 0.68%. This observation was 
somewhat anecdotal, but supports the concept that these complexes induce different 
levels and/or types of stimulation, and perhaps that CD28 co-stimulation/activation 
might promote activation induced cell death.
Since the ability to effect TCR triggering together with co-stimulation has only 
been examined with respect to the activation and the proliferation of antigen specific 
CD8+ T cells following tetramer or chimeramer stimulation, it was considered that 
further phenotypic markers need to be studied, in order to establish the properties of 
these reagents in vitro and at later stages in vivo and their impact on T cell activation, 
proliferation and differentiation.
Phenotypic characteristics of tetramer and chimeramer stimulated antigen specific 
T cells
The successful stimulation and proliferation of antigen specific T cells with 
HLA/peptide tetramer and chimeramer complexes were further examined in conjunction 
with the phenotypic markers as described in Chapter HI. PBMCs were isolated from a 
healthy CMV+ donor (blood sample, HD1) and either left unstimulated, stimulated with 
CMV tetramer, with CMV chimeramer (Tet/28, Tet/40L, Tet/4-lBB, Tet/28/40L, 
Tet/28/4-lBB or Tet/28/40L/4-lBB) or with CMV peptide. For each stimulation 
condition tested, CMV Tet+ events were gated (panel A, Figure V.5). The same marker 
combinations as these mentioned in Chapter III were used with CD45RO, CD27 and 
CCR7 stained in parallel to CMV tetramer staining. The effect of the in vitro 
stimulation on the expression of these markers was tested 7 days after stimulation and 
cell culture.
The first point that was evident from this data was the presence of Tet+ cells 
expressing high or low levels of TCR molecules at their cell surface, as visualised by 
high or low tetramer fluorescence staining intensity on panel A. If compared to the 
control cells without any antigenic stimulation, tetramer stimulated and particularly 
peptide stimulated PBMCs comprise a majority of low TCR CMV specific T cells. This 
observation may be indicative of a higher stimulation threshold for these cells if they 
were to face a subsequent antigenic challenge as there would be less density of cell 
surface ligand available for the binding of HLA/peptide molecules. Remarkably, 
PBMCs stimulated with CMV chimeramer reagents showed a different profile of TCR 
expression levels with the presence of both high and low TCR expressing cells, detected
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in higher numbers than in the control sample. All CMV chimeramer complexes tested 
but Tet/28/40L/4-lBB produced a similar phenotypic profile as seen for Tet/28 on 
Figure V.6. This indicated that antigen specific T cells stimulation with chimeramer 
reagents induced the proliferation of both high TCR and low TCR cells, which could be 
a significant advantage in the case of a secondary challenge. Additionally, the 
combination chimeramer Tet/28/40L/4-lBB induced less intense proliferation, as seen 
on Figure V.5 and Figure V.6, but the majority of these cells after 7 days in culture 
expressed high levels of TCR molecules at their surface, which would make them 
sensitive to a secondary antigenic challenge.
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Figure V.6 CMV tetramer and chimeramer stimulated antigen 
specific T cells: CD27 and CD45RO expression
Panels show CMV Tet stainings of PBMCs from a healthy CMV+ 
donor (HD1) unstimulated, after stimulation with CMV Tet, CMV 
Tet/28, CMV Tet/28/40L/4-lBB, or CMV AE42 peptide and 
cultured for 7 days. Tet+ T cells were gated (panel A ,#) and the 
cells were sub-categorised as function of their CD27 and CD45RO 
expression (panel B,#). The relative percentages of events in each 
sub-category are reported in the top comer of each panel.
Control
Forward Scatter CD45RO
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When the phenotypic markers of these Tet gated cell populations were 
examined, no changes in CCR7 expression could be detected compared to those 
previously seen in Chapter III with the majority of Tet+ cells and CD8+ cells being 
CCR7\ However, differences in CD45RO and CD27 expression, were seen depending 
on the stimulation condition examined (panel B, Figure V.6). Whilst the majority of the 
cells in the control sample were either of resting/quiescent phenotype (CD45RO' 
CD27+) or of memory/activated phenotype (CD45RO+ CD27+), stimulated cells had a 
larger proportion of cells with a more differentiated phenotype and a higher proportions 
of effector memory type cells (CD45RO+ CD27). The most differentiated phenotypes 
for CMV specific T cells were observed in the case of peptide pulsed PBMCs with the 
least resting/quiescent cells remaining compared with other stimulation conditions, and 
the most effector memory/activated and terminal effector (CD45RO* CD27 ) cells 
detected after 7 days in culture. This may reflect the fact that peptide pulsing only 
triggers the proliferation and differentiation of memory/activated and effector type cells, 
but that resting/quiescent cells might be merely maintained or kept cycling and might 
not be stimulated to proliferate and/or differentiate under these conditions. Stimulation 
with CMV specific tetramer and chimeramer reagents maintained and/or seemed to 
induce a significant proportion of resting/quiescent T cells or antigen inexperienced 
cells, which would be an important component in the response to a further CMV 
specific stimulus. It was clear from the results that certain co-stimulatory chimeramers 
appears to favour the expansion of resting/quiescent type CD8+ CMV Tet+ T cells whilst 
conserving their phenotype and inducing little effector/memory differentiation or 
proliferation. By contrast, the highest proportion of effector memory cells is seen when 
PBMCs are stimulated with Tet/28 or with peptide. In the case of stimulation with 
Tet/28 chimeramer, we can observe after 7 days in culture the expansion of both 
resting/quiescent type cells as well as memory/activated/effector type cells. Although it 
is likely that the resting/quiescent phenotype cells have proliferated compared to the 
control sample, it is also possible that these cells have survived better in culture with a 
higher cell death rate in the control. The stimulation with Tet/28 chimeramer was 
comparable to all other chimeramer stimulation conditions tested with the exception of 
Tet/28/40L/4-lBB (Figure V.6 and data not shown).
Consequently, further study of combined antigen specific stimulation and co­
stimulation using HLA/peptide chimeramer reagents might be useful to determine to 
which degree each co-stimulatory molecule contributes to survival, to proliferation, to 
the generation of differentiated memory and effector cells. However the results
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discussed above only represent a single experiment and would therefore need to be 
repeated to confirm the phenotype results obtained.
The finding that antigen specific T cells, in particular naive T cells could be 
stimulated to differentiate and/or proliferate were studied further in the context of 
primary CMV responses to test if tetramer and/or chimeramer complexes could be used 
to trigger antigen specific immunity.
Induction of CMV specific primary immune responses
Three healthy CMV donors (HD3, HD4 and HD5) as well as three CMV' recipients of 
SCT with CMV' donors were selected. In all PBMC samples used, CMV Tet+ T cells 
were found to be below the detection limit of the assay. PBMCs were plated in triplicate 
wells and either left unstimulated, stimulated with CMV tetramer or were stimulated 
with CMV Tet/28 chimeramer. The frequency of Tet+ T cells present in the samples was 
assessed after two or three rounds of stimulation and cell culture in the presence of IL7 
and IL15. The Tet/28 chimeramer reagent was chosen on the basis that it might provide 
the two signals thought to be necessary for the induction of a T cell response 
1) signalling through the TCR with the HLA/peptide molecule; 2) the CD28 co­
stimulatory signal. It was not possible to test the other chimeramer reagents 
combinations due to limiting cell numbers. A PBMC sample from a CMV+ SCT patient 
with a CMV+ donor (Patient 4) was also stimulated and represented a positive control. 
In this particular case (Figure V.7, panel B), CMV specific Tet+ T cells increased after 2 
rounds of stimulation but went back to control levels after 3 rounds of stimulation. This 
demonstrated that Tet+ cells could be stimulated and proliferate in vitro following a 
protocol identical to that was used previously to stimulate Tet+ cells from a CM V 
healthy donor (Figure V.5).
In the case of the stimulation of PBMCs from CMV' healthy individuals, no 
increase in the frequency of CMV specific T cells was detectable in tetramer or 
chimeramer stimulated wells compared to control wells (Figure V.7, panel A) following 
2 rounds of stimulation. However, after 3 rounds of stimulation, a significant increase in 
the frequency of CMV specific Tet+ CTLs could be detected when compared to the 
controls. In Addition, this increase was more pronounced in wells stimulated with CMV 
Tet/28 chimeramer reagent. As these results were consistent in all 3 CMV' healthy 
individuals tested, they further supported the concept of an enhanced stimulating 
capacity of Tet/28 chimeramer complexes compared to standard tetramer complexes
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bearing the same HLA/peptide combination. It can be noted that a significant proportion 
of the increase in the HD5 samples occurred with the sole addition of IL7 and IL15 
cytokines without antigenic challenge as can be seen with a high frequency of CD8+ 
CMV Tet+ T cells in the control. This is likely to represent the proliferation of T cells 
other than CMV specific that may be activated at the time of culture set-up and express 
high levels of CD28 on their cell surface, therefore would be more sensitive to cross- 
linking of CD28 and to cytokine exposure. This unexpected high increase in the case of 
HD5 may be explained by a high level of susceptibility to allergens in this individual, 
and raises questions about the suitability of stimulation in individuals with 
inflammatory reactions with the need for further testing and/or purification of the 
wanted T cell population after stimulation in similar cases.
However the general consistency of these stimulation results in all 3 CMV‘ 
healthy individuals was very encouraging, and constituted an alternative method to 
raising antigen specific T cell responses without recourse to infectious material. 
Therefore the PBMCs that were left over for each stimulation condition were 
cryopreserved and stored so that cytotoxicity and phenotyping assays could be 
performed later. Unfortunately due to lack of time at the end of this PhD project, these 
tests could not be performed.
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Figure V.7 In vitro stimulation with HLA/peptide chimeramers: 
primary specific immune responses
3 CMV healthy individuals were selected and PBMC isolated and 
three aliquots prepared. These correspond to: culture alone (control, 
■ and ■ ) or stimulated with HLA/peptide CMV specific tetramer 
(CMV Tet) or chimeramer (CMV Tet/28) reagents (■ and ■ , panel 
A). The frequency of CD8+ Tet+ T cells was measured after 2 rounds 
(light colour) or 3 rounds (dark colour) of stimulation and culture. 
Error bars indicate the standard deviation. The positive control 
sample comprised PBMCs from a CMV+ SCT patient 4.
In the case of CMV' SCT recipients with CMV donors, no differences were seen 
between control and stimulated PBMCs after 2 or 3 rounds of stimulation (data not 
shown). This may reflect the fact that immune reconstitution is slow after SCT and also
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that few naive T cells, which would be needed to provide a primary response, are 
transferred in the transplant procedure. Furthermore, few naive T cells are effectively 
generated especially in adult patients because of decreasing thymic activity with age 
and/or toxicity of the transplant procedure as well as immunosuppression post transplant 
in some cases. Nevertheless, it was demonstrated in Chapter IV that CMV+ recipients 
with CMV' donors are able to raise CMV T cell responses in vivo. In one particular case 
(patient 1), it was possible to test the origin of these CMV specific Tet+ CTLs by 
specific Y chromosome fluorescence in situ hybridisation of CD8+ Tet+ sorted cells 
(Figure V.l), as this patient had a female donor. The cells were confirmed to be of 
donor origin with this technique. This confirmed that it was clearly possible to generate 
primary type CMV specific responses in vivo after SCT with a CMV' graft. Therefore 
the stimulation protocol described above would need to be improved and further tested 
to determine if an anti-CMV CTL immune response could be induced in vitro in 
samples from CMV' donors and might be used for transfer to CMV+ recipients.
As CMV specific T cells could be stimulated following specific TCR triggering 
with CMV tetramer or CMV Tet/28 chimeramer reagent, this raised the possibility that 
they could also be used to boost specific T cell responses. This was tested in the context 
of tumour CML specific T cell responses.
Stimulation of CML specific T cell responses
As CML specific T cells could be detected in a proportion of CML patients, the 
possibility of boosting this response by increasing their numbers using HLA/peptide- 
antibody chimeramers was examined. Cryopreserved PBMC samples from 8 CML 
patients were selected in order to stimulate CML specific T cell responses as these 
patients were HLA-A*0301+ b3a2+. As was shown in Chapter III, CMV specific T cells 
can be detected in some patients. Therefore this raises the possibility that a memory 
type immune response might be stimulated in this cohort of patients. A sample from a 
CMV+ SCT recipient who was not treated for CML but was HLA-A*0301+ (patient 6) 
was also tested in this experiment. This would act as a control sample, and also would 
determine the possibility of triggering CML specific responses in the context of a CML 
naive subject (this has been shown to be possible in healthy donors, see Bocchia et al, 
1996; Norbury et al, 2000). As cell numbers were limiting, it was not possible to test a 
large number of conditions for stimulation, or to test multiple wells per setting. 
Predominantly, it was only possible to set up a control and 1 stimulation variable using
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the CML Tet/28/40L/4-lBB reagent. This reagent combination was chosen as it might 
provide the most diverse stimulus, as well as possibly inducing the proliferation of less 
differentiated antigen specific T cells that consequently may be better suited for a 
repetitive or durable antigenic stimulus, as would be the case for an established tumour.
Day 7 Day 14 Day 21 Day 7 Day 14 Day 21
Figure V.8 In vitro stimulation of tumour specific T cell responses 
with HLA/peptide chimeramer reagents
5/8 HLA-A*0301+ b3a2+ CML patients and 1 HLA-A*0301+ b3a2' 
CML' patient (patient 6) are shown. PBMC samples were stimulated 
with CML Tet/28/40L/4-lBB. The relative proliferation of CD8+ 
Tet+ T cells was assessed by CML tetramer staining 7, 14 and 21 
days after stimulation and culture (■). The lack of data due to cell 
death is indicated by a black cross (patient 35). The following 
controls are represented: no chimeramer stimulation followed by 
CML tetramer staining ( ■), chimeramer stimulation followed by 
no tetramer staining (■).
196
Chapter V
For 5/8 CML patients, an increase in the proportion of CML Tet+ T cells was 
observed after 2 or 3 rounds of stimulation (Figure V.8). In all of the cases where an 
increase could be detected, these were somewhat discrete but specific and represented a 
relatively small number of antigen specific T cells compared to the negative control 
stainings, as can be seen on the example dot plots, accompanying the graph for patient 
41. It should be noted that not all patients were receiving the same treatment: patients 
38,41 and 42 were treated with the tyrosine kinase inhibitor Imatinib Mesylate, whereas 
patients 35 and 40 were treated by SCT. This might suggest that CML specific T cell 
responses may be boosted in a proportion of patients, which could then promote a 
tumour specific immune response, independently of the treatment received. For 3/8 
CML patients, no CD8+ CML Tet+ T cell could be detected above the levels of the 
controls used (data not shown). This might indicate that in these patients, no 
KQSSKALQR peptide specific T cells were present or that they could not be stimulated 
by the experimental conditions used in this assay. However, the absence of CD8+ CML 
Tet+ T cells or their presence in low numbers in the 5 samples where amplification 
could be detected is not altogether surprising as immune responses to established 
tumours are notoriously difficult to generate and/or stimulate. Additionally, CML 
specific Tet+ T cells appeared to increase also in the PBMC sample from patient 6, who 
was transplanted to treat a haematological malignancy other than CML, which may be 
indicative of a primary response, and/or of the proliferation of naive T cells.
Although these results are preliminary because only a single sample could be 
tested per condition per patient and the chimeramer reagent used and/or the culture 
conditions may not be optimal, they nevertheless represent a promising novel method to 
stimulate tumour specific T cells in vitro. Although these assays are preliminary, they 
warrant repetition, along with further characterisation and testing of the CML specific T 
cells to establish their specific cytotoxicity. This strategy deserves to be investigated 
further as it may provide new immunotherapeutic opportunities.
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Discussion
As was shown in the previous chapters, the technical advance brought about by the use 
of HLA peptide tetramer complexes has been very significant for the study of antigen 
specific T cell responses. Understanding the kinetics of the CTL immune response to a 
specific pathogen has been especially useful in the context of SCT, and to tumour 
antigens in oncology, with in some cases the absence or apparent deficiency of 
responses. These have allowed for the development and impact assessment of the 
treatments used in patients and in studying the contribution of the immune system.
However applications for HLA/peptide tetramer complexes can be taken further 
and be used as a specific tools for the purification of antigen specific T cell populations 
for further characterisation (for example Vp repertoire analysis) and/or adoptive 
transfer. This provides a direct way of modulating antigen specific responses in vivo by 
the direct addition of antigen specific T cells by infusion in peripheral blood or at the 
specific site where the response is needed. Despite the fact that these areas have been 
developed relatively recently, a number of in vivo applications have been reported to 
date, for example for the prevention of CMV infection in individuals “at risk” after SCT 
(Einsele et al, 2002) or to target tumour to which antigen specific responses have been 
described such as melanoma (Dreno et al, 2002; Dudley et al, 2002; Meidenbauer et al, 
2003). These adoptive transfer studies are still limited in numbers, therefore the full 
potential and impact of such therapies has yet to be formally established for each 
clinical setting where they are applied on a sole basis or in combination with 
conventional therapy. In the clinical applications cited above, the HLA/peptide tetramer 
complexes used were synthesised and used with regular streptavidin and biotin 
molecules as described in Chapter II. No significant adverse effect have been reported 
after transfer of tetramer purified antigen specific T cells. In most cases, transferred T 
cells are shown to proliferate after transfer and to be effective towards their specific 
HLA/peptide restricted target. The majority of these transfer protocols involve a period 
of in vitro culture prior to transfer, but the impact of tetramer purification with possible 
TCR down-regulation after the purified cells get activated through the purification 
process, as well as the rate of possible activation induced cell death is not known. 
Although, the benefits of reversible tetramer staining in the context of adoptive transfer 
of antigen specific T cell concerning the parameters described above have not been 
formally studied, they may be of significant impact for the study of TCR and/or co­
stimulation cross-linking and their effect on resting T cells together with the signalling
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pathways involved. Therefore the use of 2-iminobiotin tetramers or analogue molecules 
that allow reversible staining without TCR triggering may prove to be an advantage in 
some experimental settings.
Yet the very fact that HLA/peptide tetramer complexes are able to specifically 
trigger T cell activation can also be exploited to modulate antigen specific T cell 
responses. This was attempted in vitro in this chapter with the use of HLA/peptide 
tetramer or HLA/peptide-antibody chimeramer reagents. Specific binding of the 
tetramer and chimeramer reagents to a specific antigen restricted T cell population was 
demonstrated after staining PBMCs. This point was very important in the case of the 
chimeramer reagents as it meant that both TCR activation and co-stimulation could both 
be delivered specifically to the antigen specific T cell population of interest. Although 
this was shown in the context of a well established antiviral response, this may be 
crucial to the generation or boosting of responses in more difficult cases such as anti­
tumour responses. As the combination of endogenous MHC and co-stimulation were 
shown to contribute to T cell recognition (Wiilfing et al, 2002), this may prove to be an 
advantage that chimeramer complexes have over regular tetramer complexes for the 
modulation of an antigen specific immune response.
Clearly, both HLA/peptide tetramer and chimeramer complexes were capable of 
triggering T cell activation and proliferation, with better results obtained with 
chimeramer complexes. This is in agreement with the concept cited previously, and also 
with the fact that if given a strong signal, no co-stimulation is required for the activation 
and proliferation of CD8+ T cells (Wang et al, 2000), but that co-stimulation may 
augment these. The finding that there was no statistical difference between the 
activation or proliferation of antigen specific T cells induced with the different 
chimeramer complexes was unexpected, as one might consider that the contribution of 
each co-stimulatory molecule tested in TCR signalling and T cell activation would 
differ. However in the CMV model that was studied in this chapter, there may be 
several limiting factors in the detection of these possible differences. Firstly the use of a 
relatively high dose of tetramer or chimeramer reagent might be limiting, therefore 
masking the contribution of co-stimulation with a very potent TCR signal; secondly, the 
fact that the AE42 peptide is a potent agonist might render co-stimulation dispensable to 
generating a response. It may therefore be possible to better assess these differences in 
the CMV model by studying a T cell line or clone and testing dose dependent responses 
to tetramer and chimeramer stimulation. Furthermore, different models using a weaker
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agonist response or a lower avidity complex might be better suited to highlighting these 
differences. Consequently modulation of antigen specific responses using HLA/peptide 
tetramer or chimeramer complexes offer new avenues for stimulation protocols. They 
also may constitute new tools for assessing what the requirements for generating 
antigen specific T cell responses are, as well as the respective effect of different co- 
stimulatory stimuli applied together with TCR triggering.
As opposed to specific stimulation of antigen specific T cells, HLA/peptide 
complexes have been shown to inhibit certain responses (that may be of interest for 
example in the case of allogeneic responses) if used in a low avidity complex form such 
as a dimer. This was shown in a transgenic mouse model (O’Herrin et al (2001). This 
further makes the point that the requirements for activation by positive modulation and 
tolerisation by weak interaction or targeted specific depletion need to be better 
established to induce the desired effect in an in vitro or in vivo protocol.
The important differences that could be established between peptide, tetramer 
and chimeramer stimulation were that the level of TCR down-regulation and the level of 
differentiation of the CD8+ CMV Tet+ T cells may be affected by the type of stimulus 
that was chosen. The fact that TCR down-regulation varies between experimental 
settings may have a significant impact on the subsequent susceptibility of these cells to 
further antigen specific stimuli. This is due to the fact that TCR becomes down- 
regulated after T cell activation (Cai et al, 1997) and remains marked for internalisation 
after dissociation from MHC (Coombs et al, 2002), this therefore might result in 
durable down-regulation of the number of TCR molecules present at the cell surface. As 
fewer TCR would be effectively available for binding at the cell surface, a much 
stronger stimulus would be needed to achieve activation of the targeted T cell. 
Additionally, the fluorescence intensity of tetramer binding has been shown to correlate 
with T cell avidity and anti-tumour activity (Yee et al, 1999), therefore in vitro 
stimulation protocols may benefit from the selection of a stimulus that while inducing 
proliferation might also maintain or re-induce high levels of T cell expression at the T 
cell surface. In vitro stimulation and proliferation of antigen specific T cells needs to be 
assessed to determine what the differentiation levels of the generated cells is prior to use 
in in vitro experiments or adoptive transfers, in order to maximise their efficacy and 
life-span. This may contribute to the improvement of adoptive transfer strategies where 
although the transferred cells were shown to specifically kill their targets in vitro, this 
might not be representative of their in vivo activity (Monsurro et al, 2002). Despite the
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fact that some differentiated memory cells might revert to less differentiated phenotypes 
while maintaining their functions (Van Leeuwen et al, 2002), there is also a possibility 
that these cells might reach high frequencies in vitro but reach replicative senescence 
(Oxenius et al, 2001). Yet they may remain in peripheral blood for long periods of time 
by default of apoptosis (Spaulding et al, 1999), which might after transfer constitute an 
over-representation and or compete out other responses. This could therefore be 
detrimental to a treated patient in the longer term, especially if large numbers of antigen 
specific T cells were transferred. This phenomenon can be seen in elderly individuals 
with large numbers of antigen specific T cells specific for latent viruses such as CMV or 
EBV. A good proportion of these cells are not functional, and their domination of the T 
cell pool is thought to be associated with a higher incidence of infections by other 
agents and earlier mortality in CMV and/or EBV seropositive individuals with large 
responses compared to seronegative aged matched controls (Ouyang et al, 2003). 
However this last point may not be of immediate concern for SCT recipient “at risk” of 
CMV infection or indeed for cancer patients.
The new possibilities of inducing primary and/or boosting specific T cell 
responses using artificial antigen presenting cells or complexes such as the chimeramer 
reagents described in this chapter (or other recently described non-cellular artificial 
antigen presenting cells consisting of latex beads coated with HLA/peptide tetramer 
complexes, CD80 and CD54 molecules (Oosten et al, 2002)) offer attractive 
improvements for the advance and the wider application of T cell immunotherapy.
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Chapter VI 
General Discussion and Conclusion
In the present PhD thesis, successful detection, monitoring and modulation of antigen 
specific immune responses was demonstrated. These parameters have proven to be of 
interest in the context of haematological malignancies, where their characterisation 
might benefit patients by improving previously described antigen specific T cell 
responses.
The first strong argument in favour of using such a system as HLA/peptide 
multimer complexes is their intrinsic quality of receptor specificity. This guarantees that 
the T cells which are targeted are truly specific to the HLA/peptide combination chosen 
for detection or modulation, therefore avoiding binding to other irrelevant T cells 
bearing a receptor of different specificity. This is especially important in the SCT 
setting as it is crucial to determine that the antigen specific immune reconstitution that 
is occurring is acting against tumour or virus restricted targets whilst avoiding one of 
the major post SCT complications, GvHD (caused by the presence of host reactive 
donor T cells) that would be exacerbated by a non-specific stimulus. The results 
presented in Chapter HI showed the successful detection of an immunodominant anti- 
CMV CTL response after testing several possible candidate HLA/peptide combinations. 
With a different approach, CML specific HLA/peptide complexes were detected at the 
surface of CML b3a2+ cells, and HLA/peptide multimers then allowed the detection of 
T cells restricted to that particular HLA/peptide combination in peripheral blood from 
CML patients. As illustrated in these two separate applications, HLA/peptide multimers 
can be used to test for the presence of and then to characterise antigen specific CD8+ T 
cell immune responses for new HLA/peptide combinations. Other applications of 
HLA/peptide tetramer or multimer reagents include the possible detection of antigen 
specific helper T cells (CD4+ HLA class II/peptide specific complexes), or of antigen 
specific T cell in tissues rather than in peripheral blood for example. These applications 
as well as other currently well defined procedures using HLA/peptide and MHC/peptide 
complexes were the subject of a detailed review issue of the Journal of Immunological 
Methods (2002; issue 268,1). Applications reviewed in this journal also include the
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possibility of discovering previously unknown ligands for less common HLA molecules 
such as non-classical HLA molecules (for example HLA-E). Although the specificity of 
HLA/peptide multimers for their relevant T cell receptor constitutes great advantages to 
their use, it can also constitute a limitation to their application in the detection, 
monitoring and modulation of antigen specific responses for several reasons. Firstly, it 
requires a knowledge of the target antigenic peptide. Therefore, the use of HLA/peptide 
multimer complexes would be restricted to individuals possessing the HLA molecule 
used in the HLA/peptide multimer, which would restrict the number of individuals that 
may be targeted by such studies or therapies. Furthermore the HLA frequency 
distribution of rare alleles and the high degree of HLA polymorphism would both 
contribute to these limitations. However, not all HLA polymorphisms affect the peptide 
binding capabilities to some extent within a subgroup of HLA alleles, so that the 
limitations presented above might be overcome by selecting the predominant HLA 
alleles in the majority of individuals from the ethnic population studied. Another 
important aspect to keep in mind is that even in the case of a well described 
immunodominant response (i.e. the HLA-A*0201/AE42 CMV specific CTL response), 
the detection of antigen specific immune responses with HLA/peptide multimers 
represents a fraction of the total immune response. This may be especially relevant in 
the case of an anti-tumour response where several tumour-associated and/or minor 
histocompatibility antigen specific responses are believed to contribute to the anti­
tumour immune response. Further, the diversity of the CTL immune response restricted 
to a particular pathogen or tumour is also likely to be diversified to avoid or counter 
immune escape mechanisms. Additionally, the diversity of the response would also be 
influenced by the different combinations of HLA molecules present at the cell surface, 
as well as by the viral strain or translocation type of the specific viral or tumour antigen 
targeted. Consequently, it is likely that a combination of HLA/peptide complexes 
composed of common HLA molecules in a selected patient population together with 
several important antigenic peptide targets might provide optimal detection, monitoring 
and modulation. For example, comparable CTL responses restricted to either the pp65 
or the IE1 CMV protein but not both could be detected in distinct HLA-A*0201 
individuals with different other HLA alleles combinations, providing some evidence 
that certain major HLA molecule combinations might favour the processing and/or 
presentation of an immunogenic protein over another (Khan et al, 2002; Paston et al, 
personal communication). Such HLA/peptide multimer “cocktails” containing several 
HLA/peptide complexes might be developed for routine clinical use in the detection
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and/or purification (if produced in detachable form with 2-iminobiotin or analogue) of 
antigen specific T cell pools that would include a range of known common HLA 
molecules with their restricted major antigenic peptides within a defined ethnic 
population. However, the need for multiple antigenic peptides binding to a single 
selected HLA allele might not be necessary in the case of a well-defined 
immunodominant CTL response.
In an immunodominant T cell response, such as the HLA-A*0201 restricted 
response to CMV pp65, it is possible to monitor antigen specific T cell responses, as 
was demonstrated in Chapter IV of this thesis. This strategy was used successfully in 
the clinic to assess the progress of SCT patients and their antigen specific immune 
reconstitution, together with the detection and quantification of CMV infection. This 
study is the first to formally establish a positive correlation between high levels of CMV 
specific cytotoxic T cells and protection from CMV infection. This was particularly 
useful to establish the response of patients to various treatments as well as the relative 
influence of these treatments on the CMV specific immune response. The present study, 
as well as other studies of larger patients groups allowing multivariate analyses, that are 
perhaps more adequate in the context of SCT, for the identification of factors 
influencing CMV infection. One of these factors included the occurrence of CMV 
specific T cell immunodeficiency and lymphopenia induced by steroid treatment and 
could be used as predictors of CMV infection, recurrent and/or late CMV infection, 
which are all linked to higher mortality in these patients (Aubert et al, 2001; Nichols et 
al, 2001; Boeckh et al, 2003). These findings would support the hypothesis that 
immunosuppression induced to prevent or treat GvHD might be in most cases where 
late CMV infection is observed, immunosuppression is the cause of CMV specific T 
cell immunodeficiency resulting in CMV infection. By contrast, one might argue that in 
the case of early CMV infection likely due to a yet insufficiently reconstituted immune 
system, the pro-inflammatory properties of CMV might contribute to the occurrence of 
GvHD. Furthermore, evidence from a mouse SCT model (Cooke et al, 1998) indicates 
that the transplant conditioning and procedure themselves can cause significant local 
trauma in the lung resulting in inflammation. This may be linked to alloreactive T cells 
to find sanctuary in this organ and not others, where cells are known to be susceptible to 
CMV infection and/or reactivation. Thus the transplant procedure itself might be at the 
origin of either or both GvHD and CMV infection. Consequently, the relative possible 
causative effects of CMV infection, GvHD and lung pathology on each other might 
remain unclear in the context of SCT as these appear to be connected. This specific
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question apart, the study presented in this thesis clearly demonstrated the value of 
monitoring CMV specific immune reconstitution in parallel to CMV viral load 
determination. As the study develops to include a larger number of patients with the 
description of new HLA/peptide combinations, this strategy will enable better patient 
adapted treatments with regards to CMV infection and perhaps also to GvHD treatment. 
Similar strategies with CML might identify factors or treatments that enhance the anti- 
tumour immune response in the case of CML relapse for example.
The use of HLA/peptide multimers to monitor antigen specific immune 
reconstitution after SCT also identified settings such as heavily T cell depleted 
transplants as is the case for unrelated and/or HLA mismatched transplant, where 
immune recovery is slow and inadequate and represents a risk for CMV infection. In 
these cases, patients might benefit from the adoptive transfer of CMV specific T cells. 
As shown in Chapter V, it is now possible to select purified populations of antigen 
specific T cells using HLA/peptide multimer reagents. As mentioned previously, it is 
important to consider that most of these applications are somewhat limited to a minority 
of patients because of the restriction caused by HLA/peptide specificity. However, a 
number of in vivo trials along these lines have already occurred. Although there has not 
yet been any evidence of adverse effects from the use of HLA/peptide multimer 
reagents for the purification of antigen specific T cells followed by adoptive transfer, it 
may be desirable (if only to avoid TCR triggering, or sensitisation to the complexes 
when repeat transfer might be needed) to synthesise complexes that can be separated 
from the T cell they were bound to prior to transfer or use. This has become possible 
with the use of lower affinity biotin analogues in the synthesis of HLA/peptide 
multimers that can be easily competed out by conventional biotin, therefore offering a 
more versatile system.
Furthermore, HLA/peptide multimers, by their very composition, can trigger T 
cell activation in an antigen and HLA restricted manner. In Chapter V, the option of 
including a biotinylated antibody to a T cell co-stimulatory molecule was tested as a 
new way of enhancing T cell activation and proliferation in vitro. These modified 
HLA/peptide-antibody chimera multimer complexes or chimeramers were shown to 
have maintained their antigen specificity. The influence of stimulation, induced by 
different chimeramer complexes, was tested by assessing the activation and 
proliferation of antigen specific T cells. This was achieved successfully, and although 
all chimeramers tested could induce higher levels of both specific T cell activation and 
proliferation than tetramers, it was not possible to establish consistent differences
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between the former complexes. This was likely due to the fact that PBMCs were used as 
targets for stimulation rather than an antigen specific T cell line or clone. The 
complexes used in this study were composed of biotinylated antibodies to co­
stimulatory molecules, but it would also be possible to use a biotinylated soluble form 
of the co-stimulatory ligand itself. However, results from these experiments are valuable 
as they also demonstrate the specificity of these complexes and their restricted action on 
antigen specific T cells in a complex cellular mixture that may be closer to a 
physiological setting than experiments conducted with T cell lines or clones might be. 
Some of the most significant applications for the use of these complexes in vitro in the 
context of SCT would be in the first instance to use chimeramers as “minimalist” 
antigen presenting molecules for the induction of a primary immune response. 
Unfortunately, there was not enough time at the end of this thesis to confirm the 
cytotoxic properties of T cells obtained with this method, but these experiments are 
currently under way. This may become an extremely valuable technique for the 
development of adoptive T cell transfer from non-immune donors, such as for CMV+ 
SCT patients with CMV' donors for whom adoptive transfer is not currently a possible 
treatment option. These complexes may also find applications in enhancing the potential 
of an anti-tumour immune response in vitro that after adoptive transfer or perhaps direct 
infusion might contribute to breaking the tolerance to the tumour and participating as 
well as enhancing the anti-tumour immune response. Although a lot more work needs to 
be completed before such therapeutic strategies can be applied to in vivo settings, 
HLA/peptide-antibody chimeramer complexes also offer exciting new ways of 
examining the joint effects of T cell receptor triggering and of specific co-stimulation. 
A very wide range of studies could be envisaged using these complexes, for example: 
determining antigen dependent activation threshold requirements for primary or 
memory T cell responses; testing the relative importance of co-stimulation in the case of 
low affinity peptide or low affinity HLA/peptide-TCR interaction; or testing their effect 
on activation induced cell death or T cell proliferation and survival are amongst the 
many possibilities.
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Study proposals:
C M V  s t u d y  c o n s u l t a n t  I n fo r m a tio n  s h e e t
GP/(Consultant) INFORMATION SHEET
Title of P roject
Monitoring of CMV antigen specific T cells in Bone marrow transplant 
patients before and after transplant
We at the Anthony Nolan Research Institute and Haematology Dept of the RFH are 
currently embarking on a project to investigate the reconstitution of the immune system 
after bone marrow transplantation. As you will be aware, the immune system is severely 
depleted after pre-transplant conditioning. Research has shown that specific cells in the 
normal immune system are responsible for combating many virus infections but of specific 
importance to transplant patients is CMV. The precise details of how fast these cells 
regenerate and how effective they are in fighting CMV virus in Bone marrow transplant 
patients still remains unclear. This project uses newly developed techniques which will 
provide valuable information about the levels and activity of these cells in patients after 
bone-marrow transplantation.
To help us carry out this work we require 20mls of blood These samples would be taken at 
the same time as the regular checks occuring at the hospital and will not require additional 
venepuncture.
TRANSPLANT RECIPIENTS- blood is required prior to transplant and then subsequently 
at the same times when blood is being taken for routine monitoring of CMV status, this is 
usually twice weekly during the early phase post transplant Monitoring will continue at 
outpatient appointments for up to 9 months following transplant.
DONORS- blood is required once at the pre-donation health check.
The cells extracted from these samples will only be used for the research project that the 
patient has agreed to take part in.
The proposed study will use class I soluble HLA molecules in the form of tetramers. These 
will be used to specifically detect the presence of circulating antigen specific T cells in the 
peripheral blood of patient who reactivate CMV following BMT.
CMV viraemia is a significant problem in immunosuppressed patients following BMT, and 
before their new haemopoetic system has been able to fully develop to provide the 
appropriate level o f immune response to counteract the occurrence of CMV infection de 
novo or through the reactivation of pre exisiting CMV. Monitoring the immune potential of 
a patient to mount a specific immune response to a virus such as CMV, will allow us to 
obtain a better understanding of what is happening to the CMV specific T cells in patients 
who reactivate CMV post BMT or who develop de-novo CMV viraemia following BMT. 
The acquisition of such data will allow us to correlate the ability of patients to resolve CMV 
with the concurrent expansion or development of CMV specific CD8 T cells in then- 
peripheral circulation. The analysis of such information has implications for improved 
therapy or clinical intervention at specific time points resulting in improved treatment of 
patients developing CMV disease post BMT.
The role of CMV specific CD8+ T cells in the resolution of CMV viraemia is well 
documented. However specific details about the dynamics of expanded CMV +ve 
populations the relative relevance of CD4+ T cells to die action of CD8 antigen specific 
cells and whether CD8 population expansions are productive or unable to act specifically to 
remove CMV positive cells in BMT patients are all questions which need answering. In 
addition the contribution of chimerism to the cellular dynamics of antigen specific T cells in 
BMT patients is also an important question that needs to be investigated.
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C M V  s t u d y  p a t ie n t  I n fo r m a tio n  s h e e t
 i________
PARTICIPANT INFORMATION SHEET “ I
  — ........    H .  ■■■ I - — ■ Ml !  ' I
Title of Project
Monitoring of CMV antigen specific T cells in Bone marrow transplant 
patients before and after transplant.
W e at the Anthony Nolan Research Institute are currently embarking on a 
project to investigate the reconstitution of the immune system  after bone  
marrow transplantation. As you will be aware, the immune system  is severely  
depleted after pre-transplant conditioning. Research has shown that specific 
cells in the normal immune system  are responsible for com bating many virus 
infections but of specific importance to transplant patients is CMV. The precise  
details of how fast th ese  cells regenerate and how effective they are in fighting 
CMV virus in Bone marrow transplant patients still remains unclear. This project  
u ses  newly developed techniques which will provide valuable information a b o u t  
the levels and activity of th ese  cells in patients after bone-m arrow  
transplantation.
To help us carry out this work w e require 20m ls of blood (which is 
approximately an egg  cup full). T hese sam ples would be taken at the sa m e  
time a s  the regular checks you will have at the hospital and will not require you  
to have any extra venepunctures.
TRANSPLANT RECIPIENTS- blood is required prior to transplant and at th e  
sam e tim es when blood is being taken for routine monitoring of CMV s ta tu s ,  
this is usually twice weekly during the early phase post transplant, you will then  
be monitored at your outpatient appointments for up to 1 year following 
transplant.
DONORS- blood is required once at your pre-donation health check.
The cells extracted from th ese  sam ples will only be used for the research  
project you have agreed to take part in.
If you are willing to take part in this study and agree to provide the sam p les  
requested, your medical records will also be exam ined by researchers from The 
Anthony Nolan Bone Marrow Trust's Research Institute, who are outside th e  
employment of the NHS. All information will remain confidential.
208
Appendix
C M L s t u d y  c o n s u l t a n t  I n fo r m a tio n  s h e e t
GP/(Consultant) INFORMATION SHEET
Title of Project
Monitoring of BCR-ABL antigen specific T cells in Bone marrow transplant 
patients before and after transplant
We at the Anthony Nolan Research Institute and Haematology Dept of the RFH arc 
currently embarking on a project to investigate the reconstitution of the immune system 
after bone marrow transplantation. As you will be aware, die immune system is severely 
depicted after pre-transplant conditioning. Research has shown that specific cells in the 
normal immune system are responsible for combating many virus infections but also 
possibly in combatting emergent leukaemia cells. These cells are of specific importance to 
transplant patients post grafting . The precise details of how fast these cells regenerate and 
how effective they are in fighting residual leukaemic cells in Bone marrow transplant 
patients still remains unclear. This project uses newly developed techniques which will 
provide valuable information about the levels and activity of these cells in patients before 
and after bone-marrow transplantation.
To help us carry out this work we require 20mls of blood These samples would be taken at 
the same time as the regular checks occurring at the hospital and will not require additional 
vene-puncture.
TRANSPLANT RECIPIENTS- blood is required prior to transplant and then subsequently 
at the same times when blood is being taken for routine monitoring of CMV status, this is 
usually once weekly during the early phase post transplant. Monitoring will continue at 
outpatient appointments for up to 9 months following transplant
DONORS- blood is required once at the pre-donation health check.
The cells extracted from these samples will only be used for the research project that the 
patient has agreed to take part in.
The proposed study will use class I soluble HLA molecules in the form of tetramers. These 
will be used to specifically detect the presence of circulating BCR-ABL antigen specific T 
cells in the peripheral blood of patient before and after BMT and during episodes of GVH. 
Relapse can be a significant problem in immunosuppressed patients following BMT, and 
before their new haemopoetic system has been able to frilly develop to provide the 
appropriate level of immune response to counteract the occurrence of residual leukaemic 
cells through the regrowth of pre exisitingleukaemic progenitors that have escaped 
conditioning. Monitoring the immune potential of a patient to mount a specific immune 
response to residual leukaemic cells and during relapse, will allow us to obtain a better 
understanding of what is happening to the levels of anti leukaemia specific T cells in 
patients who relapse, during DLI, and during episodes of GVHD post BMT. This will be 
compared with levels of these cells in patients pre transplant. The acquisition of such data 
will allow us to correlate the ability of patients to resolve relapse as a result of DLI with the 
concurrent expansion or development of leukaemia specific CD8+ T cells in their peripheral 
circulation. Tlie analysis of such information has implications for improved therapy or 
clinical intervention at specific time points resulting in improved treatment of patients 
relapsing post BMT.
The role of anti leukaemia specific T cells in the resolution of relapse following DLI is well 
documented. However specific details about the dynamics of expanded leukaemia specific 
populations die relative relevance of CD4+ T cells to the action of CD8+ antigen specific 
cells and whether CD8 population expansions are productive or unable to act specifically to 
remove leukaemia positive cells in BMT patients are all questions which need answering. 
In addition the contribution of chimerism to die cellular dynamics of antigen specific T cells 
in BMT patients is also an important question that needs to be investigated.
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C M L s t u d y  p a t i e n t  In fo r m a tio n  s h e e t
,
*PARTICIPANT INFORMATION SHEI
Title of Project
Monitoring of BCR-ABL antigen specific T cells in CML patients before 
and after Bone marrow transplant.
We at the Anthony Nolan Research Institute are currently embarking on a 
project to investigate the presence of naturally occurring anti leukaemic white 
cells present in the immune system before and after bone marrow 
transplantation. As you will be aware, the immune system is severely depleted 
after pre-transplant conditioning. Research has shown that specific cells in the 
normal immune system are responsible for combating many virus infections and 
also possibly malignant cells such as leukaemic cells. These cells are of specific 
importance to transplant patients with leukaemia. The precise details of how 
fast these cells regenerate and how effective they are in fighting residual 
leukaemic cells in Bone marrow transplant patients still remains unclear. Also 
unclear is why these cells fail to function properly before transplant thus 
allowing leukaemia to develop. This project uses newly developed techniques 
which will provide valuable information about the levels and activity of these  
cells in patients before and after bone-marrow transplantation.
To help us carry out this work we require 20mls of blood (which is 
approximately an egg cup full). These samples would be taken at the sam e  
time as the regular checks you will have at the hospital and will not require you 
to have any extra venepunctures.
TRANSPLANT RECIPIENTS- blood is required prior to transplant and at the 
sam e times when blood is being taken for routine monitoring of CMV status, 
this is usually once weekly during the early phase post transplant, you will then 
be monitored at your outpatient appointments for up to 1 year following 
transplant.
DONORS- blood is required once at your pre-donation health check.
The cells extracted from these samples will only be used for the research 
project you have agreed to take part in.
If you are willing to take part in this study and agree to provide the samples 
requested, your medical records will also be examined by researchers from The 
Anthony Nolan Bone Marrow Trust's Research Institute, who are outside the 
employment of the NHS. All information will remain confidential.
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Consent form
Consent forms for both studies were based on the same model:
I ------------------Pt   r f l ~ V  I
 i i I
TITLE OF PROJECT
Monitoring of BCR-ABL antigen specific T cells in CML patients pre and post 
Bone marrow transplant and during DLI therapy
The patient should complete the whole of this sheet themselves.
Have you read the Patient Information Sheets? YES I NO
Have you had an opportunity to ask questions and discuss YES I NO
this study?
Have you received satisfactory answers to all your questions? , YES I NO
Have you received enough information about the study? YES I NO
Who have you spoken to? Dr / Mr / Mrs______________________________
Do you understand that you are free to withdraw from the 
study at any time, without having to give a reason for 
withdrawing and without affecting your future medical care?
Do you agree to enter your this study and in doing so give 
permission for the researchers to have access to your 
medical notes?
Do you give permission for us to notify your GP that you have 
entered this study?
YES/NO
YES/NO
YES/NO
Do you agree to enter in this study? YES/NO
Patient s name _ 
(in block letters)
Signature_____ Date I I I
Dr s signature Date I I I I
Dr s  n a m e____
(in block letters)
File one copy in patients notes, one copy in CRF and one copy to patient.
2 1 1
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Vector maps
P C R  2 .1  v e c to r ,  I n v i t r o g e n
Map Of pCR®2.1 The map of the linearized vector, pCR®2.1, is shown below. The sequence of the multiple 
cloning site is shown with a PCR product inserted by TA Cloning®. EcoR I sites flank the 
inserted PCR product on each side. The arrow indicates the start of transcription for the T7 
RNA polymerase. The complete sequence of pCR®2.1 is available from our World Wide 
Web site (www.invitrogen.com) or by contacting Technical Service (page 20).
tocZaATG 
M13 Raverra Primer I Hind III toil Sac I SamHI Spa  I
CAG GAA ACA GCT AIQ  AC C ATG ATT ACG CCA AQC TTG GTA CCG AGC TCG GAT CCA CTA 
GTC CTT TGT CGA TAC TG GTAC TAA TQC GCT TCG AAC CAT GGC TCG AGC CTA GCT GAT
SstXI EcoR II EcoR I
CTA ACG GCC GCC ACT CTG CTG GAA TTC GGC TT  
CAT TQC COG CGG TCA CAC GAC CTT AAG CCG
GCC GAA TTC TGC 
|T  T CGG CTT AAG ACG
Aval 
Pae R7I
Xhol Nsi I Xba I
AGA T)AT CCA TCA CAC TGG CGG CCG CTC GAG CAT GCa ' TCT AGA GGG CCC AAT TCG 
TCT ATA GCT ACT CTG ACC GCC GGC GAG CTC CTA CCT AGA TCT CCC GGG TTA AGC
EcoR V BstKl Not I Apa I
CCC TAT 
GGG ATA “ ?---
T7 Promoter
ACT GAG TCG TAT TA CAAT TCA 
\  TCA CTC AGC ATA ATlGTTA ACT
M13 Forward (-201 Primer
CTG GCC CTC GTT TTA C AA CGT CCT GAC TGG GAA AAC 
GAC CGG CAG CAA AAT C TT GCA GCA CTG ACC CTT TTG
Comments for pCR®2.1 
3929 nucleotides
LacZa gene: bases 1-545
M13 Reverse priming site: bases 205-221
Multiple Cloning Site: bases 234-355
T7 promoter: bases 362-381
M13 (-20) Forward priming site: bases 389-404
f1 origin: bases 546-983
Kanamycin resistance ORF: bases 1317-2111
Ampicillin resistance ORF: bases 2129-2989
pUC origin: bases 3134-3807
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p E T  8  v e c to r ,  c o m m e r c ia l l y  a v a ila b le  p E T  3 d  m a p ,  N o v a g e n :
ECOR 1(4638) 
,ApO 1(4638)
/ <Cla 1(24)
I Hind 111(29)Aat 11(4567)
pET-3a
(4640bp)
Sea 1(4125) 
Pvu 1(4015)
Eam1105
HgiE il(3338)
AtwN 1(3168)
BspLUH 1(2752)
Aft 111(2752)
Sap 1(2636)
Bst1107 1(2523)
BsaA 1(2504)
Tth111 1(2497)
BsmB 1(2393) 
Pvu 11(2343)
Bpu1102 1(458)
BamH 1(510)
Nde 1(550)
Xba 1(588)
Bgl 11(646)
SgrA 1(687)
sph 1(843) 
EcoN 1(903) 
Sal 1(928) 
PshA 1(993)
Eag 1(1216)
Nru 1(1251) 
ApaB 1(1329) 
BspM 1(1331)
Bsm 1(1636) 
Ava 1(1702) 
MSC 1(1723) 
Bpu10 1(1868)
BscG 1(1912)
Bgiu
Ndel
T7 promoter primer #69348-3 
T 7  p r o m o t e r Xba I rtos
AGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGA
T 7 « T h g p E T - 3 o BamH I apt/11021 _____
TATACATATGGCTAGCATGACTGGTGGACAGCAAATGGGTCGCGGATCCGGCTCCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGACCAATAACTAGCATAA
N a tA I o S e r H e t T h r G I y G I y G I n G I n M e t G I y A r g G I y S a r G I y C y s E n d
G .
TTVminfttprprimer #693??-?
p E T - 3 d
A lto  I
. . . TACCATGGCTAGC. . .  
H a t A l o S a r . . .
p E T - 3 b  . . . GGTCGGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAA 
. . . G I y A r g A s p P r o A I o A I o A e n L y s A I a A  r g L y s G I u A I o G I u L a u A I o A I a A I o T h r A I o G I u G I n E n d
p E T - 3 c . d  . . . GGTCGGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAA 
. . . G l y A r q l  l a A r g L a u L a u T h r L y a P r o G l u A r g L y a L a u S a r T r p L a u L a u P r o P r o L a u S a r A a n A a n E n d ______
_____________ T7 terminator______________
CCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG
pET*3a-d cloning/expression region
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